ADAM15/PTK6/cMET interplay: Promotors of prostate cancer progression by Hurtz, Melanie
		
ADAM15/PTK6/cMET interplay: 
Promotors of prostate cancer 
progression 
 
Melanie Hurtz, MSc. 
September 2017 
 
School of Medicine 
Cardiff University 
Cardiff, CF14 4XN 
Cardiff, United Kingdom 
 
A thesis submitted in partial fulfilment of the requirements of the degree of 
Doctor of Philosophy (PhD) 
I 
 
	
	
	
DECLARATION 
 
This work has not been submitted in substance for any other degree or award at this 
or any other university or place of learning, nor is being submitted concurrently in 
candidature for any degree or other award. 
 
 
Signed   ………………………………… (candidate)       Date ………………………… 
	 	
II 
 
 
STATEMENT 1 
This thesis is being submitted in partial fulfilment of the requirements for the degree 
of PhD  
 
Signed ………………………………………(candidate)    Date ………………………… 
 
 
STATEMENT 2 
This thesis is the result of my own independent work/investigation, except where 
otherwise stated. Other sources are acknowledged by explicit references. The views 
expressed are my own. 
 
Signed ………………………………………(candidate)    Date ………………………… 
 
 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available for photocopying 
and for inter-library loan, and for the title and summary to be made available to 
outside organisations. 
 
Signed ………………………………………(candidate)     Date ………………………… 
 
 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS 
I hereby give consent for my thesis, if accepted, to be available for photocopying 
and for inter-library loans after expiry of a bar on access previously approved by the 
Academic Standards & Quality Committee.  
 
Signed ………………………………………(candidate)     Date ……………………… 
  
III 
 
 
 
 
 
 
 
Σε αυτό που βρήκα εδώ στο καρντιφ, και το μικρό μπόνους 
 
Für Joko, und all die guten Tage zum Fliegen 
 
Für Mama und Papa 
 
IV 
 
Acknowledgments 
 
This thesis would have been impossible without the support of my supervisor’s  
Dr Zara Poghosyan and Dr Vera Knäuper. 
…. and also without the support and great organization from the people behind the 
scene, Julia, Trish, Marie and AJ. 
 
I would like to say thank you to Dr Lisa Spary from the Wales Cancer Bank, for the great 
sample coordination. 
 
I would like to say thank you to my sponsor, Cancer Research Wales, for supporting 
this project. 
 
A special thank you also to all unknown patients, that were willing to support prostate 
cancer research, only with you we can try to find a way to beat cancer. 
 
 
 
  
V 
 
Abstract 
ADAM15 is a transmembrane metalloproteinase involved in disease progression and 
aggressiveness in prostate cancer (PCa). ADAM15 is composed of an extracellular 
domain, a transmembrane region and an intracellular domain, the latter being subject 
to splicing due to alternative use of exons 19 to 21. The splice variants that will be 
subject in this study are ADAM15-A, ADAM15-B, ADAM15-C, ADAM15-D and 
ADAM15-E. Previously, ADAM15 splice variant A and B were reported to associate with 
the PCa promotor PTK6 and the cMET adaptor protein Grb2. 
In order to understand the underlying mechanisms for the contribution of ADAM15 to 
disease progression in PCa, ADAM15 A-E splice variants, overexpressed in LNCaP 
and PC3 PCa cells, were biochemically and functionally characterized. 
Overexpression of ADAM15-A in PC3 led to enhanced invasion upon HGF treatment, 
which could be reverted by cMET inhibitor treatment. In addition, ADAM15-induced 
invasion was dependent on its proteolytic activity. Moreover, PC3 cells expressing 
proteolytically active ADAM15 showed more MMP2 activity compared to cells with the 
proteolytically inactive ADAM15 mutant in cell supernatants. In contrast to the 
aggressive, androgen independent PC3, androgen dependent LNCaP cells did not 
show any response to HGF treatment upon ADAM15 A-E overexpression. All ADAM15 
splice variants were found in a complex with PTK6, which could be disrupted upon 
cMET inhibition in PC3. 
Strikingly, ADAM15 was found in a complex with cMET/Gab1/Grb2/PTK6. cMET 
inhibition led to complex loss of cMET/Gab1/PTK6, however, Grb2 remained in complex 
with ADAM15 regardless of treatment. Unlike cMET, PTK6 activity was not needed for 
formation of the ADAM15 complex. 
Analysis of the ADAM15 splice profile in prostate cancer patients and comparison with 
healthy prostate tissue revealed a significant overexpression of all ADAM15 splice 
variants. 
In summary, we show for the first time that ADAM15 is found in a complex with 
cMET/Gab1/Grb2/PTK6, and importantly, that, this complex formation is dependent on 
the cMET/HGF axis in PC3 PCa cells. Moreover, we found that proteolytically active 
ADAM15 resulted in enhanced invasion upon HGF treatment in PC3s. Our data suggest 
an important role for ADAM15 in prostate cancer disease progression. 
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1 
 
1 Introduction 
The human body consists of approximately 37.2 trillion cells, which all have a distinct 
task depending on the tissue they belong to. They all divide and die in a strictly 
controlled and regulated manner. If this strict regulation is disrupted cell growth is out 
of control, which in most cases is the onset of cancer. Cancer cells possess two 
distinct characteristics, namely, they are able to reproduce independent from the 
body’s own restrains, and they are able to colonize and invade other tissues. 
Cancer has become a leading cause of death in the western world, with 14,1 million 
new identified cases only in 20141. It is multifactorial and does not depend on age or 
sex, although 1/3 of all cancer cases are found in patients above 60, whereas only 
50% of all diagnosed cases survive for 10 years or more. In 2012, 8.2 million cancer 
related deaths were reported from which 50% were linked to lung, breast and liver 
cancer. Looking at cancer on a geographical level, it turns out that organ specific 
cancers like thyroid cancer or liver cancer are predominantly found in South Korea 
and Laos, whereas breast and prostate cancer are not elevated in these countries2. 
The disease burden is tremendous for patients and for their families. Even though the 
patient will undergo a successful first treatment, the chance of a disease relapse is 
never eliminated.  
1.1 Cancer  
The name cancer, in greek, karkinos (καρκινος), goes back to Hippocrates (460-
370BC). He used this word to describe the structure of cancerous tissue that he 
observed, which reminded him of the arms of a moving crab, the translation of the 
word cancer3. Cancer is classified due to its origin, i.e. cell type and the organ from 
which it originated. There are five classes to be mentioned, carcinomas, sarcomas, 
leukaemia, myelomas and lymphomas.  
According to Cancer Research UK, carcinomas make up 85% of all cancers 
diagnosed in the UK, and are of epithelial origin. Sarcomas, are cancers which 
originate from the bone, cartilage, muscles, fat and blood vessels. Myelomas and 
lymphomas are cancers originating and affecting the immune system; approximately 
6% of cancer diagnosis are related to these categories of cancer. 3% of cancer 
patients are diagnosed with leukaemia. Brain and spinal cord cancer are classified as 
cancers of the nervous system and affect less than 3% of all patients. The most 
common form of brain cancer is called glioma, arising from the glial cells. One out of 
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100 diagnosed cancer cases are classified as sarcomas. Leukaemia develops from 
blood forming tissues, such as bone marrow.  
Once classified, cancer types can be described based on their developmental stage, 
as in situ, namely, a still isolated accumulation of tumour cells, or as invasive, which 
means the cancer cells start to invade the surrounding tissue. Cells have found a way 
to escape the primary tumour and spread through the body to initiate the formation of 
new tumours, known as metastasis. 
1.2 Prostate Cancer 
The World Health Organisation (WHO) cancer statistic from 2014 for the UK shows 
that from 557,000 deaths within the UK, in men, 86,300 can be assigned to prostate 
cancer (PCa). It is the second leading cause of death in men, with 14.0% of all cancer 
related deaths. PCa affects one out of eight men, and in 2014, 45,406 cases only in 
the UK have been registered4. PCa has multiple faces, from slow growing with good 
treatment chances, to highly invasive and metastatic. When diagnosed at an early 
stage, the chances of complete recovery are almost 100%, however, there are no 
clinical symptoms associated with early disease onset. In a US study, 1/3 of autopsy 
samples from men above 50, a PCa incidence was identified histologically, although 
the patients were non-symptomatic5. 
The most common form of prostate tumours are adenocarcinomas, which show 
similarities with epithelial malignancies such as breast and colon cancers6,7. 
Established risk factors such as ethnicity, family history, age and hormones are linked 
to PCa onset, however they do not give a satisfying explanation of disease onset1,4,8–
10.  
One hypothesis for PCa onset is that it arises from a lesion within the prostate 
epithelium, which progresses over decades, leading to proliferative inflammatory 
atropy (PIA), which is characterized as the precursor of PCa. PIA can be stimulated 
by chronic inflammation, infection or even the exposure to carcinogens, and is 
characterized by an increased epithelial proliferation, which can progress to  prostatic 
intraepithelial neoplasia (PIN), which is characterized as low to high-grade prostate 
cancer (HGPIN) 11.  
In contrast to this, Maitland et al. postulate the theory of prostate cancer stem cells. 
Prostate cancer appears as heterogenic disease, although most therapies aim to 
eliminate the tumour mass, the disease progresses and reaches an incurable stage, 
raising the question about the origin of resistance 12.  
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1.2.1 The Prostate  
The prostate is a walnut shaped, exocrine gland. It is located underneath the bladder 
and surrounds via its peripheral zone (PZ) the urethra. It is connected via ducts to the 
urethra and composed of approximately 50 single tubuloalveolar glands, regulated 
via testosterone13(Figure 1.1).  
 
Figure 1.1 The anatomy of the human prostate. 
(A) Overview of the male prostate and its location within the reproductive system. The 
prostate is located underneath the bladder and surrounds the peripheral zone and the 
urethra. (B) A closer look to the prostate anatomy, three different prostate zones surround 
the urethra starting from the internal transition zone, which is surrounded by the central 
zone and the outer peripheral zone, the most prominent site of prostate tumours. Adapted 
from the Canadian Cancer Society. 
 
During ejaculation, the prostate epithelial cells produce an alkaline secretion (pH 6.4), 
which makes up 30% of the male seminal plasma. This seminal plasma contains 
prostate specific antigen (PSA), a kallikrein-like serine protease, which liquefies the 
seminal plasma due to degradation of semenogelin and fibronectin14. PSA is found in 
the blood when changes in the prostate epithelial architecture occur15, and these PSA 
levels are a prognostic tool for prostate malfunction and for prostate cancer 
screening16.  
1.2.2 PCa screening 
The purpose of any cancer related screening program is to identify the cancer in a 
curable, early stage, as an early diagnosis is associated with a complete recovery for 
the patient17. For PCa detection, three techniques are commonly used, such as digital 
rectal examination (DRE), transrectal ultra sound (TRUS) and biomarker screening 
for prostate specific antigen (PSA)18. As an early prognostic tool PSA testing is used 
in men to evaluate risk19,20. From an epidemiological point of view, age is the most 
outstanding factor to define men at risk. The chances of being diagnosed with PCa at 
an age below 40 is 1 in 10,000, from 40 to 60 the chances are 1 in 103 and from 60 
A B
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to 80, 1 in 85. Independent studies from the European Union, The Randomised study 
of Screening for Prostate Cancer (ERSPC) and the United States, The Prostate, 
Lung, Colorectal and Ovarian Cancer Screening Randomized Controlled Trial 
(PLCO), showed that PSA screening is able to reduce prostate cancer mortality. 
However, PCa screening is debatable due to the high risk of over-diagnosis, which 
affects up to 50% of all cases 21.  
1.2.3 Prostate cancer grading, the Gleason Score 
Prostate cancers are in most cases adenocarcinomas. A key histological grading 
system on which prognosis and therapy is based, is the Gleason score. This scoring 
system was developed in 1966 by Dr Donald F. Gleason and is based on hematoxylin 
and eosin (H&E) staining of tumour structures from initially 270 patients22,23. The 
system was refined by Gleason and Mellinger from 1974-1977 by including samples 
of 1032 patients 24. It was updated to common modern practice during The 2005 
International Society of Urology and Pathology (ISUP) Consensus Conference on 
Gleason Grading of Prostate Carcinoma25. The tumour grading for the Gleason score 
is divided into 5 classes, each representing a morphological progression in PCa. 
Grade 1 to 3 tumours show high similarity with the normal prostatic tissue, whereas 
tumours graded with 4 and 5 show abnormal morphological pattern. During the 1960s, 
two biopsy samples were taken directly from the area showing the abnormality, via a 
thick-gauge needle. During the 1980s this was replaced via an 18-gauge 
needle23,26,27. Nowadays, 6-8 different core samples from areas of the prostate are 
taken. The Gleason score is an average measure of the most common primary and 
most common secondary patterns within the biopsied sample. The two most 
prominent Gleason grades (i.e. 1-5), present in the prostate core samples, are 
combined to the Gleason score, i.e. 3+4 =7. An overview of the histological grades 
by Gleason is given in Figure 1.2.  
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Figure 1.2 Prostate cancer grading by the Gleason score and its pathological pattern. 
The Gleason score is the grading system developed by Gleason and Mellinger in 1977, 
including 1032 patient samples. The original system is divided into 5 classes with respect 
to abnormalities in morphology. Gleason score 1 to 3 show high morphological similarity 
with normal prostate tissue, whereas scores 4 to 5 show abnormal morphologies. For each 
score stage tumour shape, invasion, tumour cell arrangement and gland size are described. 
Adapted from Gleason et al.  
 
1.2.4 Androgen dependent PCa development 
Androgens and the signalling via the androgen receptor (AR) play a crucial role in the 
development of the prostate, and the growth of prostate epithelium28. Morphological 
changes of the prostate are induced during puberty via increasing androgen levels. 
The result is an encapsulated glandular structure at a mature age. This encapsulated 
structure of the prostate needs constant supply and control of androgens. The 
production of androgen is regulated via luteinizing hormone (LH), which underlies the 
levels of gonadotropin-releasing hormone (GnRH) within the adrenal glands, the 
peripheral tissues and the prostate. In more the detail, GnRH is released from the 
hypothalamus and stimulates the anterior pituitary gland leading to the production 
and release of LH and follicle stimulating hormone (FSH). FSH  stimulates the sertoli 
cells facilitating spermatogenesis. The LH stimulates the Leydig cells within the testis 
leading to the production of testosterone. The testosterone further stimulates the 
sertoli cells, inducting spermatogenesis, and moreover, it acts as inhibitor on the 
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pituitary gland and the hypothalamus, regulating the production and release of GnRH 
and FSH29,30. As much as androgens are needed for development and maintenance, 
at a later stage in life, androgens can become the main drivers of pathological 
damage within the prostate leading to cancer31.  
Upon entering the prostate cell, the androgen testosterone is converted to 
dihydrotestosterone (DHT), by 5-a-reductase. The AR is bound to heat-shock 
proteins (HSP) within the cytoplasm, which dissociate upon DHT binding. The AR-
DHT complex dimerizes and becomes phosphorylated, leading to receptor 
translocation to the nucleus. The AR-DHT complex allows the association with 
androgen responsive elements (ARE) in the promoter region of target genes, such as 
PSA, Cdk1 and Cdk2, or TMPRSS232 (Figure 1.3). Co-activators and co-repressors, 
for instance ARA70, are recruited to the promoter region, initiating or preventing 
transcription. Under physiological conditions, this complex maintains the homeostasis 
between proliferation, growth and survival. During cancer these genes induce 
enhanced proliferation and prevent apoptosis33. At an early stage PCa is highly 
dependent on the stimulation by androgens.  
Androgen depletion therapy (ADT) is an outstanding treatment for an early stage PCa. 
The aim of ADT is to reduce androgen levels in a therapeutic way, as they have also 
a major impact on development, maturation and differentiation of the male 
reproductive system34. Two target sites are used for ADT, first, gonadotropin-
hormone analogues, leading to suppression of testosterone production and chemical 
castration, or androgen-analogues, binding directly to the AR, impairing androgens to 
bind to the receptor35. However, in most cases the cancer progresses within 2-3 years 
after ADT start, and overcomes the androgen-deprivation. Disease recurrence is 
termed castration-resistant PCa (CRPC)36. 
1.2.5 Androgen independent PCa 
During the first stage of PCa the AR signalling is predominant, however, as soon as 
it progresses, the signalling pathways that are involved become more diverse, 
although androgen signalling is still involved. For example, although CRPC is 
resistant to androgen deprivation therapy it still involves gene amplification and 
increased AR expression, or splice variants of the AR which allow not only androgens 
to bind but also steroids, estrogens or tyrosine kinases (TKs) 34,36. Until today, the 
development from androgen dependent to androgen independent prostate cancer 
remained unclear. In 2001, Feldman et al. published five hypothetic mechanisms, 
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indicating possible reasons for prostate cancer to progress from androgen dependent 
to androgen independent and becoming resistant to ADT32 (Figure 1.3). 
The first mechanism how prostate cancer cells are able to overcome ADT is the 
hypersensitivity to androgens, by gene amplification of the AR, by hypersensitivity 
towards DHT, or local production of androgens. Visakorpi et al. showed that 30% of 
patient tumours with normal AR expression levels prior to ADT, had AR amplification 
after ADT, indicating a specific selection of those cells32,37. Gregory et al. confirmed 
that androgen hypersensitivity of tumours was related not only to AR amplification but 
further to enhanced DHT binding, AR-DHT complex stability, and enhanced nuclear 
localization of the complex38. Within this context the local production of androgens 
would be another way to overcome ADT, which is described by Labrie et al.. Although 
circulating androgen levels remain low due to ADT, the peripheral prostate tissue is 
able to produce androgens locally, maintaining the AR signalling39. 
The second mechanism of PCa progression is the promiscuous pathway, extending 
the ligands for the AR due to mutations in the binding site. Veldscholte et al. first 
published a change in the AR-ligand binding site from alanine to threonine at Amino 
Acid position 877, leading to androgen insensitivity and response to different ligands, 
i.e. corticosteroids of the receptor40. Flutamide, an androgen analogue used for ADT, 
caused a rapid increased in PSA-levels in patients, who had the A877T mutation. The 
antagonistic effect of Flutamide is changed to an agonistic, AR-stimulating effect in 
those patients41.  
In the outlaw pathway, receptor tyrosine kinases (RTK) phosphorylate and activate 
the AR via the MAPK or Akt signalling pathway, leading to an ‘outlaw-AR’ signalling. 
One RTK which is overexpressed in patients is the HER-2/neu. The MAPK-pathway 
is activated via Her-2/neu induced phosphorylation leading to a ligand independent 
activation of the AR42.  Loss of the tumour suppressor PTEN can also induce AR-
outlaw-signalling via activation of PI3K/Akt. Moreover, the PI3K/Akt pathway is 
downstream of other RTKs, such as cMET and EGFR43. 
The bypass pathway introduces a parallel signalling pathway, avoiding AR signalling, 
while maintaining the survival of prostate cancer cells. The BCL2 gene is 
overexpressed in patients with prostatic intraepithelial neoplasia (PIN), but also in 
patients with CRPC, and is linked to apoptosis inhibition44. Gleave et al. showed, that 
upon BCL-2 antisense oligonucleotide treatment of castrated mice, the progression 
of androgen-independent PCa could be delayed45.  
8 
 
The fifth mechanism of prostate cancer progression is the lurker cell pathway, which 
involved the take-over of prostate cancer stem cells, which are androgen 
independent. Craft et al. showed that upon androgen deprivation LAPC-9 cells went 
to a dormant stage for approximately 6 months, however after this period cells could 
escape and showed androgen independent growth46. Maitland et al. followed the idea 
and identified a subpopulation of CD133+/a1b2 expressing cells as tumour initiating 
and as possible targets in prostate cancer therapy47. 
 
Figure 1.3 From androgen dependent to androgen independent prostate cancer 
At an early stage, when prostate cancer is androgen dependent, upon entering the prostate 
tissue, testosterone is converted into DHT by 5-a-reductase. Once bound to the androgen 
receptor, HSP detaches and the active DHT-androgen-receptor complex can translocate to 
the nucleus, where it actives the ARE, leading to promotion of growth, upregulation of PSA 
and survival. Enhanced androgen dependent signalling can be inhibited via androgen 
ablation therapy; however, 5 mechanisms are postulated, which might lead to the androgen 
independent progression of prostate cancer. The mechanisms are as follows: 1) AR 
upregulation, causing DHT hypersensitivity, 2) activation of the AR by new ligands, 3) 
activation of the AR via RTKs, 4) activation growth and survival via independent 
mechanisms, and 5) prostate cancer stem cells which are androgen independent. 
 
androgen	
dependent androgen	independent
1.AR	amplification/	
hypersensitivity	
towards	DHT
2.	Promiscuous	
activation	of	the	AR,	
with	new	ligands
3.	Outlaw activation	of	
the	AR	by	RTKs
4.	Bypass	signaling,	by	
parallel	pathways,	
maintaining	cell	
survival
5.	Lurker	cells,	prostate	
cancer	stem	cells
survivalgrowth PSA
PP
HSP
PP
HSP
5-a-reductase
ARE ARE ARE
HSP
ARE
Heat	shock	protein
Androgen	receptor
Testosterone
Dihydrotestosterone	
(DHT)
Androgen	responsive	
elements
9 
 
1.2.6 Alternative splicing, a promotor of prostate cancer? 
To elucidate the molecular steps that contribute to the change in therapy susceptibility 
and identify new biomarkers, mRNA expression analysis of alternative splice (AS) 
variants were performed in two independent studies. Zhang et al.  and Li et al. were 
able to identify 1532 mRNA splice variants form 364 prostate cancer related genes in 
38 patients. In both studies it was possible via the alternative splice profile to 
distinguish normal from cancerous prostate tissue48–50. Two examples for AS in 
prostate cancer are discussed as new therapeutic targets, the AR gene, and the 
CCND1 gene. 
The AR is a transcription factor, activated via its ligand binding domain51. It is located 
at position Xq11-12, and men only possess one copy. The AR belongs to the steroid 
receptor transcription factor family, involved in regulation of testosterone and  DHT. 
The AR shows a modular design consisting of a N-Terminal domain (NTD), encoded 
by exon 1, a DNA-binding domain (DBD), encoded by exons 2 and 3, and the C-
terminal domain (CTD), encoded by exons 5-8. The NTD makes 60% of the AR 
cDNA, which is 10.6kb (Figure 1.4). One naturally occurring splice variant is known, 
AR45, arising from an exon within exon 1, termed exon 1a52 (Figure 1.4). The AR 
CTD contains the ligand binding domain, which is subject to alternative splicing 
leading to PCa disease progression. The AR splice variants lack the ligand binding 
domain and become independent of androgens,  which might be a reason for the shift 
from androgen dependent to androgen independent PCa53. Dehm et al., further 
identified AR splice variants which show duplication of exon 3 within the DBD, and a 
new exon 2a, which is attached to the 3’ end. Especially, exon 2a variant led to 
androgen independent AR signalling in a xenograft-based model of androgen 
resistance therapy54. Another splice variant of the AR is AR-V7, lacking the CTD 
(Figure 1.4). This splice variant has been linked to treatment failures of patients with 
androgen resistant tumours. Enzalutamide, a non-steroid androgen, is used in the 
clinic with high efficacy in treatment of castration resistance metastatic prostate 
cancer (CRMPC) 55. Abiraterone, an androgen synthesis inhibitor, is also used to treat 
patients with CRMPC56. However, although both drugs show high efficiency in first 
instance, there is also a high failure rate. Antonarakis et al. linked the AR splice variant 
7 (AR-V7) to treatment resistance and failure in patients, which showed high 
abundance of this splice variant in clinical samples57,58. Currently, clinical trials are 
investigating new drugs, for instance Galeterone, targeting the AR-V7 in patients, 
showing efficacy in CRMPC patients in early clinical trials (ARMOR2)59.  
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Figure 1.4 Overview of the Androgen receptor splice variants 
The AR is subject to alternative splicing. An example of AR splicing is shown for 
the splice variants AR-45 and AR-V7 compared to the AR-wild type (WT). 
 
The CCND1 is classified as a proto-oncogene and used as a biomarker for disease 
progression in cancer60. It encodes cyclin D1, which is involved in cell cycle 
progression. During the cell cycle, cyclin D1 binds to cyclin-dependent kinase 4 
(CDK4) triggering the G1 phase of the cell cycle. Two distinct splice variants of cyclin 
D have been identified in prostate cancer, cyclin D1a and cyclin D1b. Expression of 
cyclin D1b was linked to poor patient prognosis in prostate cancer61. One splice factor 
that was identified promoting cyclin D1b expression in prostate cancer is Sam68. The 
binding site for Sam68 was identified by Paronetto et al. in intron 4 leading to a 
transcription failure at the exon4/intron4 boundary and the stop codon present in 
intron 4 leads to a translation termination.  They suggested that Sam68 is a splice 
factor of CCND1 leading to alternative splicing. They assumed that increasing  
expression of Sam68 leads to enhanced expression of the cyclin D1b splice 
variant61,62. Cyclin D1 is suggested as potential therapeutic target in cancer therapy, 
however patients need to be carefully selected based on tumour genetics and 
proteomic signature to ensure treatment efficacy60.  
 
 
1.3 Zinc Metalloproteinases 
Metalloproteases, which are mostly zinc dependent, are able to cleave peptide bonds 
and maintain many physiological and pathophysiological processes63. The super 
family of zinc metalloproteinases contains a conserved Met-turn and a zinc binding 
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motif, which contains a glutamic acid (E), flanked by two histidines (H), HEXXH. The 
histidines are required for zinc binding, whereas the glutamic acid deprotonates H2O 
to OH-, which is able to act as nucleophile during peptide bond cleavage 64,65. This 
family can be further subdivided into three distinct subfamiles; gluzincin, aspzincin 
and metzincin. The metzincin family shows an elongated zinc binding motif, 
HEXXHXXGXXH , and the metzincin family will be the focus of this work. Due to 
structural conservation, Bode et al. suggested the subdivision of this family into 
different classes; serralysin, pappalysin, the matrix metalloproteinases, astacins and 
the A Distintegrin and Metalloproteinase (ADAMs) family64,66,67. 
1.3.1 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs), or matrixins, contribute to remodelling and 
maintenance of tissue due to their ability to degrade extracellular matrix components. 
The extracellular matrix is the main regulator for cellular function due to cell-matrix 
interactions. Extracellular matrix degradation regulates cell growth, morphology, 
apoptosis, invasion and migration, and it is mainly regulated by MMPs and serine 
proteases. Changes in regulation of this important function leads to cell invasion of 
surrounding tissue as seen in metastasis formation68.  
The first MMP discovered was the collagenase by Gross and Lapiere in 196265. There 
are 23 MMPs have been identified in humans69. The conserved structures throughout 
the MMP family are the cysteine switch motif that regulates MMP activity, as it 
maintains the zymogen form, and the zinc-binding motif in the catalytic domain, a 
hinge region and some members contain a hemopexin domain. The only exception 
lacking the zinc-binding domain is MMP-23. 
Since the first discovery in 1962, MMPs became more important as they are key 
players in diseases such as rheumatoid arthritis and cancer.  
1.3.2 ADAMs 
The ADAMs are a family of multi-domain transmembrane glycoproteins that are 
essential regulators of cell surface events such as cell adhesion, shedding, migration 
and fertilization. They also belong to the metzincins family (Figure 1.5). Their name 
summarizes the conserved structures, as they all contain a Met residue within the 
active site and require zinc ions for the catalytic enzymatic reaction70. The human 
genome comprises 21 ADAM genes and five pseudogenes71,  all of which contain a 
metalloproteinase (MP) domain, however, only 13 ADAMs are proteolytically active. 
They further contain a modular conserved domain structure consisting of the N-
terminal extracellular domain, the transmembrane region and the C-terminal 
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intracellular domain. They were identified during an analysis of proteolytic processing 
of fertilin (PH-30) involved in sperm-egg fusion, and were first described by Wolfsberg 
et al.  and later by Blobel et al. 72–74.  
Most ADAM family members are type I transmembrane proteins, which are located 
at the cell surface, however, soluble splice variants for ADAM12 and ADAM33 
exist75,76.  
1.3.2.1 ADAMs modular protein structure and function 
ADAMs are synthesised as inactive precursor proteins, as zymogens. The inactive 
state of the ADAMs is maintained via the interaction of a cysteine residue in the pro-
domain and the zinc ion in the MP-domain. The activation of the protease occurs 
either via furin-like convertases or via autocatalysis77. The activation mechanism is 
known as cysteine switch78. The pro-domain is further important in its function as 
intramolecular chaperon, enabling proper protein folding79.  The protease domain 
comprises the catalytic conserved sequence, HEXXH. Only  those ADAMs containing 
the HEXXH motif in their protease domain are catalytically active70 (Figure 1.5). 
Substrates that are target sites of the protease function are growth factors, adhesion 
molecules, cytokines, and cytokine receptors77. The disintegrin-domain, downstream 
of the protease domain, is conserved in all 21 ADAM family members. It contains a 
14-amino acid sequence known as the disintegrin loop, allowing association with 
integrins. Most integrin ligand binding occurs via an Arginine-Glycine-Aspartic Acid – 
motif, RGD-motif, which is only present in ADAM15, which enables specific binding 
to αvβ3 and α5β1 integrins80. The conserved sequence, Arginine-X-6-Aspartic Acid-
Leucine-Proline-Glutamic Acid-Phenylalanine (RX6DLPEF), enables other ADAM 
family members to associate with integrins. Downstream of the disintegrin domain is 
the cysteine-rich region, which is involved in cell adhesion and substrate recognition. 
The transmembrane region or linker region connects the N-terminal extracellular 
domain (ECD) and C-terminal intracellular domain (ICD) (Figure 1.5). The  ICD is 
highly variable within the ADAM family and differs in sequence and size, with common 
proline-rich regions enable interaction with Src homology 3 – domain (SH3) 
containing proteins. ADAM specific interaction partners, such as Src, Grb2, growth 
factor receptor binding protein 2 (GFRBP2), phosphatidylinositol 3-kinase (PI-3K), 
protein tyrosine kinase 6 (PTK6) have been identified79,81.  
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Figure 1.5 ADAMs modular protein structure and their functions. 
The ADAMs family belongs to the family of endopeptidases and is further classified as 
metalloproteinase, due to the metalloproteinase domain, which is conserved in the 
proteolytically active ADAMs. Metalloproteinases are further classified as metzincins and 
Adamlysis, leading to the ADAM family. Proteolytically active ADAMs, such as ADAM9, 
ADAM12, ADAM10, ADAM17 and ADAM15, all contain the zinc binding metalloproteinase 
domain. Further they exhibit a disintegrin and cysteine-rich domain. ADAM15, has a RGD 
motif within the Disintegrin-domain, which enables association with the integrins αvβ3 and 
α5β3.  Compared to the others, ADAM15 further has a EGF-domain. ADAM9 and ADAM12 
can be present as membrane anchored or as soluble (indicated by the asterisk), i.e. not 
membrane anchored. The soluble variants lack the cytoplasmic domain, important for 
intracellular signalling. 
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1.3.2.2 The physiological and pathological roles of ADAMs 
The ADAMs family is essential during fertilization, development of the central nervous 
system, the heart, the lung and the epithelium. The first ADAMs to be identified were 
ADAM1 and 2 which were found to be involved in sperm-egg fusion, an essential 
process in human development82. ADAM3 was also linked to sperm-egg fusion and 
membrane adhesion. Yuan et al. found upon comparison with ADAM2, that ADAM3 
is involved in the adhesion of sperm and egg, leading to the fusion of both83. The 
Phenotype of knock out mice showed a prenatal lethality for ADAM1084 and 
ADAM1785 knock out models. For ADAM17 faulty EGFR signalling could be identified 
leading to prenatal lethality86. ADAM12 knock-outs had a 30% prenatal death rate87, 
and ADAM19 knock out models were up to 80% lethal postnatally due to defects in 
cardiac morphology 88.   
Although ADAMs are linked to disease progression in cancer, they are also known to 
be involved in non-cancer diseases such as rheumatoid arthritis, chronic renal 
diseases, asthma and Crohn disease70. ADAM8 is commonly expressed on 
leukocytes, neurons and osteoclasts. It has been identified to be involved in 
neurogenerative processes and osteoclastogenesis, however its function is not yet 
fully understood. Gomez-Gaviro et al. identified a higher amount of expressed 
ADAM8 on neutrophils isolated from the synovial fluid of rheumatoid arthritis patients. 
The level of ADAM8 expression correlated with the degree of joint inflammation in 
those patients89. ADAM10 on the other hand has been identified to shed the APP, a 
key protein in Alzheimer’s plaque formation. ADAM33 overexpression is linked to 
asthma susceptibility. The ADAMs 11, 22 and 23 are predominantly expressed in the 
central nervous system (CNS) 90,91. ADAM11 has been linked to pain transmission 
due to its expression in the CNS. In neuropathic animal pain models such as Von 
Frey or Hot-plate, ADAM11 showed a role in pain transmission and perception. The 
role in neuropathic pain maintenance, caused by inflammation, was suggested to be 
mediated by adhesion to β1 integrin92, as ADAM11 is able to bind to α6β1 and α9β193. 
ADAM17 is a key player in  rheumatoid arthritis and inflammatory diseases, as it is 
known to produce soluble TNF-α94. With regard to its major role in inflammatory 
diseases, ADAM17 is also thought to be a mediator of inflammation-related 
cancer77,95.  
Most of the ADAMs are reported to be upregulated during disease progression, for 
instance, cancer or rheumatoid arthritis. Mochizuki et al. concluded that the 
upregulation in cancer might be linked to the multiple function of the ADAMs in cancer 
15 
 
biology. They described five distinct functional interactions: 1) The zymogen transition 
to the active, functional state of ADAMs, via furin or MMPs, which are also 
upregulated during cancer96, 2) the proteolytic cleavage of growth factors and their 
receptors, and further the downstream activation via the intracellular domain of PKC 
or MAPK pathway, inducing cell proliferation and increased survival, 3) the interaction 
via their disintegrin-like and cysteine-rich domain with integrin and syndecans, 
leading to impaired cell-cell or cell-matrix interaction, 4) the proteolytic disruption via 
the metalloproteinase domain of the extracellular matrix, 5) the proteolytic cleavage 
of membrane bound cytokines or chemokines leading to cancer progression and 
proliferation.97 ADAM10 and ADAM17 are extensively investigated in relation to 
cancer, which might be due to their shedding of the epidermal growth factor receptor 
(EGFR) ligands EGF and TGF-α98. ADAM8, ADAM15 and ADAM19 on the other hand 
are linked to invasion of cancer cells99,100.  
1.3.2.3 Prostate cancer and ADAMs 
ADAMs are considered as promotors of metastasis in prostate cancer due to two key 
features. Their ability to degrade the extracellular matrix (ECM) via their 
metalloproteinase domain and their ability to induce cell migration. ADAMs are known 
to degrade a variety of ECM components such as collagen IV, laminin, vitronectin, 
fibronectin and gelatin101. To be able to metastasise, cells further need to migrate 
through the degraded matrix. ADAMs are able to bind integrins leading to formation 
of cell-cell or cell-ECM interactions. Enabeling the cell to move through the ECM. 
McCulloch et al. identified ADAM9, ADAM10, ADAM11, ADAM15 and ADAM17 to be 
present in the LNCaP, ALVA-41, DU-145 and PC3 human prostate cancer cell 
lines102. They further revealed the androgen-dependent regulation of ADAM9, 10 and 
-17 expression in the LNCaP cell line. Arima et al. showed that in benign prostate 
cancer ADAM10 is localized to the plasma membrane. During disease progression, 
localization of ADAM10 is shifted form the membrane to the nucleus103. ADAM9 is 
described as an independent prognostic marker in prostate cancer by Fritzsche et al. 
104. In addition, Najy et al. identified ADAM15 as a metastatic promotor in prostate 
cancer. Downregulation of ADAM15 in a PC3 cell model reduced adhesion and 
migration and further weakened the bone-homing effect of those cells in a SCID 
mouse model105. 
Although ADAMs play a role in prostate cancer progression and are a promising 
target due to their involvement in pathways such as EFGR or MAPK, they have so far 
not been considered as key target site for prostate cancer66.  
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1.3.3 ADAM9 
ADAM9, Meltrin-γ was first identified as a myoblast fusion protein by Yagami-
Hiromasa et al.106. It was characterized as a membrane-anchored glycoprotein with a 
molecular weight of 84kDa. Weskamp et al., proposed a role in cell-cell interaction107. 
Although most of the ADAM9 structure is conserved when compared to the ADAMs 
family, it contains a Threonine-Serine-Glutamic acid-Cysteine motif (TSEC) within the 
disintegrin domain107. To identify the physiological role of ADAM9 in development, 
knock out mice were created and they developed normally, suggesting that ADAM9 
itself is not essential for development108. Proteolytic substrates that have been 
identified for ADAM9 are the EGFR ligand HB-EGF109, the extracellular matrix protein 
laminin110, and the epithelial adhesion molecule collagen XVII 111. Recently Moss et 
al., identified the family member ADAM10 as substrate for ADAM9112.  
Like most ADAMs, ADAM9 is upregulated in various types of cancer to the extent that 
the ADAM9 levels correlate with cancer progression. In prostate cancer ADAM9 has 
been validated as a prognostic marker. By characterization of 198 patient 
immunohistostainings, Fritzsche et al. found that ADAM9 expression can be used as 
independent marker for disease relapse. They showed high levels of ADAM9 in 
prostate cancer samples from patients which had undergone prostatectomy 
correlated with relapse free survival. High expression levels of ADAM9 and 
aggressive disease progression, were identified in younger patients diagnosed with 
prostate cancer104. In general, ADAM9 is found in several prostate cancer cell lines 
which are androgen independent or dependent113. Overexpression of ADAM9 in the 
androgen dependent prostate cancer cell line LNCaP leads to increased cell survival, 
and knock down of ADAM9  resulted in higher cell death114. Martin et al. identified the 
recombinant disintegrin domain of ADAM9 as anti-adhesive molecule inhibiting cell 
adhesion, migration and invasion via interaction with the integrin α6β1. Furthermore, 
they suggested ADAM9 as key to reduce metastatic spread, when adding an artificial 
ADAM9 disintegrin domain to cells115.  
1.3.4 ADAM10 
ADAM10 is a 748 amino acid type I transmembrane glycoprotein. It was identified by 
Chantry et al. in bovine brain myelin membrane as myelin basic protein (MBP) 
degrading protein116. Lammich et al.  identified the amyloid precursor protein (APP) 
as a substrate for ADAM10.  Cleaved fragments of the APP, such as amyloid β 
peptide (Aβ), are major components of amyloid plaques in Alzheimer’s disease117.  
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ADAM10 was shown to have an important role in Alzheimer’s disease and is also an 
important promotor in prostate cancer. McCulloch et al. showed ADAM10 
overexpression in the androgen dependent prostate cancer cell line LNCaP, and they 
linked increased DHT levels to increased ADAM10 expression118. Importantly, they 
were able to show a translocation of ADAM10 from the plasma membrane in benign 
prostate cancer to the nucleus in advanced prostate cancer102. Notably Arima et al. 
identified ADAM10 as a factor regulating cell proliferation in LNCaPs due to nuclear 
translocation. This translocation from the membrane to the nucleus is androgen 
dependent and is important for tumour progression103. ADAM10 was identified to shed 
E-cadherin, important for cell-cell adhesion, migration, differentiation and tissue 
development, when overexpressed in ADAM10-/- fibroblasts, and HaCaT epithelial 
cells. Shedding of E-cadherin further modulated b-catenin translocation. b-catenin is 
involved in controlling cell proliferation by binding to transcription factors, such as 
lymphocyte enhancer-binding factor 1, regulating c-myc and cyclin D1. Translocation 
of b-catenin leads to enhanced cell proliferation119. In the nasopharyngeal carcinoma 
cell line CNE-2, epithelial-mesenchymal transition (EMT), proliferation and migration 
was significantly reduced upon ADAM10 siRNA knock down120 (Figure 1.6).  
The molecular mechanism leading to cMET shedding upon treatment with the anti-
cMET antibody DN30, inhibiting anchorage independent growth and HGF dependent 
invasion, remained unclear for a long time. Schelter et al. identified that ADAM10 is 
necessary to induce DN30 mediated cMET shedding. Previously, Kopitz et al. 
identified that down-regulation of ADAM10 prevents shedding of cMET in patient liver 
tumour samples with elevated tissue inhibitor of metalloproteinases-1 (TIMP1) levels, 
a known ADAM10 inhibitor121. Shedding of cell surface receptors such as NOTCH 
and Axl, overexpressed in aggressive cancers like glioblastoma or triple negative 
breast cancer, was also identified to be caused by ADAM10. Shedding of NOTCH by 
ADAM10 leads to receptor activation, and results in a remaining transmembrane 
NOTCH fragment. The NOTCH intracellular domain (NICD) is processed by g-
secretase, leading to its translocation to the nucleus, and upregulation of gene 
transcription containing recombinant binding protein suppressor of hairless (RBP-J) 
binding sits84,122. Miller et al., showed that down regulation of ADAM10 by siRNA in 
MDA-MB-231 breast cancer cells, results in reduced soluble Axl in the medium, and 
enhanced surface level. Combined Axl inhibition and ADAM10 knock down results in 
decreased cell growth and proliferation123 (Figure 1.6). 
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1.3.5 ADAM17 
The tumour necrosis factor (TNF) –α converting enzyme (TACE), ADAM17, was 
identified by Moss et al. in 1997. Compared to the structural domains of the ADAM 
family, ADAM17 does not contain the EGF-like and the cysteine-rich domain. Instead, 
it possesses a disulfide-regulated membrane-proximal domain (MPD) and a stalk 
region, the conserved ADAM17 Dynamic Interaction Sequence (CANDIS). Both 
mentioned domains, are important for ADAM17 substrate recognition and binding, 
and further regulate the protease activity via interaction with the plasma membrane124. 
pro-TNF-α is a 26kDa membrane bound precursor form of TNF-α. ADAM17 cleaves 
pro-TNF-α between Alanine at position 76 and Valine at position 77, resulting in a 
17kDa active form125. TNF-α is involved in inflammatory diseases and ADAM17 
cleavage of pro-TNF-α is thought to be a key initiator of inflamation126. ADAM17 is 
further characterized as regulator of immune responses ,due to its function to cleave 
ErbB ligands and their receptors interleukin-6 receptor (IL-6R) and the cell adhesion 
molecules L-selectin and ICAM-195.  
In prostate cancer, ADAM17 was identified as regulator for cell proliferation by Lin et 
al.127. Via shedding of epidermal growth factor receptor (EGFR) - pro ligands, such 
as transforming growth factor – α (TGF-α), it regulates the EGFR/PI3K/AKT signalling 
cascade. Upon EGFR signalling cascade activation, cancer cell proliferation is 
enhanced due to downstream activation of cell cycle coordinators, such as cyclin-
dependent kinases (CDKs). As a result Lin et al. postulated ADAM17 as a promotor 
of prostate cancer progression127. Different from the effect on cell proliferation, 
overexpression of ADAM17 enables cell invasion in androgen independent prostate 
cancer cell lines, DU-145 and PC3. ADAM17 is able to upregulate matrix 
metalloproteinase (MMP)-2 and MMP-9, involved in tumour metastasis. Enhanced 
EGFR-MEK-Erk activation due to ADAM17 overexpression, leads to upregulation of 
MMP-2 and MMP9, enhanced TGF-a media levels, and increased cell invasion of 
DU-145 and PC3 prostate cancer cells128 (Figure 1.6).  
ADAM17 was also identified as a sheddase of RTKs such as Axl and cMET, which 
are highly overexpressed in primary tumours and metatstatsis129,130. Van 
Schaeybroeck et al. identified that inhibition of MEK in KRAS-mutant colorectal 
cancer, caused increased cMET signalling, due to inhibition of ADAM17. Combined 
treatment, including cMET inhibitors, leads to increased apoptosis and decreased 
tumour growth in-vivo131. 
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Figure 1.6 Overview of ADAM10, ADAM17 and ADAM15 functions and their 
consequences in cancer 
Overexpression of ADAM10 (green), ADAM17 (blue) or ADAM15 (red) is linked to disease 
progression in cancer. The proteolytic activity is required and leads to shedding of receptors 
such as cMET, Axl or NOTCH, or ligands such as TGF-a, or cell-adhesion proteins like E-
cadherin or N-cadherin, which all lead to enhanced invasion, migration, proliferation and 
tumour growth. ADAM10 is shed by ADAM15, leading to the translocation of the ICD to the 
nucleus and might be linked to upregulation of gene expression.  
 
1.4 ADAM15 
ADAM15 is a transmembrane multi-domain, multi-functional metalloprotease and is 
upregulated in many cancers. During prostate cancer, the upregulation of ADAM15 
correlates with disease progression132 which is linked to ADAM15s multi-functional 
domain structure81. ADAM15 is involved in reduction of tumour cell adhesion, 
reduction of cell-cell adhesion and further promotes metastatic spread of cells via its 
disintegrin and metalloproteinase domain100. In its function as protease, it is able to 
influence cell signalling via growth factor shedding, which leads to receptor 
activation100. ADAM15 is therefore considered as key player in cancer progression 
and could be an important therapeutic target. 
1.4.1 ADAM15 discovery 
ADAM15 was first described and biochemically analysed by Kraetzschmar et al. in 
1996133. A 2740bp cDNA for ADAM15 was identified with an open reading frame 
encoding a 814 amino acid protein with a calculated molecular weight of 85kDa.  
1.4.2 ADAM15 gene structure 
ADAM15 is localized on chromosome 1q21.3, a region that is often rearranged in 
prostate and breast cancer134.  From translation initiation to the polyadenylation 
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signal, the ADAM15 gene spans a region of 11.4kb. It includes 23 exons and 22 
introns. The exon size varies between 63 to 316bp, whereas the intron size varies 
from 79bp to 1283bp. Exons 19 to 21 encoding the intracellular domain (ICD) of 
ADAM15, are alternatively used and the resulting splice variants have varying 
expression levels in different tissues135. So far, 13 different splice variants have been 
identified135. 
1.4.3 The modular structure of ADAM15 
1.4.3.1 Pro-domain 
The N-terminal pro-domain of ADAM15 consists of the signal peptide, which is 17 
amino acids in length and the pro-peptide consisting of 189 amino acids (Figure 1.7). 
The signal peptide targets ADAM15 to the plasma membrane136. At position 179 of 
the pro-domain, ADAM15 contains a cysteine, which is conserved within the 
metzincin family. The cysteine binds the catalytic zinc ion and due to this, the inactive 
state as a zymogen is maintained. Furin-like endopeptidases, cleave within the pro-
domain causing a structural destabilization, known as the cysteine-switch-
mechanism, and leading to the activation of ADAM1566,78.  
1.4.3.2 Metalloproteinase domain 
The active site of ADAM15 is downstream of the pro-domain and is comprised of 210 
amino acids in total. Within this domain, the zinc-binding motif, the Met-turn, is 
important for metalloproteinase activity of ADAM15 (Figure 1.7). The Met-turn of 
ADAM15 starts from position 376 to 382 with the following one-letter amino acid code: 
CIMEAST137. Tallant et al. reveal the importance of the Met-turn via crystallography, 
which is found in all metzincins metalloproteases138. In a 3D-model the Met-turn is 
directly found below the zinc-binding motif. The Met-turn seems to be important for 
folding as when it was replaced, proteolytic activity was reduced up to 50%138. Tallant 
et al. concluded that the structure of the Met-turn itself maintains the architecture of 
the zinc-binding site due to hydrogen bonds that are formed via the Met-turn. The 
zinc-binding domain of ADAM15 is upstream of the Met-turn and starts at position 
348 to 359 with the following amino acid sequence: HELGHSLGLDHD. The 
underlined structures are conserved within the metzincin family. The histidines (H) 
starting from position 348 enable zinc binding. In more detail, the 3 histidines within 
this domain show a tetrahedral molecular arrangement, an additional H2O molecule 
guides the zinc towards the binding domain. Glutamic acid (E) at position 349 initiates 
catalysis139.  
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1.4.3.3 Disintegrin domain 
The disintegrin domain of ADAM15 spans 90 amino acids. Within the disintegrin 
domain, 15 cysteines are present which are conserved with other ADAMs of the 
metzincin family139. Further, the domain contains an arginine-glycine-aspartic acid 
(RGD) binding motif at position 484-486 (Figure 1.7). This RGD motif is a unique motif 
of ADAM15 among ADAMs, which is also found in snake venom disintegrins and in 
most disintegrin-like proteins139. The disintegrin domain enables ADAM15 to interact 
with intergrins, a family of heterodimeric transmembrane glycoproteins. The binding 
occurs via the disintegrin loop which is conserved in all ADAMs. The disintegrin loop 
ADAM15 starts from position 480 and ends at 493: CRPTRGDCDLPEFC, the 
underlined amino acids are the conserved ones. The RGD-motif within the 
extracellular disintegrin domain enables ADAM15 to specifically bind to αvβ3 and 
α5β3 integrins as Zhang et al. described80, and more over leads to the proposed name 
as metargidin i.e. metalloprotease-RGD-disintegrin protein136. Trochon-Joseph et al. 
showed the importance of the RGD domain of ADAM15, as melanoma cells with 
impaired ADAM15 RGD-motif showed reduced migration and metastasis140.  
1.4.3.4 Cysteine-rich domain 
Within the metzincin family the cysteine-rich domain is linked to membrane fusion and 
regulation of protease function73. However, little is known and published about the 
ADAM15 cysteine-rich domain and its’ function. It starts downstream of the disintegrin 
domain (Figure 1.7) and it comprises in total 12 cysteine-residues. Due to the lack of 
a hydrophobic region within this domain (e.g. ASRPVIGTNAVSIETNIPLQQGGRIL 
for i.e ADAM12141 ), which is essential for ADAM dependent membrane fusion, it is 
debatable whether this domain is linked to membrane fusion142.  
1.4.3.5 EGF-like domain 
The EGF-like domain of ADAM15 is the last functional domain of the ADAM15 ECD. 
The name EGF-like derives from its sequence similarity with epidermal growth factors 
(EGF). It starts with a cysteine (C), contains 29 amino acids and is the shortest of all 
functional domains of ADAM15 (Figure 1.7). The domain is structurally stabilized by 
three disulphide bonds, and shows a β-sheet fold143.  
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Figure 1.7 Overview of the ADAM15 amino acid domain structure 
ADAM15 has a modular structure and is composed of five ECDs, a transmembrane region 
and the ICD. The ECD starts with the signal peptide (amino acid 1-17), targeting ADAM15 
to the membrane and the pro-domain (amino acid 18-212), keeping ADAM15 in an inactive 
state. Downstream (amino acid 213-420), the proteolytic domain, the metalloproteinase 
domain is located. The zinc-binding motif is located within the metalloproteinase domain 
from position 348-359. The Met-turn, upstream of the metalloproteinase domain, is 
responsible for maintaining zinc-binding. The disintegrin domain (amino acid 421-510) 
contains the integrin binding motif RGD (amino acid 480-491), enabling ADAM15 to bind 
αvβ3 and α5β3 integrins. The cysteine rich domain follows form position (amino acid 511 
to 656), however little is known about its function. The last domain of the ECD is the EGF-
like domain (amino acid 657 - 685) enabling ADAM15 to contribute to NOTCH-signalling. 
The transmembrane region (amino acid 686- 711), links ECD and ICD. The ICD of ADAM15 
is subject to alternative splicing. This example shows the amino acid structure of ADAM15-
A, starting from amino acid position 712 and exhibiting proline-rich regions, which enable 
SH3-domain containing proteins to associate.  
 
1.4.3.6 The intracellular domain (ICD) 
The extracellular domain (ECD) of ADAM15 is connected via the transmembrane 
region to the intracellular domain (ICD) (Figure 1.7). The ADAM15 ICD is subject to 
alternative splicing, with 13 splice variants identified, spanning amino acid sequences 
between 772 and 863144. The main difference within the splice variants is the number 
of proline rich regions, which enable ADAM15 to associate with SH3 containing 
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signalling molecules, such as Src-family kinases145. A detailed overview of identified 
ADAM15 interaction partners will be given in section 1.4.5. Tyrosines within the 
ADAM15 ICD are subject to phosphorylation and enable binding with SH2 domain 
containing proteins145.  
Although 13 ICD splice variants have been identified, the focus of this study will be 
on splice variant 2, 4a, 6a, 1 and 5135. These splice variants are from high interest in 
our study as these are the only splice variants which show proline rich binding motif 
within the ICD144, they are expressed within cancerous tissue146, they have been 
linked to functional consequences when overexpressed in breast cancer cells and 
further have have been linked to different disease outcome in patients81. The 
terminology which will be used here, is ADAM15-A (2), ADAM15-B (4a), ADAM15-C 
(6a), ADAM15-D (1) and ADAM15-E (5). All of them differ in their number of proline-
rich regions due to the alternative use of exons 19 to 21. ADAM15-D lacks proline 
rich binding motifs because a frameshift mutation in exon 18 leads to the insertion of 
a premature stop codon resulting in the lack of proline rich regions. ADAM15-C is the 
longest variant, with 863 amino acid and the highest number of proline-rich regions, 
containing exon 19,20a and 21. ADAM15-B and E consist of 839 amino acid and differ 
in the alternative exon use of 20a for B and 21 for E. ADAM15 splice variant A consists 
of 814 amino acid, the alternative exon present is 1981,135. A schematic overview of the 
ADAM15 ICD splice variants is shown in Figure 1.9. 
 
Figure 1.8 Overview of the 13 ADAM15 splice variants 
Alternative exon use of the ADAM15 ICD leading to the presence of 13 splice 
variants. Splice varaints highlighted with the asterisk are the splice variants which 
are subject in this study.  
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1.4.4 ADAM15 alternative exon use of the ICD 
13 different variants of the ICD of ADAM15 have been identified which is due to an 
alternative exon use of 19 to 21135 (Figure 1.9). Kleino et al., described the alternative 
exon use as physiological post-transcriptional mechanism which regulates the 
expression of ADAM15 splice variants in human tissue. The mechanism leading to 
the different splice variants is unknown, however, as splice variants from human, and 
mouse match, it is likely that a common factor regulates the splicing of ADAM15135 
(Figure 1.9). 
As indicated before, the mechanism that gives rise to the 13 different splice variants 
is unknown, however Kleino et al. discussed possible factors that might lead to the 
alternative exon use. They suggested that ADAM15 splicing might be controlled via 
the exonic splice enhancer (ESS) motifs which are flanking exons 19, 20a/b and 21a. 
Kleino et al. postulated a looping out mechanism that regulated the alternative exon 
use, and they based their hypothesis on the presence of heterogenous nuclear 
ribonucleoproteins (hnRNP) binding motifs within exon 19, 20 and 21135. HnRNPs are 
a family of RNA-binding proteins that recognize specific sequences of RNA. They are 
involved in RNA processing and can further act as a factor regulating gene 
expression147. The introns which are next to the exons contain even more ESS motifs 
compared to the exons. The introns further show a number of alternative splicing-
elements, such as FOX, Nova1/2, CELF/BrunoL, MBNL1 and ESACG135. Warzecha 
et al. found that ESRP1 and ESRP2 are also involved in ADAM15 splicing, as they 
regulate enhanced use of exon 20 and 21148. Kleino et al. showed that introns 18, 19 
and 21 contain ESACG binding motifs. ESACG is known to recognize C- and G-rich 
motifs which are found in high numbers in introns 18, 19 and 21 and this is linked to 
exon skipping135. 
Although some splice related elements and regions have been found in the introns 
and exons of the ICD of ADAM15, no potential regulator has been identified. The 
identification of an ADAM15 ICD splice regulator would be helpful as only a few of the 
ADAM15 ICD splice variants are associated with aggressive disease progression in 
cancer. 
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Figure 1.9 Overview of the ADAM15 ICD splice variants. 
(A)Splice variants are shown as used throughout the thesis, with their name, DNA and 
protein sequence number, gene bank variant nomenclature, number of proline rich regions 
and the number of amino acids. (B) The ADAM15 ICD with the corresponding exons 18 to 
23 is shown, from which exons 19 to 21 are alternatively used. (C) The alternative used of 
exons 19 to 21 give rise to the 5 different splice variants, subject of this study, all varying in 
their number of proline-rich regions. ADAM15 splice variant D lacks proline rich regions, 
due to a premature stop codon, upstream exon 19. 
 
1.4.5 Identified interaction partners of the ADAM15 ICD 
The proline-rich regions of the ICD enable the binding of Src homology-3 (SH3) – 
domain containing proteins. The different number of proline-rich regions, impact 
protein binding and might contribute to intracellular signalling, protein regulation and 
cellular function144. Out of the 13 splice variants, ADAM15 ICD splice variants A, B 
and C have been extensively characterized for different association partners, with the 
aim to identify splice variant specific protein/protein complexes.   
Zhong et al. identified equal association of the adaptor proteins Grb2 and Tks5/Fish 
and the serine/threonine kinase ERK to ADAM15 A, B and C. Splice variant specific 
interaction was shown for the adaptor protein NcK, which associates with ADAM15- B 
A
B
C
D
E
PGPPQR	 PAKPPPPRK	 PLPADP	 PSRPAPPPP	
PAPP	SRPLPPDP
PNPPTRPLPADP	
PGPPQR	
PGPPQR	
PGPPQR	
PAPP	SRPLPPDP
PNPPTRPLPADP	
PAKPPPPRK	 PLPADP	
PAKPPPPRK	 PLPADP	
PAKPPPPRK	 PLPADP	
PSRPAPPPP	
PSRPAPPPP	
PSRPAPPPP	
18 22 2319 20 21
ADAM15	ICD	exons
Splice	
variant
Kleino et	
al.	
DNA	variant	
sequence
Protein
sequence
Gene	Bank	
variant
Proline- rich	
regions
Amino	
acids
A 2 NM003815.4 NP003806.3 2 3 814
B 4a NM	207194.2	 NP	997077.1	 3 4 839
C 6a NM	207196.2	 NP	997079.1	 5 5 862
D 1 NM	207191.2	 NP	997074.1 1 0 772
E 5 NM	207195.2	 NP	997078.1	 4 4 838
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and C but not with A. Src associates strongly with B and C but shows only weak 
interaction with ADAM15 A. Another tyrosine kinase, PTK6, was found to associate 
with A and B but not with C81. Poghosyan et al. identified the association of ADAM15-
A with Src family kinases Lck and Hck. Here, the binding via the SH3 domains for Lck 
is the main factor leading to the association, however phosphorylation of ADAM15 
seems to be required. Next to the SH3-domains, Hck possesses an SH2-domain, 
allowing binding to phosphorylated tyrosines. Upon ADAM15 phosphorylation Hck 
showed enhanced binding145. This finding was also confirmed by Yasui et al., which 
validated the phosphorylation dependent interaction between ADAM15 and Lck and 
further showed that ADAM15-C binds Lck and Hck upon ADAM15 phosphorylation149. 
To enable the screening of more association partners for ADAM15 ICD splice 
variants, Kleino et al. used the yeast two hybrid approach and identified the sorting 
nexins SNX33 and SNX9 as strong interaction partners for ADAM15-A and C. For 
ADAM15-C they also identified Nephrocystin and the Src family kinase member 
Lyn144. They also identified Neutrophil cytosolic factor 1 (NCF1) (I), Osteoclast-
Stimulating Factor 1 (OSTF1) and the adaptor protein p85α 150. An overview of 
published, identified interaction partners of the ADAM15 ICD is shown below (Table 
1). 
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Table 1 Overview of identified ADAM15 ICD interaction partners 
 
 
1.4.6 Substrates for ADAM15 
Via its metalloproteinase domain ADAM15 is able to proteolytically process cytokines, 
growth factors and membrane bound receptors151,152. 
Until now 11 substrates for ADAM15 have been identified (Table 2). The first ADAM15 
substrate was identified by Martin et al. in 2002. They identified collagen IV as 
ADAM15 substrate in human mesangial cells. They showed that ADAM15 is able to 
proteolytically process collagen IV in a dose dependent manner, and this effect could 
only be inhibited with EDTA. They concluded that ADAM15 might have a significant 
role in mesangial cell migration due to processing of collagen IV153. To further identify 
ADAM15 specific substrates Fourie et al. screened a library of synthetic peptides and 
found the CD23 receptor as a substrate. Soluble CD23 is a ligand for the IgE receptor, 
which is known to be involved in inflammatory diseases when overexpressed154. 
However, the tissue distribution of ADAM15 and CD23 do not correspond to each 
other. They concluded that although CD23 is an ADAM15 substrate, it is more likely 
to be processed by other ADAMs151.  Maretzky et al. identified  fibroblast growth factor 
receptor 2iiib (FGFR2iiib) as a substrate for ADAM15, although the physiological role 
in this proteolytic event is unclear155. ADAM15-B contains an additional Src-binding 
domain in contrast to A and interaction enhances the proteolytic activity of ADAM15-
B which could be inhibited by Src-inhibitors such as PP1, PP2 and dasatinib156. They 
concluded, that Src inhibition could be used in patients who display overexpression 
Src Family	
kinases Sorting	Nexin Tyrosine	kinases
Serine/
Threonine	
kinases
Adaptor	Proteins	 other
Lck
Poghosyan
(2002),	Yasui
(2004)
SNX9 Kleino(2009) PTK6
Zhong
(2008) Erk
Zhong	
(2008) Grb2
Poghosyan
(2002) Nephrocystin
Kleino
(2009)
Fyn Poghosyan(2002)
SNX18	
(SH3PX1) 
Howard	
(1999) Btk
Kleino
(2015)
Tsk5/
Fish
Zhong	
(2008) Endophilin 1
Howard	
(1999)
Abl Poghosyan(2002)
SNX33	
(SNX30)
Kleino
(2009) Nck
Zhong	
(2008)
Intersectin 1	
(III)
Kleino
(2015)
Src Poghosyan(2002)
Tks5	
(V) 
Kleino
(2015) NCF1
Kleino
(2009)
Hck* Yasui (2004) Tks5	(I) Kleino(2015) OSTF1
Kleino
(2015)
Yes Karkkainen(2006)
p85α	
(PIK3R1) 
Kleino
(2009)
*association	via	
SH2	
28 
 
of ADAM15-B81,156. They further investigated possible substrates, such as the 
membrane bound EGFR ligands ampiregulin, betacellulin, TGF-α, and TNF-α. 
However, ADAM15 was unable to cleave these substrates155. Dong et al. found that 
ADAM15 is able to enhance lung cancer cell invasion. The presence of ADAM15 
induced MMP9 overexpression via activation of the MEK-ERK pathway.  ADAM15 
cleaved pro-MMP9 to the active form MMP9, thus enhancing cell invasion and 
metastasis. Thus, ADAM15 is able to induce cell migration in lung cancer via MMP9 
activation 157 (Figure 1.6).  
Although Maretzky et al. showed that ADAM15 cannot cleave amphiregulin or TGF-
α and TNF-a, Schäfer et al. showed that ADAM15 is involved in EGFR signalling via 
cleavage of pro-amphiregulin and pro-TGFα enabling EGFR signalling158. Hart et al. 
showed that ADAM15 is able to shed pro-heparin-binding EGF-like growth factor (pro-
HB-EGF) which induced thrombin related EGFR phosphorylation. Upon ADAM15 
knock down, they showed that the EGFR phosphorylation is reduced159. 
Najy et al. described that ADAM15 is involved in processing of the adhesion molecule 
CD44 and the integrin αv, as ADAM15 expression correlated with less detectable 
amount of both molecules105. They further showed that the expression of αv integrin 
was reduced in cells expressing ADAM15, which might indicate a role of ADAM15 in 
reducing cell interactions with the extracellular matrix leading to disease progression 
and metastatic spread. 
Duan et al. identified major histocompatibility complex class I polypeptide-related 
sequence B (MICB) as an ADAM15 substrate. Upregulation of MICB is observed in 
lung, prostate, breast and kidney cancer, although it is usually restricted to the 
gastrointestinal tract160. 
ADAM15 is not only able to cleave growth factors or receptors, but also other ADAMs. 
One ADAM that is an ADAM15 substrate is ADAM10. Tousseyn et al. published that 
ADAM15 mediates ectodomain shedding of ADAM10. ADAM15 cleaves ADAM10 
from the membrane and ADAM10 ectodomain is released, thus modifying cell 
signalling events that require cell surface associated ADAM10, such as NOTCH, 
APP, cMET and Axl161 (Figure 1.6).  
Although substrates have been identified up until recently no selective ADAM15 
metalloproteinase inhibitor was available. In 2016 Hiles et al. showed that after 
administration of the selective inhibitor for the ADAM15 metalloproteinase function, 
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adamastat, cell viability was reduced in bladder cancer162. They further showed, that 
via administration of adamastat, bladder tumour growth was reduced in mice.   
Table 2 Overview of identified ADAM15 substrates 
 
 
1.4.7 ADAM15 splice variants as biomarkers  
Alternative use of exons can be used as prognostic marker in cancer, as alternative 
splice variants are linked to oncogenic function163.  
In 48 breast cancer patients, Zhong et al., compared the expression level of ADAM15-
A, B, C and D, against healthy control tissue. A significant increase was found for 
mRNA levels of ADAM15-B and C, however not for A and D. In a follow up study, 
they investigated expression levels of ADAM15-A, B and C, in 229 breast cancer 
patients. Upon correlation of expression levels with age, tumour size and grade, 
menopausal status, hormone receptor expression and node status, ADAM15 
expression levels could not be linked to any of those. However, when patients were 
grouped based on mRNA expression for ADAM15, overexpression of ADAM15-A and 
B were linked to poor prognosis for patients, without lymph node metastasis. 
However, lymph node metastasis and overexpression of ADAM15-C, patients’ 
prognosis was positive81. Zhong et al. concluded, that ADAM15 splice variant 
expression levels could affect disease outcome in breast cancer patients. 
Maretzky et al., showed that the additional proline-rich region present in ADAM15-B 
allows Src to bind leading to enhanced proteolytic activity of ADAM15-B compared to 
A156. 
Substrate
Collagen IV Martin	(2002)
E-cadherin Najy (2008)
Pro-Amphiregulin,	
Pro-TGFa
Schafer (2004)
Pro-HB-EGF Hart	(2005)
CD23 Fourie (2003)
FGFR2IIIb Maretzky (2009)
ADAM10 Tousseyn (2009)
Pro-MMP9 Dong	(2015)
MCIB Duan (2013)
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Therefore, ADAM15-B overexpression in breast cancer could be treated by Src 
inhibitor to reduce FGFR2iib shedding in these patients, which might provide a new 
therapeutic approach. 
1.5 Protein Tyrosine kinases 
Intra- and extracellular phosphorylation of protein tyrosines is a strictly regulated post-
translational process, and is used as signal transduction within eukaryotes. Proteins 
that execute phosphoryl-transfer, i.e. the transfer of a phosphate group to a tyrosine, 
by using phosphoanhydrates, such as adenosine triphosphate (ATP) are called 
Protein Tyrosine kinases (PTKs). PTKs are a multiprotein family and essential 
mediators of signal transmission for cellular processes such as growth, metabolism 
or apoptosis164,165. They have been identified to contribute to diseases including 
cancer. Within the human genome 90 genes have been identified, exclusively 
encoding PTKs which can be divided into two classes, the transmembrane receptors 
known as receptor tyrosine kinases (RTK) with 20 subfamilies, and the intracellular 
kinases, PTKs with 10 subfamilies. Of the 90 tyrosine kinase genes, 58 encode for 
RTKs, and 32 encode for PTKs166.  
1.6 RTKs 
RTKs are type I single-pass transmembrane receptors.  Their function relies on the 
kinase domain, located in the intracellular domain. With the exception of the insulin-
receptor (IR), the RTKs are single transmembrane proteins, which are able to form 
non-covalent dimers. The IR family-members, insulin-like growth factor I-receptor 
(IGF-IR) and insulin receptor-related receptor (IRR), are expressed as single unit, 
however, they undergo processing into α and β polypeptides. These can assemble 
into a heterotetramer, consisting of 2 α and 2 β units, or into a homodimer, linked by 
disulfide bonds167. 
1.6.1 RTK modular organization 
Generally the RTKs consist of 3 domains, the N-terminal extracellular domain (ECD), 
the transmembrane region and the C-terminal intracellular domain (ICD). The ECD is 
variable in length and composed of different structural domains, thus leading to 20 
distinct subclasses. Domains that are present within the 20 subclasses are, leucine-
rich domains, cysteine-rich domains, immunoglobulin-like domain, EGF-regions, 
type-L domain, Ephrin binding-domain, furin-like domain or fibronectin type III 
domains (Table 3). Within the ECD there are multiple disulfide bonds and N-linked 
glycosylation sites. The variability of the ECD enables high specificity for ligands such 
as growth factors. ECD and the C-terminal ICD are linked by a transmembrane 
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hydrophobic region. The ICD contains the conserved kinase domain, which is flanked 
by tyrosine residues, and a C-terminal tail. Both the tyrosine kinase domain and the 
tail, differ in size and tyrosine residues within the RTK family. Especially the total 
number of tyrosines is variable, for instance the EGFR family shows the highest 
number of tyrosine residues, with 20, of which 12 can be phosphorylated167. The ATP-
binding site of the kinase domain is surrounded by N-lobe and C-lobe, and becomes 
accessible upon RTK activation.  
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Table 3 Overview of the 20 RTK family members 
 
Receptor	 tyrosine	kinase-
family	name Family	members ECD-characteristics
EGFR	(epidermal	growth	factor	
receptor) EGFR, ERBB2, ERBB3, ERBB4 2	cysteine-rich	 domains
IR	(insulin	receptor) INSR, IGF-1R, IRR 2	chains	α	and	β,	one	cysteine	rich	and	2	FNII	domains
PDGFR	(platelet-derived	growth	
factor	receptor)
PDGFR-a, PDGFR-b, CSF-1R,
KIT/SCFR, FLK2/FLT3 5	Ig-like	domains
VEGFR	(vascular	endothelial	
growth	factor	receptor) VEGFR1, VEGFR2, VEGFR3 7	Ig-like	domains
FGFR	(fibroblast	growth	factor	
receptor)
FGFR-1, FGFR-2, FGFR-3, FGFR-3,
FGFR-4 3	Ig-like	domains,	1	acidic	box
KLG/CCK	(colon	carcinoma	kinase) CCK4 7	Ig-like	domains
NGFR	(nerve	growth	factor	
receptor) TRKA, TRKB, TRKC
2	Ig-like	domaisn,	leucin-rich	
domains
HGFR	(hepatocyte	growth	factor	
receptor) MET, RON
1	transmembrane	 α-chain,	linked	
with	one	ICD	β-chain
EPHR		(ephrin receptor)
EPHA1, EPHA2, EPHA3, EPHA4,
EPHA5, EPHA6, EPHA7, EPHA8,
EPHB1, EPHB2, EPHB3, EPHB4
EPHB5, EPHB6
1	Ig-like,	1	cysteine-rich,	 and	2	
FNIII-like	domains
AXL	(a	Tyro3	PTK) AXL, MER, TYRO3 2	Ig-like,	2	FNIII-like	domains
TIE	(tyrosine	kinase	receptor	in	
endothelial	cells) TIE, TEK
2	Ig-like,	1	1	EGF,	and	3	FNIII-like	
domains
RYK	(receptor	related	to	tyrosine	
kinases) RYK
1	transmembrane	 β-chain,	 linked	
with	one	ECD	α-chain
DDR	(discoidine domain	receptor) DDR1, DDR2 1	discoidin-like	 domain
RET	 (rearranged	during	
transfection) RET 1	cadherin-like	 domain
ROS	 (PPTK	expressed	in	some	
epithelial	cell	types) ROS 6	FNIII-like	domains
LTK	(leukocyte	tyrosine	kinase) LTK 1	cysteine-rich	 domain
ROR	 (receptor	orphan) ROR1, ROR2 1	Ig-domain,	1	cystein-rich	domain,	 1	kringle-like	domain
MUSK	(muscle-specific	kinase) MUSK 4	Ig-like	and	1	cysteine-rich	domain
LMR	(Lemur) AATYK, AATYK2, AATYK3, ALK a	short	 ECD
NN	(not	named) RTK106 A	short	 receptor	 chain	with	a	short	ECD
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1.6.2 RTK activation 
RTKs become activated upon ligand binding to the extracellular binding domain. The 
ligand is able to concurrently interact with two receptor monomers, which leads to 
dimer formation168. The dimerization of the RTKs leads to the juxtaposition of the 
intracellular tyrosine kinase domains, subsequently inducing trans-
autophosphorylation of tyrosines, revealing the nucleotide and substrate binding-
sites. Within the RTK family there are four distinct activation mechanism. For instance 
EGFR-family RTKs are activated upon growth factor binding which reveals a 
dimerization arm, exposed after domain rearrangement, leading to receptor 
dimerization169. PDGFR-family RTKs, such as KIT, dimerize upon ligand binding to 
the D1-D3 Ig-like ECD-domains. D4-D5 Ig-like domains of the KIT-ECD undergo a 
sterical change upon dimerization, leading to kinase activation170. FGFR-family RTKs, 
dimerize by contact of two FGFR monomers via their ECD Ig-like D2 domain, which 
is accompanied by accessory proteins, such as heparin, and additionally the FGFR-
ligand FGF bound to D2 and D3 Ig-like domains171. NGFR-family RTKs dimerize upon 
ligand binding. The ECD of both monomers does not contact one another, the 
monomers are linked via Ig-like C2 domains binding to the ligand172. To summarize, 
RTK dimerization is either exclusively ligand mediated, without prior receptor contact, 
or the ligand leads to direct binding of the receptor monomers. However, in some 
cases, receptor dimerization can involve a combination of both173. The essential 
function of RTK dimerization and trans-autophosphorylation is the generation of 
cytoplasmic ligand binding sites for downstream signalling- or adaptor-proteins 
containing Src homology-2 (SH2) domains, phosphotyrosine binding sites (PTB) or 
phosphotyrosine recognition domains, and the activation of the receptor enzymatic 
function, as tyrosine kinase174,175.  
1.6.3 The HGFR family 
The hepatocyte growth factor receptor (HGFR) family comprises two family members, 
the macrophage stimulating protein receptor, recepteur d’origine Nantais (RON), and 
the hepatocyte growth factor receptor (cMET) (Table 3).  RON and cMET showing 
25% sequence homology of the ECD and 63% sequence homology within the ICD176. 
The ligands of cMET and RON also show 45% sequence homology. The RON ligand 
is the hepatocyte growth factor receptor-like (HGF-like) protein secreted by 
hepatocytes, whereas the cMET ligand is HGF and secreted by mesenchymal cells. 
cMET was identified in 1995 by Humphreys et al., expressed in androgen 
independent prostate cancer cell lines, DU145 and PC3, with lower expression in 
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LNCaPs. However, upon androgen deprivation, cMET expression was upregulated in 
LNCaPs. They identified cMET in 45% of patients’ prostate carcinoma, and it was 
significantly overexpressed in patients with metastatic growth177. 
1.6.3.1 cMET 
The cMET receptor, predominantly expressed on epithelial tissue, was identified by 
Giordano et al. in 1988. They described it as 190 kDa tyrosyl phosphoprotein, a 
product of the c-met proto-oncogene located on chromosome 7q21-31178,179. cMET is 
synthesised as 190 kDa precursor, in the post-Golgi compartment, and is cleaved into 
an extracellular 50kDa α-subunit and a transmembrane 145kDa β-subunit. Both 
subunits become glycosylated, which is essential for formation of the mature αβ-
heterodimer linked by disulfide bonds.  
The ECD is composed of a semaphorin (Sema) domain, a plexin-sema-integrin (PSI) 
domain and four Ig-like domains also found in plexins, semaphorins and 
transcriptional factors (IPT) domains. α-chain and β-chain are linked via the Sema 
domain. The ICD contains a juxtamembrane region with a serine at position 975 and 
a tyrosine at amino acid position 1003. Both residues keep the cMET kinase in an 
inactive state. Downstream of the juxtamembrane domain, the catalytic domain is 
situated, containing the tyrosine residues 1234 and 1235, which are able to modulate 
the kinase activity. Towards the C-terminal end, the multi-adaptor protein docking site 
is located containing the terminal tyrosines at position 1349 and 1356180 (Figure 1.8). 
1.6.3.1.1 The cMET ligand HGF 
HGF was identified by Nakamura et al.  in 1989 as unknown hepatotrophic factor181, 
and by Weidner et al. in 1991, as Scatter factor (SF)182. They were able to isolate 
HGF via heparin-affinity chromatography from rat platelets as HGF shows high affinity 
for heparin. By SDS-PAGE they were able to identify a 84 kDa band. However, under 
reducing conditions a 69 kDa, the α-chain, and 34 kDa band, the β-chain, were 
detectable, indicating a dimeric molecule linked by disulfide bonds183.  The hepatocyte 
growth factor (HGF) belongs to the plasminogen family and is secreted by 
mesenchymal cells as inactive matrix-associated precursor, pro-HGF. It is involved in 
embryogenesis, cell scattering, cell motility, morphology, cellular invasion, 
angiogenesis and mitogenesis177. 
It is proteolytically processed into a two chain protein by the HGF-activating serine 
protease (HGFA) to the mature HGF (Figure 1.8). The serine protease, matriptase, 
involved in the proteolytic cleavage of pro-HGF was identified by Shimomura et al. in 
1997184. HGF consists of a N-terminal hairpin loop domain, followed by four kringle 
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domains, K1-K4, the α-chain, and the C-terminal β-chain domain consisting of a 
serine protease homology (SPH) domain. HGF α and β-chain are formed by cleavage 
of the linker between the K4-domain and the SPH-domain. The single chain pro-HGF 
is able to bind to cMET, however, this does not activate the receptor180,185. There is 
an ongoing discussion in literature, whether the α or β-chain lead to receptor 
activation186,187. 
1.6.3.1.2 cMET activation  
The Sema domain of the cMET receptor is responsible for HGF binding, which leads 
to receptor dimerization and trans-phosphorylation of the tyrosine residues 1234 and 
1235 in the active site.  Additionally, the multiple binding site (MBS) tyrosines, 1349 
and 1356 become phosphorylated. The docking site enables protein binding of SH2 
domain containing adaptor proteins such as growth factor receptor-bound protein 2 
(Grb2), Grb2-associated adaptor protein (Gab1), phospholipaseC-γ, son of sevenless 
(SOS), the adaptor protein Shc, Src homology protein tyrosine phosphatase 2 (Shp2), 
phosphatidylinositol-3-kinase (PI3K), SH2 domain containing inositol phosphatase-1 
(Ship1), and signal transducer and activator of transcription 3 (STAT3) 188–190. 
Proteins associating to the cMET docking motifs activate downstream signalling 
pathways, inducing cell proliferation, invasion, migration, such as the Erk/MAPK and 
STAT3 pathway or they induce survival upon PI3K/Akt activation.  
Although HGF is the only known ligand for cMET, activation of cMET can occur in 
different ways. Conrotto et al., showed that cMET is able to interact with plexins via 
its Semaphorin domain, in a ligand independent manner191. Plexin B1 associates with 
cMET via the extracellular semaphorin domain. Upon binding to plexin B1, cMET 
becomes transphosphorylated, leading to cell invasion and proliferation. Trusolino et 
al. identified that upon HGF activation of cMET, α6β4 becomes phosphorylated and 
associates with PI3K and Shc, multiplying the cMET signaling, enhancing cell 
invasion192. Orian-Rousseau et al. identified that the CD44 splice variant v6 enables 
HGF activated cMET to be linked to the actin cytoskeleton via Grb2 and SOS, leading 
to Ras-ERK signalling193.  
cMET activation via RTK crosstalk has been extensively investigated in the literature. 
It is especially important in tumour resistance to treatment interventions. In the 
absence of HGF, cMET is able to interact with EGFR after ligand stimulation of EGFR 
with TGF-α and EGF194. cMET is also known to interact with RON195, PDGFR-α and 
Axl196, leading to transphosphorylation and activation of cMET in the absence of HGF. 
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To control cMET downstream signalling within the cell, protein tyrosine phosphatases 
(PTP) dephosphorylate tyrosines at the catalytic site or at the docking site, leading to 
kinase inactivation197. 
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Figure 1.10 The cMET/HGF signalling cascade 
(A) Schematic structure of cMET, top, and HGF, bottom. cMET consists of 3 ECDs and two 
ICDs, connected via a transmembrane region. (B) HGF, is synthesized as inactive 
precursor pro-HGF. Via the serine protease HGFA, it becomes activated. (C) cMET is 
present in the cell as monomer (1). HGF activation by HGFA, enables HGF binding to the 
sema-domain of cMET (2), inducing the dimerization of cMET and downstream 
transphosphorylation of the cMET kinase domain. The cMET transphosphorylation enables 
the association of downstream signalling mediators to the multidocking site (3), such as 
Gab1, Grb2, PI3K or STAT3. Gab1 further allows binding of multiple proteins, when bound 
to cMET. Association of proteins to the mutidocking site leads to induction of survival, 
invasion, migration or proliferation. Association of Cbl to P1003, upstream of the kinase 
domain, leads to lysosomal degradation of cMET. 
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1.6.3.1.3 The cMET adaptor proteins Grb2 and Gab1 
Growth factor receptor bound protein 2 (Grb2) and Grb2 associated binding protein 1 
(Gab1) are important regulators of cMET signalling, however they do not have 
enzymatic activity themselves198. The C-terminal MBS of cMET from position 1344 to 
1361 includes the Grb2 and Gab1 binding phosphotyrosines Y1356 and Y1349, 
allowing them to associate and initiate key signalling pathways involved in cell 
invasion, proliferation, migration or cell cycle progression199 (Figure 1.8). 
Grb2 is a 25kDa protein, containing one SH2 domain, flanked by two SH3 domains 
at the C- and N-terminus. Via its SH2 domain, Grb2 can associate directly with RTKs, 
such as cMET, and via its SH3 domain, it can bind proline rich regions200. Grb2 can 
associate directly with cMET at Y1349, or indirectly via Gab1201. When bound to 
cMET, Grb2 can induce invasion of tumour cells via the interaction with son of 
sevenless (SOS), which links this complex to membrane bound RAS. SOS activates 
RAS by GDP/GTP exchange enabling the RAS mediated activation of RAF 
(MAPKKK), which leads to downstream activation of MEK (MAPKK) and Erk (MAPK) 
phosphorylation202–204 (Figure 1.10). This leads to Erk translocation to the nucleus 
enabling the control of gene transcription, cell proliferation and cell motility197. 
Inhibition of the Grb2 SH2-domain leads to decrease in cell motility, due to decreased 
Grb2 localization to the membrane in A-341 epidermoid carcinoma cells205. 
Gab1 belongs to a group of proteins that are substrates for RTKs such as cMET. 
Gab1 has an N-terminal PH-domain targeting it to the plasma membrane, and a 
central phosphotyrosine binding (PTB) domain enabling the association with RTKs. 
Lock et al., identified a unique 13 amino acid sequence, enabling the direct binding 
to cMET, MET binding site (MBS)206. Binding to cMET initiates Gab1 phosphorylation 
and the recruitment of Gab1 adaptor proteins, such as Shp2, PI3K, or PLC-g via their 
SH2 domains. Adaptor protein recruitment to cMET leads to activation of the 
MAPK/Erk pathway. Schaeper et al., identified the importance of the Gab1-Shp2 
coupling to activate the MAPK/Erk pathway, as only Shp2 binding to Gab1 in MDCK 
cells induced branching morphology207. Grb2 can associate with cMET via the SH2 
domain and binds Gab1 via SH3 stabilizing the Gab1-cMET association207. Disruption 
of Grb2 association to Y1349 in mice was found to reduce presence of limb muscle208.  
1.6.3.1.4 cMET endocytosis and degradation  
cMET signalling is terminated by endocytosis, which involves invagination of the 
plasma membrane resulting in vesicl formation. It involves rapid internalization upon 
activation and transport to the lysosome leading to degradation. Endosomal signalling 
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of cMET is an important regulator of cell function, and further enables the direct 
transport of the cMET complex to its intracellular targets209. 
Binding of HGF leads to cMET dimerization and recognition by clathrin, present at the 
cell membrane. The recognition via clathrin follows the rapid internalization of cMET 
into clathrin coated vesicles, called peripheral endosomes189. cMET trafficking from 
the peripheral endosomal compartment to the perinuclear compartment to the Golgi, 
is guided by the microtubule network, and is mediated by protein kinase Cα (PKCα) 
210. The internalization and degradation of cMET can be inhibited by the proteosomal 
inhibitor lactacystin211. Within the endosomal compartment, cMET remains active. 
The active state of cMET is required for full activation of the ERK1/2 and Rac-1 
pathways. Activated ERK1/2 relocates to the plasma membrane and associates with 
the focal adhesion complexes. The regulator for ERK1/2 and Rac-1 relocation is 
PKCε.  This leads to the formation of lamellipodia, resulting in the HGF/cMET induced 
cell migration, mediated by PKCε. Alongside the microtubule network, cMET traffics, 
guided by PKCα, from the early endosomal compartment, to the perinuclear 
compartment leading to the accumulation and translocation of STAT3212. 
A different way of cMET signal termination is the binding of casitas B-lineage 
lymphoma (c-Cbl) to tyrosine 1003 located at the juxamembrane domain of cMET, 
leading to ubiquitination and endocytosis. Endocytosis leads to accumulation of cMET 
in multivesicular bodies, which subsequently fuse with the lysosome leading to 
degradation of cMET. The point-mutations D1246N and M1268T within the tyrosine 
kinase domain of cMET lead to cMET being constitutively recycled and relocalized to 
the plasma membrane. Jeffers et al. justified this finding, with a change in receptor 
conformation altering the association of SH2-binding proteins, such as c-Cbl213.  
Degradation of cMET can also be induced via proteolytically active transmembrane 
proteins, such as ADAMs. ADAM10 and 17 cleavage of cMET results in an 
extracellular domain fragment, known as ‘decoy’ fragment, able to interfere with 
dimerized cMET leading to impaired signalling214. Proteolytic cleavage can be 
enhanced by phorbol esters, such as PMA214. Further processing of cMET is 
performed intracellularly by γ-secretase. The generated fragment is internalized and 
degraded within proteasomes215. 
1.6.4 The cMET/HGF axis  
1.6.4.1 Physiological activity 
cMET is essential for normal development, as it is a key promotor of morphogenic 
differentiation and tissue remodelling. Using knock out of cMET in a cell model, 
40 
 
Schmidt et al. and Ebens et al., showed that cMET is important for cell migration, liver 
and placental development216,217. Knock out mice embryos showed reduced liver and 
size, and reduced placental size, which led to death of embryos in utero. Liver or 
kidney damages also require cMET activation and signalling, which was shown in a 
liver cirrhosis and renal fibrosis patient study conducted by Tsubouchi et al. and 
Nakamura et al.218,219. Patients showed increased cMET signalling due to increased 
HGF expression, which leads to the conclusion that the cMET/HGF axis is involved 
in tissue regeneration in those patients.  
Expression of cMET in haematopoeitic cells is needed to regulate immune functions. 
Galimi et al. showed that HGF is able to induce cell migration and secretion of 
cytokines in monocytes, and further, it can activate monocytes to secrete HGF, in an 
autocrine manner220. Van der Voort et al. identified cMET/HGF axis as regulator of B-
cell adhesion, since upon HGF stimulation, integrin-mediated adhesion to fibronectin 
and VCAM-1 was enhanced. They concluded, that HGF was able to induce migration 
and morphogenic response of B-cells221. 
In a recent study, Baek et al. showed that the HGF/cMET axis is able to induce 
dendritic cell migration in the skin222. They showed that cMET signalling was required 
to initiate dendritic cell release from the soft tissue, to reach the draining lymph node, 
maintaining immune function of the skin, where it regulates MMP2 and 9 activity, 
which in turn enables dendritic cells to migrate through the ECM222.  
1.6.4.2 cMET in cancer as a therapeutic target 
cMET mutations, translocations, amplifications and transcriptional upregulation, or 
ligand independent signalling are the key principles of cMET contributions to 
tumourgenesis223. There is a need to develop tumour therapies that allow blockage 
of the cMET downstream signalling pathways in cancer. 
Cooper et al. identified cMET as oncogene in an osteosarcoma cell line224. cMET was 
fused to the translocating promoter region (TPR) leading to cMET overexpression. 
When expressed in an animal model, TPR-cMET leads to multiple mammary tumour 
formation225. Additionally, TRP-cMET translocation was found in 22 gastric carcinoma 
patients226. 
Gene amplification of cMET is found in many metastatic tumours such as in liver, 
prostate, and oesophageal carcinomas, however, not in primary tumours, indicating 
that cMET amplification might be a gain-of function during cancer progression. 
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Amplification of cMET in lung cancers shows treatment resistance to EGFR inhibitor, 
which might be an indication for a combined drug treatment in those patients180. 
Although genetic alterations, such as translocations, play a role in dysregulation of 
the HGF/cMET axis in cancer, cMET transcriptional upregulation without gene 
amplification is the most common. Hypoxia is one cause of cMET transcriptional 
upregulation, as the transcription factor hypoxia inducible factor 1α (HIF1α) activates 
the cMET promoter, leading to increased transcription227. cMET transcriptional 
upregulation can be particularly induced by the HGF ligand itself228. 
In cancer, ligand dependent activation of cMET is based on an autocrine HGF-loop. 
Tumour cells are able to overexpress cMET and HGF simultaneously, leading to 
constitutive autocrine cMET activation. Cancers that have been identified with 
autocrine cMET activation are breast, lung, osteosarcomas, and prostate cancers, 
which has been linked to a poor patient prognosis180,229–231. 
Based on the evidence provided previously, cMET and HGF present valid clinical 
targets in various solid cancers, where increased signalling via this axis has been 
identified to contribute to rapid tumour growth and metastasis. 
Monoclonal antibodies, targeting HGF have been tested in clinical settings; one of 
those is Rilotumumab (AMD-102), a monoclonal IgG2 antibody (Figure 1.11). It 
neutralizes HGF upon binding and further prevents downstream signalling. 
Rilotumumab is supposed to have antineoplastic potential, leading to tumour cell 
apoptosis. Phase I/Ib (NCT01791374) studies showed a 70% increase in relapse free 
survival for 8 to 40 weeks in patients with advanced-carcinomas and lymphomas 
232,233. However, in glioblastoma patients, Rilotumumab treatment in 60 patients was 
ineffective234. 
Onartuzumab (MetMAb), is a monoclonal antibody, which binds to the sema-domain 
of cMET, inhibiting HGF binding to cMET, receptor dimerization and downstream 
activation. In a phase II study, 137 NSCLC patients did not show a significant 
difference on Onartuzumab monotherapy. However, combined treatment with the 
EGFR inhibitor erlotinib significantly increased the survival to 2.9 months235 (Figure 
1.11). 
An obvious target site to block cMET is the tyrosine kinase domain. However, the 
challenge here is the high degree of homology of the ATP binding site across different 
families and thus existing tyrosine kinase inhibitors (TKIs) are either non-selective 
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and broad spectrum, or MET-selective and both TKI sets may have advantages or 
disadvantages in cancer therapy, which will be discussed below.  
The non-selective TKI cabozantinib, inhibits a broad spectrum of TKs such as, 
VEGFR, AXL, TIE2, RET and cMET. Cabozantinib (Cabometyx, Exelixis, Inc.) was 
approved by FDA and EMA in 2016 for treatment of medullary thyroid cancer and 
advanced renal cell carcinoma236. The administered form of cabozantinib is the s-
malate salt, which is orally bioavailable, and was used in patients with metastatic 
thyroid cancer, where an application of a daily dose 140 mg showed a 28% response 
rate and increased relapse free survival in 47% of patients for more than 14 
months237. Currently cabozantinib is in clinical trials for triple negative breast 
(NCT01738438) and metastatic prostate cancer (NCT01834651). 
A selective MET TKI is tivantinib (Figure 1.11), the most developed and extensively 
studied TKI until now. It is orally bioavailable and has an anti-neoplastic effect. It binds 
to unphosphorylated, inactive cMET, and inhibits cMET autophosphorylation. This in 
turn leads to disruption of the signalling pathway, leading to apoptosis, decreased 
invasion and reduction of angiogenesis238. In a Phase I clinical trial, tivantinib was 
able to reduce cMET phosphorylation, and reduced circulating tumour cells in 30% of 
patients239. A study in NSCLC showed that patients with KRAS mutations responded 
better to combined tivantinib and erlotinib (EGFR-inhibitor) treatment, as patient 
relapse free survival was increased to 3.8 months, compared to the 2.3 month survival 
of the control group240. 
Broad spectrum inhibitors are more effective in clinical trials than selective MET 
inhibitors. Therefore, the broad spectrum inhibitors are approved by EMA and FDA 
for thyroid and renal cancer. 
As discussed, primary PCa is androgen-dependent and usually treated with androgen 
ablation therapy or surgery241. However, metastatic PCa is androgen-independent 
and other treatments have to be applied. RTKs play a role in disease initiation, 
progression, metastasis and tumour growth, which is why TKIs gained compliance as 
effective treatment option35,242,243.  
The most successful applied chemotherapeutic drugs for metastatic PCa are 
Docetaxel244, the second generation taxene Cabazitaxel245, or Estramustine246 to 
mention only a few. Taxenes such as Docetaxel or Cabazitaxel, or the alkylating 
agent Estramustine are antimitotic drugs and act on microtubule formation by 
promoting the assembly and inhibiting the disassembly of microtubules. Inhibition of 
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microtubule disassembly leads to the stabilization of microtubules, an inhibition of 
mitosis and induces the apoptotic cell death. 
RTKs however play a role in disease initiation, progression, metastasis and tumour 
growth, which is why TKIs gained compliance as effective treatment option (Table 4). 
Clinical studies for PCa with TKIs such as AMG208, Cabozantinib showed lack of 
efficacy when applied in patients. However, results of a re-designed study for 
Cabozantinib treatment of PCa patients are highly anticipated as a daily dose showed 
efficacy to slow down disease progression or and prevent disease relapse in a small 
patient population (NTCT01834651).  
 
Table 4 FDA approved studies for cMET inhibitors for treatment of PCa 
Agent Target site Conditions Interventions  Study Code Finished   
AMG102 
(Rilotumumab) HGF PCa 
15mg/kg 
every 3 
weeks IV 
(12 cycles) 
NCT007708
48 2014 
No results 
posted 
AMG 208 RTKi PCa 
400mg/day 
orally in 6 
weeks cycle 
NCT024205
87 2015 
withdrawn 
prior to 
enrolment 
Cabozantinib 
RTKi PCa 
60mg orally 
daily until 
disease 
progression 
NCT018346
51 
on 
going  
RTKi PCa 60mg orally NCT01428219 2016 
terminated 
due to 
negative 
results  
Tivantinib RTKi PCa nn NCT01519414 
on  
going   
 
 
The major site of metastasis in prostate cancer is the bone. In a study by Tu et al., 
the cMET inhibitors PHA-665752 and PF-2341066 were used to assess tumour 
formation and progression in in-vitro and in-vivo models. cMET inhibition with PF-
2341066 showed reduction of androgen-dependent tumours in mice and further 
reduced the tumour progression in castrated mice247. The overexpression of cMET 
can be correlated with a reduced survival of PCa patients248.  This makes cMET a 
promising target for PCa therapy. Although TKIs seem to be a promising target, their 
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effect in PCa related studies can only be seen in a subset of patients, which makes it 
even more important to understand the underlying mechanisms249–251.   
cMET is a valid clinical target for multiple cancers. However, combined treatments 
are favourable for patients as cMET can be activated by RTK cross-talk via EGFR for 
example. The major challenge that research is facing now, is to identify cMET 
dependent tumours which have become resistant to TKI therapy. New selective 
biomarkers for individual patients need to be identified, to inhibit the HGF/cMET on 
the long run, which in turn would extened relapse free survival188,252,253. 
 
Figure 1.11 Target sites of the cMET/HGF axis 
Five different targets have been validated to inhibit the HGF/cMET axis. (1) HGF specific 
antibodies, and (2) HGF analogues inhibit HGF activation or HGF binding to cMET. (3) Two 
cMET specific antibodies have been developed, both targeting the sema-domain of cMET, 
inhibiting HGF binding and dimerization of cMET. The next target of the cMET receptor is 
the ICD, containing the kinase domain and the multiple docking site. The kinase domain is 
target site for ATP-competitive inhibitors (4), whereas the multiple docking site inhibitor is 
Non-ATP-competitive (5). 
 
 
1.7 Intracellular PTKs 
PTKs are subdivided into 10 families, due to their homology of domain structures such 
as Sarcoma family kinase (Src) Homology-1 (SH1), SH2, SH3, integrin binding 
domains, or DNA binding domains254,255 (Table 5). PTK members are i.e. the Src 
S975
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P1234
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P1356
S-S
HGFA S-S
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NK2
NK4
cMET specific	antibodies
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LY-2875358
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[ATP-competitive]
Capmatinib
SU11274
Foretinib
PF-04217903
PHA-665752
AMG-458
Golvatinib
NON-ATP	 competitive
Tivatinib
HGF	specific	antibodies
Rilotumamumab
TK701
Ficlatuzumab
2
1
3
4
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members, located within the cytoplasm, or Abelson murine leukemia (Abl) family 
members, which are found predominantly in the nucleus. However, on a genetic level 
during cancer development these pathways are often altered and due to this PTK 
functions are impaired leading to an enhancement of processes which are usually 
under strict control. As a result, TKs are termed oncoproteins256. 
 
Table 5 The family of intracellular protein tyrosine kinases (PTKs) 
 
 
1.7.1 SRC 
The largest subgroup of the PTKs is the Src family, which includes 9 family members 
Fyn, Lck, Hck, Lyn, Blk, Fgr, Yes, Yrk and Src (Table 5). They are ubiquitously 
expressed in human cells and are signal transducers and regulators of the cellular 
response towards cytokines, growth factors, or cell adhesion.  The SH1, SH2 and 
SH3 domains are conserved within the Src family. They further contain an N-terminal 
membrane-targeting SH4 domain, a myristoylation sequence. Src is located within 
the cytoplasma the perinuclear or the endosomal membrane. Src was identified as 
an oncogene by Simmons et al. in 1989 and localized to chromosome, 20q11.23257. 
Src is highly overexpressed in various human cancers, and the upregulation of Src 
correlated with its activity, leading to cancer progression, growth and invasion258.  
Cytoplasmic	protein	tyrosine	kinases-
family	name	 Family	members	 Key-domains
Src FGR, FYN, SRC, YES1, BLK,HCK, LCK, LYN SH2,	SH3
ABL ABL1, ARG SH2,	SH3,	DNA-binding,	Actin-binding
JAK JAK1, JAK2, JAK3, TYK2 Integrin-binding,	pseudokinase-domain
ACK ACK1, ACK2 SH3,	Cdc42-binding
CSK CSK, MATK/CTK SH2,	SH3	
FAK FAK, PYK2 Integrin-binding
FES FER, FES CIP4-homology	domain,	SH2
FRK PTK6, FRK, SRMS SH2,	SH3	
TEC BMX, BTK, ITK, TEC, TXK Pleckstrin homology	domain,	SH2,	SH3,	Btk motif
SYK SYK, ZAP70 Two	SH2	domains
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1.7.1.1 Src domain structure 
Src has a molecular weight of 60kDa, consisting of 535 amino acid. Starting from the 
N-terminus Src contains a myristoylation sequences. The myristoylation of Src is a 
post-translational modification, in which the N-terminal methionine is replaced and the 
now exposed glycine becomes myristoylated. The myristoylation of Src targets it to 
the plasma membrane. The SH3 domain, downstream of the N-terminus comprises 
60 amino acid and is able to associate with proline-rich regions in a variety of proteins. 
The SH2 domain of Src is composed of 100 amino acid and allows Src association to 
phosphorylated tyrosines (Figure 1.12). The SH1 domain of Src is subdivided into two 
units by the catalytic site, which exhibits the ATP and substrate binding site, 
facilitating phosphate transfer. The catalytic site forms the activation loop, in which 
the activating tyrosine (Y419) is located. At the C-terminus Src contains an 
autoinhibitory phosphorylation site, located at position 530. Two kinases have been 
identified in regulating Src inactivation, which are Csk259 and Chk260. The C-terminal 
phosphorylation of Src causes the association with SH2 leading to the autoinhibitory 
conformation of Src, and masking Y419 activation (Figure 1.12). 
1.7.2 Scr-like tyrosine kinases, the FRK family 
The FRK-family of tyrosine kinases comprises SRMS, PTK6 and FRK. They are 
related to the Src-family kinases, however they show an exon-intron structure deviant 
from Src-family members261. FRK family members consist of a tyrosine kinase 
domain, an SH2 and SH3 domain and an autoinhibitory domain at the C-terminus. 
Different from Src-family members, FRK-members lack a myristoylation sequence. 
As a result, they can shuttle within different cellular compartments. FRK itself contains 
a nuclear localization sequence within its SH2 domain, which can target FRK to the 
nucleus262.  
1.7.3 PTK6 
Protein tyrosine kinase 6 (PTK6) or BRK (Breast tumour kinase) belongs to the Src-
related kinases lacking the C-terminal regulatory tyrosine and N-terminal 
myristoylation sites (SRMS) of RTKs263. Herein, the term PTK6 will be used. PTK6 
was first identified by Lee et al. (1993) in human melanocytes and later in breast 
tumour cells by Mitchell et al.(1994)263. Via FISH analysis the human chromosomal 
region 20q13.3 was identified to contain PTK6. 
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Figure 1.12 Schematic overview of Src and PTK6 protein structure. 
The protein structure of PTK6 consists of three domains, the C-terminal kinase domain, the 
SH2 domain, and the N-terminal SH3-domain, containing the ATP-binding site at position 
219 and the Y342, which becomes autophosphorylated upon PTK6 activation. The Y447 
downstream is necessary for PTK6 autoinhibition. The splice variant of PTK6, ALT-PTK6 
lacks the SH3- and kinase-domain. Although PTK6 and Src show a sequence homology of 
44%, Src contains an N-terminal myristoylation sequence, targeting it to the membrane. 
 
1.7.3.1 Characteristics of PTK6 
PTK6 consists of 451 amino acids and has an estimated molecular weight of 52kDa. 
The structure of PTK6 varies, as the SH3 domain consists mainly of β-sheets, 
whereas the SH2 domains consist of α-helices and β-sheets. Tyrosines (Y) in PTK6 
are essential for its activation and inhibition. Upon autophosphorylation of Y342, 
PTK6 activity is increased. However, phosphorylation of Y447 results in decreased 
activity as it binds to the SH2 domain (Figure 1.12). When Y447 was mutated to 
phenylalanine (F), PTK6 became up to 2.5fold more active as the auto-inhibition via 
P-Y447-SH2 interaction cannot occur 264,265,266. By mutating K219 the kinase domain 
became inactive due to the change of the ATP-binding site, required for kinase activity 
(Figure 1.12).  
The sequence homology of PTK6 with Src family members is approximately 44% 
which includes the exon boundaries between exon 1/2 and 7/8. These boundaries 
are of high significance as they code for the Src-Homology-3 (SH3) and SH2 domains 
and the C-terminal region of the kinase domain. Compared to Src-family members, 
PTK6 lacks the SH4 domain which targets Src-family members to the plasma 
membrane which results in increased flexibility in the intracellular localization of PTK6 
COOH
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NH2
NH2
Myristoylation sequence
SH3-domain
SH2-domain
Kinase-domain
K219
K298
Y342
Y416
Y447
Y527
KXXX
YXXX
YXXX
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in epithelial cells. One splice variant for PTK6 has been identified so far. Alternative 
splicing results in the exclusion of exon 2 leading to a frameshift and a premature 
stop-codon at position 172 lacking the SH2 and the kinase domain, and this is known 
as ALT-PTK6264 (Figure 1.12). ALT-PTK6 is thought to negatively regulate growth and 
promote the PTK6 related inhibition of its substrate β-catenin. Upon co-expression of 
PTK6 and ALT-PTK6, ALT-PTK6 induced PTK6 nuclear translocation and inhibited 
PTK6-inhibition of b-catenin transcription. Expression of ALT-PTK6 lead to reduction 
of b-catenin targets cyclin D1 and c-Myc in PC3, resulting in reduced proliferation and 
growth267. Transcription factors that have been identified to regulate PTK6 expression 
are NF-κB and Sp1 268. 
1.7.3.2 PTK6 expression and physiological role  
PTK6 is expressed in the epithelial tissue, with the purpose to regulate cell 
differentiation and negatively regulate cell proliferation. Vasioukhin et al. identified 
PTK6 expression to be exclusively restricted to the proliferative zone of the 
epithelium269. PTK6 gene disruption in mice leads to increased growth and reduced 
differentiation of the small intestinal epithelium. Moreover, AKT activation was 
increased, suggesting a physiological role of PTK6 in AKT inhibition270. Ptk6-/- mice 
showed increased nuclear localization of β-catenin within the small intestinal crypts, 
proposing an inhibitory role for PTK6 in regulating β-catenin nuclear translocation270. 
The highest expression level of PTK6 is found in the gastrointestinal tract (GI), in the 
non-dividing villus epithelium of the small intestine, as well as in the crypt cells271. 
Within the GI, PTK6 is essential for growth and differentiation of the small intestine, 
as Ptk6-/- mice showed impaired differentiation and growth of the GI tract272. In the 
prostate, PTK6 is found in the nucleus of prostate epithelium where it regulates gland 
tissue differentiation273. Nuclear expression of PTK6 was also confirmed for oral 
epithelium274. Within the skin, PTK6 is found predominantly within the suprabasal 
keratinocytes where it positively regulates the differentiation in a calcium dependent 
manner269.  Recently, Peng et al. confirmed the expression of inactive PTK6 in normal 
mammary gland tissue. Active PTK6, phospho-PTK6 (pPTK6), was detectable in 
tumour tissue predominantly at the plasma membrane275. 
1.7.3.3 PTK6 signalling partners 
The physiological role of PTK6 is characterized as differentiation regulator, whereas 
in cancer, it facilitates proliferation and cell survival.   
PTK6 is known to associate with other membrane proteins, such as the ErbB receptor 
family, ADAM15 and IGF-1R. Within the cytoplasm, PTK6 interaction partners are 
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AKT, paxillin, STAT3, STAT5, IRS-4 and β-catenin, while it interacts with Sam68, 
SLM-1 and SLM-2 in the nucleus. All four ErbB family members are known to interact 
with PTK6, leading to downstream substrate activation. Co-expression of ErbB3 leads 
to increased EGF signalling by AKT and PI-3K. The insulin receptor substrate-4 (IRS-
4) was identified by Qui et al. as a PTK6 interaction partner, as IRS-4 presence 
induces PTK6 phosphorylation. IGF signalling is linked to poor prognosis for breast 
cancer patients, and may contribute to trastuzumab treatment resistance276. Zheng et 
al. identified that AKT is a direct substrate of PTK6. PTK6 phosphorylates AKT on 
Y315 and Y326, leading to AKT activation277. AKT signalling facilitates cell growth, 
proliferation and survival, as Haegebarth et al. showed that overexpression of PTK6 
in Rat1a cells did not activate AKT272. The ADAM15/PTK6 interaction was identified 
by Zhong et al., and only ADAM15 splice variants A and B were shown to interact 
with PTK6. ADAM15-A and B expression in breast cancer was linked to decreased 
relapse-free survival, whereas expression of ADAM15-C was linked to better patient 
prognosis81. PTK6 is able to activate STAT3 and STAT5b, known regulators of 
differentiation, proliferation, and apoptosis. STAT3 was identified by Liu et al., as 
tyrosine phosphorylated substrate for PTK6278. PTK6 was able to phosphorylate 
STAT5b at Y699, leading to enhanced transcriptional activity. Knock down of either 
PTK6 or STAT5b in BT-20 breast cancer cells resulted in decreased DNA 
synthesis279. Derry et al. identified the co-localization of Sam68 and PTK6 within small 
nuclear bodies (SNBs). The RNA-binding function of Sam68 is negatively regulated 
by PTK6 expression, as phosphorylated Sam68 is inactive. The Sam68-like 
mammalian proteins 1 and 4 (SLM-1, SLM-4) are also inactivated upon 
phosphorylation by PTK6. Phosphorylation of SLM-1 and SLM-4 leads to reduced 
RNA-binding and cell cycle disruption, which impact posttranslational epithelial 
development and differentiation280 (Table 6). 
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Table 6 PTK6 interaction partners 
 
 
1.7.4 PTK6 role in prostate cancer 
As mentioned in the previous paragraph, PTK6 lacks the myristolation sequence, 
which would target it to the cell membrane. In normal epithelial cells, PTK6 is thought 
to inhibit proliferation but enhances differentiation, which was calcium dependent. 
Increased calcium levels lead to increased PTK6 expression in those cells269. PTK6 
further plays a key role in the regulation of apoptosis pathways in non-transformed 
cells272.In prostate epithelia, PTK6 localization is predominantly nuclear. However, 
during prostate cancer development PTK6 is found to be cytoplasmic. In the LNCaP, 
androgen dependent prostate cancer cell line, PTK6 is predominantly found in the 
nucleus. However, the androgen independent prostate cancer cell line PC3 shows 
predominantly cytoplasmic PTK6 expression273. Re-localization of PTK6 in prostate 
cancer has been used as an indicator for disease progression, as it induces epithelial 
mesenchymal transition281.  
Localization Factor
Membrane ADAM15 Zhong et	al.(2008)
ErbB1 Kamalati et	al.(1995)
ErbB2 Aubele	et	al.(2008)
ErbB3 Kamalati	et	al.(2000)
ErbB4 Aubele	et	al.(2008)
Cytoplasm AKT Zhang	et	al.	(2005)
MAPK Aubele	et	al.(2008)
Paxillin Qui	et	al. (2005)
STAT3 Liu	et	al. (2006)
STAT5b Weaver	et	al.	(2007)
β-catenin Palka-Hamblin	et	al. (2010)
Nucleus Sam68 Derry	et	al.	(2000)
SLM-1 Haegebarth	et	al.	(2004)
SLM-2 Haegebarth et	al.(2004)
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1.8 Work leading to this project 
ADAM15 ICD is subject to alternative splicing. These variants show differences in 
abundance of their proline rich regions, allowing them to associate with SH3-domain 
containing cytoplasmic proteins. Our group has identified that ADAM15 splice 
variants A and B interact with PTK6, however splice variant C does not81. Preliminary 
data further showed that this interaction is independent of the PTK6 kinase activity. 
In breast cancer cells, data from our group further indicated a HGF-dependency of 
ADAM15 and PTK6 complex formation, as upon HGF treatment the interaction was 
enhanced. The HGF/cMET axis is a major regulator for cell invasion and migration. 
Individually, ADAM15105 and PTK6282 have been linked to promote cell invasion and 
migration. 
Unpublished data from our lab showed differences in the splice profile of ADAM15 in 
the androgen dependent prostate cancer cell line LNCaP and the androgen 
independent prostate cancer cell line PC3. LNCaP express predominantly splice 
variants A and D, whereas PC3 predominantly express A. In breast cancer, our group   
linked expression of splice variant A and B to a poor prognosis for patients, whereas 
splice variant C was considered to be favourable for patients prognosis81. 
Our data indicate an important role for the ADAM15 and PTK6 interaction in prostate 
cancer progression. This interaction could further represent a promising target for 
prostate cancer therapy.  
 
1.9 Aims of the project 
To elucidate the importance of ADAM15 ICD splicing as well as the ADAM15 complex 
formation with PTK6 and cMET in prostate cancer progression the aims of this project 
are: 
Aim 1 
• To analyse a splice profile of ADAM15 with samples from prostate cancer 
patients and correlate this profile with  
o disease relapse 
o Gleason score 
o nodal Status 
o and tumour grade 
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Aim 2 
• To investigate the role of ADAM15 splice variant overexpression on  
o cell size 
o cell cycle 
o actin cytoskeleton rearrangement 
o migration  
o and invasion of the prostate cancer cell lines PC3 and LNCaP.  
Aim 3 
• To assess the effect of ADAM15 overexpression on PTK6 localization in PC3 
and LNCaP cells. 
• To identify the splice variant dependent interaction of ADAM15 and PTK6 in 
PC3s and LNCaPs.  
• To identify if PTK6 activity is needed for the interaction and if it can be 
enhanced via the HGF/cMET signalling axis. 
Aim 4 
• To elucidate the role of the cMET signalling axis in the complex formation 
between ADAM15 and PTK6. 
• To elucidate the role of cMET inhibition of prostate cancer cell invasion. 
• and moreover, to elucidate the role of ADAM15 catalytic function in prostate 
cancer cell invasion.  
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2 Materials and Methods 
2.1 Cell Culture 
The human androgen dependent prostate cancer cell line LNCaP, the androgen 
independent aggressive human prostate cancer cell line PC3, the human embryonic 
kidney cell line HEK293FT and the breast cancer cell line MDA-MB-231 were 
previously purchased from ATCC and kindly provided by Dr. Z. Poghosyan.  
2.1.1 Subculturing of cell lines 
Cell lines were cultivated at 37 °C in humidified air, supplemented with 5 % CO2.  
Upon confluency, cells were passaged. They were washed with PBS (without Mg 2+ 
and Ca 2+), and incubated for either 5 min for HEK293FT or 60 min for PC3 and 
LNCaP with 1 mL trypsin/EDTA (0.5 g/L porcine trypsin and 0.2 g/L EDTA *4Na) per 
75 mm2 flask. To stop trypsinisation, 5 mL cell culture medium (Table 7) was added, 
and cells were resuspended by pipetting up and down. Cells were diluted to the 
following ratios; 1:5 for PC3, and 1:3 for LNCaP and HEK293. PC3 cells were 
passaged once a week, whereas LNCaPs and HEK293FT were passaged twice a 
week. 
Table 7 Cultivation medium for PC3, LNCaP and HEK293FT 
Cell line Origin Medium Supplements Concentration 
PC3 Human prostate adenocarcinoma 
F12K 
+L-
glutamine 
FBS 10 % 
Penicillin/Streptomycin 100 µg/mL 
LNCaP Human prostate adenocarcinoma RPMI 
FBS 10 % 
Penicillin/Streptomycin 100 µg/mL 
L-Glutamine 2 mM 
HEK293FT 
Human 
embryonic 
kidney 
DMEM 
FBS 10 % 
Penicillin/Streptomycin 100 µg/mL 
L-Glutamine 2 mM 
NEAA 1 mM 
NA-Pyruvate 1 mM 
MDA-MB-
231 
 
DMEM 
FBS 10 % 
Human breast 
tumour cells 
Penicillin/Streptomycin 100 µg/mL 
L-Glutamine 2 mM 
Hygromycin 450µg/mL 
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2.1.2 Freezing and thawing of cell lines 
Cell lines were kept in liquid nitrogen for long term storage. Cells were removed from 
liquid nitrogen storage and thawed at 37 °C in a water bath. Cells were transferred 
into a new centrifugation tube containing 5 mL cell culture medium and centrifuged at 
200 xg for 10 min. The supernatant was aspirated and the cells were resuspended in 
new culture medium and transferred to a new T75 flask.  
Freezing of cell lines was performed as follows. Cells were trypsinized, resuspendend 
in culture medium, centrifuged at 200 xg for 10 min and resuspended in freezing 
medium (10 % DMSO, 40 % FBS and 50 % culture medium). Cells were transferred 
to the Mr. Frosty™ Freezing Container and slowly frozen overnight (O/N) in a - 80 °C 
freezer, then transferred to liquid nitrogen for long term storage. 
2.1.3 Stable transfection of PC3 and LNCaPs using lentiviral transduction 
Replication incompetent lentiviral particles of the ADAM15 expression vectors in 
pcDNA4-V5/His-A were produced and kindly provided by Dr Z. Poghosyan 
(Supplementary Data Figure 8.1). Within this system three packaging plasmids 
(PLP1, PLp2 and pLP/ VSVG) were provided which supply helper functions, structural 
and replication proteins (Supplementary Data Figure 8.2). 
LNCaP and PC3 were seeded in 24 -well tissue culture dishes at a cell density of 
1.2 x105/ well in growth medium without antibiotics. Cells were incubated for 24 h and 
infected with lentiviral particles. Polybrene (8 μg/ μL) was used as an infection 
enhancer. Cells were maintained in DMEM containing 10 % FBS. Afterwards, cells 
were trypsinized and transferred to T75 flasks containing selection medium (Table 8). 
Cells were kept in selection medium for 3 weeks. Afterwards, they were cultured in 
medium containing penicillin/streptomycin (Table 7 and Table 8). 
Table 8 Selection medium for LNCaP and PC3 stable expressing the ADAM15 splice 
variants 
Cell line Medium Supplements Concentration  Selection Concentration 
PC3 
ADAM15-
A-E and 
Vector 
F12K 
FBS 10 %  G418 500 µg/mL 
  
  
 
LNCaP 
ADAM15-
A-E and 
Vector 
RPMI 
FBS 10 %  G418 500 µg/mL  
L-Glutamine 2 mM    
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2.1.4 ADAM15 proteolytic activity E349A mutant 
PC3 cells stably expressing the ADAM15 splice variant proteolytically inactive E349A 
mutants, were made and validated and kindly provided by Dr. Z. Poghosyan. 
Expression plasmids of ADAM15 EA mutants were designed and validated by Dr. Z. 
Poghosyan. 
2.1.5 MDA-MB-231 breast cancer cells 
MDA-MB-231 vector control and ADAM15-A stably expressing cells were made, 
validated and kindly provided by Dr. Z. Poghosyan. 
2.1.6 Stable transfection of PC3 with shRNA encoding plasmids 
PC3 cells expressing shRNA targeting PTK6 were validated and kindly provided by 
Dr. Z. Poghosyan (Table 9). Cells were cultivated in F12K medium, containing 10 % 
FBS, 100 μg/mL penicillin/streptomycin and 1 μg/mL puromycin as the selection 
marker. 
Table 9 shPTK6 and sh non-target sequences 
Target Catalogue number Hairpin sequence Vector  
Clone ID Regi
on 
Human 
PTK6 
TRCN0000196912 
 
5'-CCGG-
GTGCAGGAAAGGTTCA
CAAAT-CTCGAG-
ATTTGTGAACCTTTCCT
GCAC-TTTTTTG-3' 
pLKO
.1 
NM_00597
5.2-
1506s1c1 
3’UT
R 
Target 
sequence 
Oligo design 
for arrayed 
cloning FWD 
Oligo design 
for arrayed 
cloning REV 
   
GTGCAGGAA
AGG 
TTCACAAAT 
 
5'-
CCGGGTGCAGGAAAGG 
TTCACAAATCTCGAGATT
TG 
TGAACCTTTCCTGCACTT
TTTG-3' 
 
5'-
AATTCAAAAAGTGCAGGA
A 
AGGTTCACAAATCTCGAG
ATTT 
GTGAACCTTTCCTGCAC-
3' 
 
   
 
2.1.7 Transient transfection of HEK293FT with overexpression plasmids 
Plasmids for full-length ADAM15-A was provided by Dr. Z. Poghosyan, and PTK6-
wild type and PTK6 K219M-mutant, were kindly provided by Dr. Amanda Harvey 
(Brunel University, London). 
HEK293FTs were transiently transfected using Lipofectamine 2000, in a 3:1 
Lipofectamine to plasmid ratio. Cells were seeded in culture medium without 
antibiotics at a density of 5 x105 cell / well of a 6-well-dish, and incubated for 24 h. 
Lipofectamine was diluted in serum-reduced Opti-MEM and incubated for 5 min. 
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Plasmids were diluted to a final concentration of 2.5 μg plasmid/transfection in Opti-
MEM and added to the Lipofectamine, followed by 15min incubation at room 
temperature (RT) (Table 10). The complexes were added onto the cells and incubated 
for 24 h. Following the 24 h incubation period, the medium was changed to culture 
medium and cells were cultured for 24 h post-transfection before they were further 
analysed. For co-transfection of plasmids, plasmids were mixed at ratio of 1:1. 
Table 10 Plasmid overview used for transient HEK293FT transfection 
 Plasmid backbone Tag 
ADAM15-A pcDNA-4- A V5, His 
PTK6 wild type pcMV3 FLAG 
PTK6 K219M-mutant pcMV3 FLAG 
 
2.2 Molecular biology methods 
2.2.1 RNA extraction 
For RNA extraction cells were grown in 60 mm tissue culture dishes until they were 
80 % confluent. Cells were harvested, resuspended in PBS, followed by centrifugation 
at 200 xg for 5 min. The supernatant was aspirated. RNA extraction was performed 
as detailed in the RNeasy Qiagen Kit. 
2.2.2 DNA and RNA quantification 
DNA and RNA quantification was performed using the NanoDrop Spectrophotometer. 
1 µL of sample was quantified by measuring the absorbance at 260 nm or 280 nm. 
Concentration was calculated using the Lambert-Beer law. Measurements were 
repeated three times, the mean calculated to determine the nucleic acid concentration 
in ng/ µL. 
2.2.3 cDNA synthesis 
The Superscript II kit (Invitrogen) was used, using 1 µg RNA per reaction. All steps 
were performed according to the manufacturer’s protocol in a total volume of 20 µL 
(Table 11). RNA, dNTPs, Random Hexamers and H2O were added and incubated for 
5 min at 72 °C. 5 x single strand buffer and DTT were added and samples were 
incubated for 2 min at 25 °C in the Thermocycler. Superscript II was added and 
samples were incubated for 10 min at 42 °C, 50 min at 72 °C and 15 min at 70 °C. 
cDNA-Samples were stored at – 80 °C until further processed. 
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Table 11 Composition of RT reaction 
Compounds Concentration Volume 
RNA 1 µg  
dNTPs 0.5 mM 1 µL 
Random Hexamers 0.4 µM 1 µL 
5 x single strand buffer 1 x 4 µL 
DTT 0.01 M 2 µL 
Superscript II  1 µL 
H2O  to 20 µL 
 
2.2.4 Primer design for PCR 
Primer design for PCR and qPCR was done via the Primer  BLAST tool from NCBi 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). The NCBI Reference Sequences 
of the genes of interest were acquired using the Pubmed gene database (Table 12). 
The following parameters were applied for each primer design: Primer must span an 
exon-exon junction, 3’ end of primer contain C or G residues, the GC content of the 
primer should be less than 60%, primer-dimer formation should be avoided. Primers 
were purchased from Eurofins 
Table 12 NCBI Reference Sequence overview 
Gene	of	
interest	
NICB	Reference	
Sequence	
ADAM15-A	 NM_003815.4	
ADAM15-B	 NM_207194.2	
ADAM15-C	 NM_207196.2	
ADAM15-D	 NM_207191.2	
ADAM15-E	 NM_207195.2	
ADAM15-
MP	 NM_003815.4	
PTK6	 NM_001256358.1	
GAPDH	 NM_001256799.2	
 
2.2.5 PCR and Agarose gel electrophoresis 
For PCR, the KAPA HiFi PCR kit was used. A PCR mix for a final reaction volume of 
25 µL was prepared, containing PCR-grade water, forward and reverse primers 
(Table 13) at a final concentration of 0.3 µM, in 2.5 mM MgCl2, 0.3 mM dNTP, 0.5 U 
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of KAPA Hifi HotStart DNA Polymerase and 100 ng of template DNA. Cycler 
conditions are shown in Table 14. Samples were analysed using 1 % agarose gels 
containing 1:10,000 gelRED®. 
Table 13 PCR primer overview 
Primer Sequence 5’-3’ Tm 
ADAM15-FWD CTT GGT GCC AGC TAC TGG TAC CGT GCC CG 60 
ADAM15-REV CAG AGG TAG AGC GAG GAC ACT GTC GGA GG  
GAPDH-FWD CGTCAAGGCTGAGAACGGGAAGCTTGTCATCAATG 66 
GAPDH-REV CATGCCAGTGAGCTTCCCGTTCAGCTCAGGGATG  
 
Table 14 PCR cycler conditions 
 
2.2.6 qPCR using KAPA SYBR® Fast 
To detect the relative gene expression level of ADAM15 A-E splice variants and PTK6 
using cDNA samples generated from prostate cancer patients’ RNA, quantitative 
PCR (qPCR) was used. 
A standard qPCR protocol was set up according to the MIQE-Guidelines by Bustin et 
al. (2009). cDNA was used as template for qPCR, using the KAPA SYBR® Fast mix. 
30 ng cDNA was mixed with 400 nM of forward and reverse primers per reaction. 
Primer sets and cDNA was diluted in ultra pure DNAse/RNase-Free deionized H2O. 
5 µL of diluted cDNA was added to 96-well plate. 5µl master-Mix containing the 
primers( Table 15) and the KAPA SYBR® Fast mix was prepared and added per 
reaction. The final reaction volume per qPCR sample was 10µL. For each primer-set, 
a No-Template-Control (NTC) was used. The thermal cycler BioRad CFX was used 
with the following protocol (Table 16). Data analysis was performed according to the 
instrument-specific instructions, using the ADAM15 splice variant or PTK6 Ct, divided 
by the Ct value of the endogenous control, GAPDH.  
 Temperature Duration Cycles 
Initial denaturation 95 °C 3 min 1 
Denaturation 95 °C 30 sec 
25 Annealing Primer Tm dependent 30 sec 
Extension 72 °C 1 min 
Final extension 72 °C 10 min 1 
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Table 15 qPCR primer sets for prostate cancer patients ADAM15 splice profile and PTK6 
expression level analysis 
Primer 
Sets 
 Sequence (5’->3’) Tm 
ADAM15-A 
FWD GTGACAGCAACAGGCACTGCTACTG 
66 
REV GCCCCTGAGACTTAGTGCCTC 
ADAM15-B 
FWD CGAGGCACTAAGCAGGCTAGTGCTC 
64 
REV GCCCCTGAGACTGGAGTCTC 
ADAM15-C 
FWD CGAGGCACTAAGGCTAGTGCTCTC 
66 
REV GCCCCTGAGACTTCGGGCTTC 
ADAM15-D 
FWD GTGACAGCAACAGGCACTGCTACTG 
64 
REV GCCCCTGAGACTGTACTGGC 
ADAM15-E 
FWD CGAGGCACTAAGGCTGAGCTGG 
66 
REV GCCCCTGAGACTTCGGGCTTC 
ADAM15-
MP 
FWD GCTGATCACTCGGAGGCCCAGAAATACCGGGACTTC 
66 
REV CCTGGTAGGAAGTCTGTGGAGGCCTCC 
GAPDH 
FWD GGCACCGTCAAGGCTGAGAACGGGAAGC 
64 and 66 
REV CCCTGCAAATGAGCCCCAGCCTTCTCC 
PTK6 
FWD GATCAGGGTCAGCGAGAAGC 
64 
REV GGCCCTGTGGTAGTTCACAA 
 
Table 16 qPCR condition cycle overview 
 Temperature Duration Cycles 
Enzyme activation 95°C 3min 1 
Denaturation 95°C 10sec 
39 
Annealing/extension Primer Tm dependent 30sec 
Dissociation/ Melt curve Primer Tm dependent - 95°C 
increment 0.5°C 
for 5sec 1 
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2.3 SDS-PAGE & Western blot 
2.3.1 Preparation of whole-cell lysate 
All steps were performed on ice. Cells were washed twice with ice cold PBS. RIPA 
lysis buffer (20mM Tris-HCl pH7.5, 150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 1% 
NP-40, 1% SDS, 2.5mM Sodium Pyrophosphate, 1mM  b-glycerophosphate, 1mM 
Na3VO4, 1ug/ml leupeptin) containing phosphatase (25x PhosphoStop, Roche), 
protease inhibitors (20x Proteinase inhibitor, Sigma), and phenanthroline 10 mM 
(pan-metalloproteinase inhibitor) was added. Cells were incubated for 5 min and 
detached using a cell scraper. The lysate was transferred into a pre-cooled test tube, 
incubated for 10 min on ice and sonicated 3 times (Bioruptor-Sonicator, Diagenoide) 
for 30 sec at 50% amplitude. Lysates were centrifuged at 14800 rpm for 10 min at 
4 °C, and the supernatant was transferred into a new test tube. Lysates were stored 
at – 80 °C. 
2.3.2 Protein quantification 
The protein concentration was assessed in whole cell lysates, using the bicinchoninic 
acid (BCA) Pierce assay kit. This assay kit is based on a copper redox reaction 
leading to the formation of coloured complexes with BCA. The assay was performed 
in 96 -well plates according to the supplier’s protocol. Samples were assayed in 
triplicate. Plates were incubated for a 2 h period at 37 °C after the addition of 200 µL 
BCA working reagent. Absorbance was measured at 562 nm on a plate reader. 
Sample protein concentration in µg /mL was calculated from a standard curve using 
a 3rd order polynomial trend line function in Microsoft Excel. 
2.3.3 Sample preparation 
Following cell lysis and protein quantification, samples were diluted to a total protein 
amount of 20- 40 µg/ 20 µL in RIPA-buffer. 6 x loading dye (Table 17) was added and 
samples were incubated for 5 min at 95 °C. Samples were centrifuged for 2 min at 
14800 rpm before loading on gels. 
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Table 17 6x protein loading dye 
 Final concentration in Buffer Volume 
0.5 M Tris pH 6.8 300 mM 6 mL 
Bromophenol blue (1 %) 0.05 % 0.5 mL 
Glycerol 20 % 2 mL 
SDS (10 %) 1.5 % 1.5 mL 
b-mercaptoethanol  0.625 mL 
 
2.3.4 SDS-Polyacrylamide gel casting 
Resolving and stacking gel solution were prepared, as shown in Table 16 and Table 
17, and stored at 4 °C wrapped in wet tissue and cellophane for 24 h.  
Table 18 SDS-Polyacrylamide resolving gel schematic overview 
 6 % 8 % 12 % 
H2O 6 mL 5.5 mL 4.5 mL 
1.5 M Tris pH 8.8 2.5 mL 2.5 mL 2.5 mL 
40 % Acryl:Bis 
29:1 1.5 mL 2 mL 3 mL 
10 % SDS 100 µL 100 µL 100 µL 
10 % APS 100 µL 100 µL 100 µL 
TEMED 10 µL 10 µL 10 µL 
 
Table 19 SDS-Polyacrylamide stacking gel schematic overview 
 4 % 
H2O 6.5 mL 
0.5M Tris pH 6.8 2.5 mL 
40% Acryl:Bis 29:1 1.0 mL 
10% SDS 100 µL 
10% APS 100 µL 
TEMED 10 µL 
 
2.3.5 Electrophoresis 
Gels were assembled in the electrophoresis cell. Inner and outer chamber were filled 
with 1 x SDS-PAGE running buffer, diluted 1:10 from 10 x SDS-PAGE Running buffer 
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stock (Table 20). The electrophoresis cell was connected to the power supply for 
90 min at 100 V. Afterwards the electrical leads were disconnected and the gel 
cassette was opened. The gel was removed by floating it off the plate into 1 x transfer 
buffer (Table 21). 
 
Table 20 SDS-Page running buffer  
 Compound concentration For 1L 
10 x SDS-PAGE Running 
buffer/ L 
250 mM Tris-Base 30.28 g 
1.92 M Glycine 144.13 g 
1 % SDS (from 20 %) 50 mL 
 
2.3.6 Western blot 
The 1x transfer buffer (prepared from 10x (Table 21) and supplemented with 0.02% 
SDS, 20% Methanol) was prepared 24 h in advance and stored at 4 °C. PVDF 
membranes were incubated for 10 min in 100 % methanol and transferred to 1 x 
transfer buffer (Table 21). Filter paper and fiber pads were soaked in 1 x transfer 
buffer. The blot was transferred for 2 h at 400 mA. Upon run completion the cassette 
was disassembled and PVDF membranes were incubated at RT for 1 h in 5 % non-
fat milk dissolved in 1 x TBST, i.e. 1x TBS containing Tween-20 (1:1000), with gentle 
shaking (Table 21). 
Table 21 Western blot transfer and wash buffer 
 Compound concentration For 1 L 
10 x TBS pH 7.6 stock 
wash buffer 
200 mM Tris-Base 24.2 g 
150 mM NaCl 88 g 
10 x Transfer buffer stock 
0.1 M NaHCO3 8.4 g 
0.03 M Na2CO3 3.1 g 
1x Transfer buffer 
1:10 10 x transfer buffer 100 mL 
0.02 % SDS 2 mL 
20 % Methanol 200 mL 
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2.3.7 Detection 
The primary antibody was diluted in 5% BSA dissolved in 1x TBST (Table 22). 
Following PVDF membrane blocking, the primary antibody was added and incubated 
over night at 4°C with gentle shaking. The primary antibody was removed and 
membranes were washed 3 x in TBST for 15 min. The blot was incubated with 
secondary antibody (Cell Signaling Anti-mouse (7076) or Anti-rabbit (7074) IgG,HRP- 
linked Antibody) diluted in 5% non-fat milk in 1x TBST, for 1h at RT. The secondary 
antibody was removed and membranes were washed 3 x with TBST for 15min. The 
PierceTM ECL plus (Thermo Fisher) was added per membrane and incubated for 3 min 
at RT. Membranes were exposed to ECL films. Films were developed using an 
automated ECL film developer (Xograph). 
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Table 22 Western Blotting primary and secondary antibody dilution 
Antibody Supplier Catalogue number Species 
Detected 
bands 
Primary 
antibody  
Secondary 
antibody  
4G10 
(pan 
phosphor 
tyrosine) 
Merck 
Millipore 05-1050 mouse 45kDa 1:1000 1:3000 
Actin Sigma A2066 rabbit 42kDa 1:5000 1:6000 
ADAM15 
(ICD) Abcam Ab39159 rabbit 
95-115kDa 
(splice 
variant 
dependent) 
1:1000 1:3000 
ADAM10 Abcam Ab39177 rabbit 100kDa 1:1000 1:2000 
Gab1 Cell signalling 3232 rabbit 110kDa 1:1000 1:3000 
Grb2 Cell signaling 3972 rabbit 25kDa 1:2000 1:4000 
Grb2 Santa Cruz sc-255 goat 25kDa 1:2000 1:4000 
Met-ECD Millipore Merck 05-1049 mouse 170kDa 1:1000 1:3000 
pMet Millipore Merck 07-810 rabbit 150kDa 1:1000 1:3000 
pPTK6-
Y342 
Millipore 
Merck 09-144 rabbit 45kDa 1:1000 1:3000 
pPTK6-
Y447 Invitrogen 
PA5-
38413 rabbit 45kDa 1:1000 1:3000 
PTK6 Invitrogen PA5-14787 rabbit 45kDa 1:1000 1:1000 
PTK6 Invitrogen MA5-15328 mouse 45kDa 1:1000 1:3000 
V5 Sigma 46-0705 mouse 
95-115kDa 
(detecting 
exogenous 
ADAM15) 
1:5000 1:8000 
 
2.3.8 Densitometry 
Protein band intensities were quantified using ImageJ. Scanned membranes (600dpi) 
were loaded into ImageJ and the relative density per lane was identified using the plot 
lane option. The resulting peaks, displayed in a separate window were enclosed using 
the straight line tool, by drawing a line across the peak base. The wand tool was used 
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to quantify the peak height, and obtained values were copied to Excel. Protein band 
intensities were compared to the actin loading control and the ratio was calculated. 
For statistical analysis, blots from three independent experiments were analysed.  
2.3.9 Immunoprecipitation (IP) using Dynabeads® 
A total volume of 15 µL (5 µg protein binding capacity) Protein G Dynabeads® were 
used per IP reaction. First, the antibody-Dynabead® (Table 23) incubations were 
performed at 4 °C for 1 h with gentle rotation, followed by sample incubation at 4 °C 
O/N. Samples were washed 3 times with 200 µL RIPA buffer. As elution buffer the 6 x 
loading buffer was used. Samples were analysed via SDS-PAGE and Immunoblotting 
as described before. 
Table 23 Overview of antibodies used for IP 
Antibody Catalogue number Supplier Species Concentration 
µg protein/ 
volume 
cMET sc-161 Santa Cruz rabbit 5 µg/IP 
400µg/200µL 
PTK6 PA5-14787 Invitrogen rabbit 2.5 µg/IP 
350µg/200µL 
Grb2 3972 Cell signaling rabbit 10 µg/IP 
200µg/200µL 
 
2.3.10 IP using V5-coated agarose beads 
A total volume of 5 µL agarose coated V5 beads were used per IP reaction. They 
were incubated in a total volume of 300 µL containing 250 µg total lysate, diluted in 
RIPA buffer, O/N at 4 °C. Samples were centrifuged for 1 min at 14,800 rpm. The 
supernatant was aspirated and 200 µL of RIPA buffer were added. This step was 
repeated three times. As elution buffer the 6 x loading buffer was used. Samples were 
analysed via SDS-PAGE and Immunoblotting as described before. 
2.4 Immunocytochemistry and Confocal Microscopy 
2.4.1 Sample preparation 
Coverslips were transferred into 35 mm tissue culture dishes and coated using cell 
line specific medium for 24 h at 37 °C/5 % CO2 in the incubator. 4 x105 cells were 
grown on coverslips afterwards for 3 days. Cells were washed 3 x with PBS and fixed 
using 4 % paraformaldehyde for 15 min at RT. Cells were permeabilized using 0.1 % 
of Saponin in PBS for 5 min at RT. Blocking was performed with 1 % BSA in PBS for 
30 min at RT. The primary antibody was added and samples were incubated at 4 °C 
O/N (Table 24). The following day, coverslips were washed three times with PBS, the 
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fluorochrome labelled secondary antibody was added, and incubated for 1 h at RT in 
the dark (Table 24). The mounting medium containing the counter stain DAPI was 
added onto a microscope slide, following three times washing with PBS, the coverslip 
was placed on top of the mounting medium with the cells facing the microscope slide. 
Microscope slides were incubated at RT in the dark O/N. For long term storage they 
were kept at 4 °C in the dark. They were analysed using the Leica TCS SP5 Confocal 
Microscope. 
Table 24 Antibodies used for Immunocytochemistry 
Antibody Supplier Catalogue number Species 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution 
PTK6 Invitrogen PA5-14787 Rabbit 1:600 
Anti-rabbit 
AlexaFluor®488 
1:1000 
V5 Sigma 46-0705 Mouse 1:1000 
Anti-mouse 
AlexaFluor®568 
1:1000 
 
2.4.2 Immunocytochemistry- image acquisition 
The Leica TCS SP5 Confocal Microscope equipped with argon (488 line) and HeNe 
(543 and 633 lines) lasers was used for IF-image acquisition. Cells were analysed 
using the HCX PL APO CS 63.0x1.4 Oil UV objective. The LAS AF lite software was 
used to acquire the images. A positive control was used to adjust the settings for 
confocal analysis. Gain was adjusted until saturated pixels appeared and reversed 
until pixels completely disappeared in the lookup-table. The offset was set to 0. Zoom 
was set between 1.5 and 2 or 4 for detailed structural analysis.  
2.5 Cell volume (cell size) determination using Flow cytometry 
The cell volume of each cell line was determined using flow cytometry. Cells were 
seeded in 35 mm dishes and incubated for 48 h. Cells were counted and harvested 
at a concentration of 0.5 x106/ mL. They were centrifuged for 5 min at 200 xg and 
resuspended in 200 µL PBS. Cells were centrifuged, resuspended in 1.5 mL ice cold 
ethanol and incubated for 1 h at - 20 °C, centrifuged and washed with 1 mL PBS three 
times. Cell suspensions were measured using the BD Accuri C6 flow cytometer. The 
side scatter -areas (SSC-A) was plotted versus the forward scatter-area (FSC-A). Cell 
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aggregates and debris were removed from the analysis by gating the cells (Figure 
2.1). Doubles were excluded by plotting FSC-A versus the FSC-height (FSC-H). 
Living cells (live cells) were than shown as histogram using the FL-2 channel. To 
obtain the initial cell size, by determine the median, living cells were plotted as 
histogram and the median was determined automatically by Flow Jo V10, and used 
as a read-out of cell size. 
 
Figure 2.1 Overview of cell size analysis using flow cytometry 
(A)FSC-A was plotted versus the SSC-A to exclude cell debris and gate the cells. (B) Gated 
cells are shown via FSC-H versus FSC-A, excluding doublets. (C) Histogram plot of living 
cells using the FL1-A channel. (D) By choosing the FSC-A channel in the histogram option, 
Flow Jo V10 determined the FSC-A Median, which is given as dimensionless number and 
used as read out for the cell volume (cell size).  
 
2.6 Cell cycle analysis 
The NucleoCounter NC-3000 was used and the two-step cell cycle analysis protocol 
was followed. 1 x106 cells were used per analysis and the assay was performed in 
triplicate. Cells were grown in 35 mm dishes for two days, trypsinized, counted and 
FSC-A	Median
A B
C D
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harvested in PBS after centrifugation (1 x10 6cells per analysis). The DAPI containing 
solution was added and cells were incubated for 5 min at 37 °C. Cells were analysed 
by quantifying cellular fluorescence and DNA content, and were shown as histogram 
on the screen of the NC-3000 software®. Percentile values for each cell cycle stage 
(i.e. G1/G0, S, G2/M) were exported and analysed using GraphPad Prism.  
2.7 PTK6 kinase assay 
PC3 vector and ADAM15-A expressing cells were seeded and grown until 80 % 
confluent. They were serum starved for 30h, followed by 30 min of HGF treatment 
(20ng /mL). Cells were lysed and 500 µg/200 µL of total protein was used per IP with 
anti-PTK6. IPs were incubated O/N at 4 °C rotating. Samples were washed 3 times 
with RIPA-buffer and resuspended in 40 μL kinase buffer (Table 23) supplemented 
with 5 μM ATP. Samples were incubated shaking for 1 h at 37 °C. The reaction was 
terminated using 6 x loading dye. Samples were analysed using western blotting, and 
probing with a pan-phospho tyrosine antibody 4G10. 
Table 25 Kinase assay buffer components 
Kinase assay buffer 
Compounds 
 
Concentration 
MOPS 25 mM pH 7.2 
β-glycerol-phosphate 12.5 mM 
MgCl2 20 mM 
MnCl2 12.5 mM 
EGTA 5 mM 
EDTA 2 mM 
DTT 0.25 mM 
 
2.8 cMET and PTK6 treatments  
For the PC3 and LNCaP cell panels inhibitor treatments (Table 26) were used 
targeting either cMET or PTK6. 1x105- 1x106 cells were grown in tissue culture plates 
(35 mm-100 mm) until 80 % confluent and serum starved (serum free culture medium 
containing antibiotics) for 30 h. 
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Table 26 Overview of inhibitor concentrations 
Inhibitor	 Company	 Target	
Stock	
concentration	
Final	
concentration	
Capmatinib	 Selleckchem	 cMET	 2	µM	 200	nM	
SU11274	 Selleckchem	 cMET	 100	nM	 10	nM	
Tifrinib	 Axon	Medchem	 PTK6	 10	µM	 1	µM	
 
 
Following serum starvation, the medium was removed and cells were treated with 
either a single or combined treatment of the inhibitors (Table 27). Control cells were 
supplemented with HGF 20 ng/mL as stimulation control, or 0.001 % DMSO as 
solvent control. After the treatment, cells were lysed, the total protein amount was 
quantified, followed by IP and analysis via western blotting.  
Table 27 LNCaP and PC3 treatment overview 
	 Capmatinib	 SU11274	 Tilfrinib	
single	 30	min	 30	min	 30	min	
combined	 30	min	+	30	min	HGF	20	ng/mL	
30	min	+	
30	min	HGF	20	ng/mL	
30	min	+	
30	min	HGF	20	ng/mL	
 
 
2.9 Metabolic Cell proliferation Assay 
The colorimetric MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) metabolic cell proliferation assay was used for the 
PC3 ADAM15 A-E panel. The MTS is reduced by the dehydrogenase enzyme of 
viable cells into the coloured formazan, which is detectable at an absorbance of 
490 nm. 
Cells were seeded in triplicate at 3 x103 /100 µL in a 96-well plate. The plates were 
incubated for 24 h in the 37 °C/5 % CO2 incubator. After 24 h, 20 µL of the CellTiter 
96® AQueous One Solution Reagent was added per well. After 1 h incubation, the 
absorbance was measured at 490 nm using a plate reader.  
2.10 Invasion assay  
Corning Matrigel Matrix, was thawed at 4 °C O/N. All materials i.e. pipet tips, 24-well 
plate, invasion chambers (transparent PET membrane with 8 µm pores) were chilled 
prior to the start of the experiment. All coating steps were performed on ice. The 
coating solution, containing the Matrigel Matrix at a final concentration of 0.3 mg /mL, 
was prepared using the sterile coating buffer (0.01 M Tris (pH 8.0), 0.7 %NaCl). The 
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solution was mixed gently and kept on ice. 50 µL of the coating solution were added 
to the invasion chambers and distributed equally. Plates with invasion chambers were 
incubated for 2 h at 37 °C in the incubator. The remaining liquid was removed 
carefully. 2 x104 cells, in 0.5 mL serum free medium, were seeded into each coated 
invasion chamber. Cells were incubated O/N with serum free medium in top chamber 
at 37 °C in the incubator. The next day,  0.75 mL of the chemo-attractant, cell culture 
medium containing 10 % FBS or 20 ng /mL HGF, were added to the bottom of each 
well, followed by 24h incubation at 37 °C in the incubator.  
The Opti-MEM medium was removed by pipetting and a moistened cotton swab was 
inserted on top of the invasion chamber to gently remove the non-invaded cells. The 
invaded cells on the lower surface were stained using a 1 % crystal violet aqueous 
solution for 10 min followed by a 2 min methanol (100 %) fixation step. The invasion 
chambers were then rinsed with H2O to remove excess staining solution. The invasion 
chambers were air dried O/N with the bottom facing up. Invaded cells were analysed 
under the microscope at 4 x magnification. Invaded cells in 4 different fields of view 
were counted manually in triplicate. The number of invading cells was calculated by 
dividing the mean number of invaded cells, divided by the number of seeded cells. 
Manual cell count was performed using ImageJ, by clicking on each cell individually. 
Data analysis was performed using GraphPad Prism and One-way-ANOVA. 
2.11 cMET dependent cell invasion  
PC3 ADAM15 splice variant expressing cells were used in invasion assay, as 
described previously (Section 2.10). Cells were incubated for O/N in serum free 
medium at 37°C in the incubator. On the next day, the inhibitor was added 1h prior to 
HGF to the top chamber. HGF was added to the bottom chamber and cells were 
incubated for 24h at 37°C in the incubator. Cells were analysed as described earlier 
(Section 2.10). 
 
Table 28 Invasion assay treatment overview 
		 untreated	 HGF	 SU11274	 SU11274/HGF	
top	chamber	
serum	free	
medium	
serum	free	
medium	 10nM	 10nM	
bottom	chamber	
serum	free	
medium	 20ng/mL	
serum	free	
medium	 20ng/mL	
 
 
71 
 
2.12 Cell migration using permeable supports 
Cells were seeded at 2 x104 /0.5 mL in permeable supports (8 µm pore size) to 
analyse cell migration. For each time point, one permeable support per cell lines was 
used. The following time points were used, 1 h, 8 h, 24 h and 48 h after seeding. Cells 
were fixed using 100 % methanol for 2 min followed by 10 min staining with 1 % 
crystal violet. Migrated cells were analysed under the microscope at 4 x magnification. 
Migrated cells in 4 different fields throughout the membrane were counted in triplicate. 
The number of migrated cells was calculated by dividing the number of seeded cells. 
Cells were counted manually using ImageJ. Data analysis was performed with 
GraphPad Prism using One-Way-ANOVA. 
2.13 Detecting ADAM15 dimers by crosslinking 
To assess ADAM15 dimerization, chemical crosslinking of ADAM15-A and D stably 
expressing cells or transiently transfected HEK293 cells was applied. 
HEK293 cells, transiently transfected with pcDNA4-ADAM15-A or D, or PC3 
ADAM15-A and D stably expressing cells were grown until confluent on 10 cm dishes 
and harvested, resuspended in homogenization buffer and sonicated to lyse the cells 
(Table 29). Homogenates were centrifuged at 14,800 rpm for 10 min at 4 °C, and 
18 μL aliquots were subsequently crosslinked with 2 µL of the crosslinker 
glutaraldehyde (0.0025 % v/v). Samples were incubated for 2, 5, 10, 15, 20, 30 and 
60 min with the cross-linker solution and stopped with 2 µL of 20 % hydrazine per 
sample. The control sample (zero time point) did not contain any cross-linker, but was 
treated also with 2 μL of hydrazine. 6 x loading dye was added to each sample and 
samples were analysed via SDS-PAGE and western blotting. 
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Table 29 Homogenisation buffer composition for chemical cross linking 
Buffer Compound concentration 
Homogenisation buffer pH7.4 
5mM Hepes 
0.3M Sucrose 
 
2.14 Zymogram 
To assess proteolytic activity of ADAM15-A-WT and mutant ADMA15-A-EA in PC3 
cells, a gelatin zymogram was used.  
PC3 cells expressing either ADAM15-A-WT or ADAM15-A-EA and vector control 
were grown and serum starved for 30 h using serum free culture medium. Cells 
supernatants were collected and 40 µL were run on a zymogram containing 
100µg/mL gelatine in a 6% SDS-PAGE gel. Sample loading dye was prepared without 
b–mercaptoethanol or other reducing agents. The gel was run followed by a 1h 
incubation in wash buffer (Table 30), and O/N incubation in developing buffer (Table 
30), and 2h staining in Coomassie brilliant blue. Three independent repeats of 
collected cell supernatants were run on the same zymogram.  
Table 30 Zymogram buffer overview 
Buffer Compounds and concentration 
Wash buffer 
0.05mM Tris HCl 
5mM CaCl2 
2.5% Triton-X-100 
Developing buffer 
0.05mM Tris HCl 
5mM CaCl2 
 
2.15 Statistical analysis 
Within this Thesis if not stated otherwise statistical analysis was performed 
using GraphPad Prism 6.01 for Mac.  One Way Anova was performed with the 
following setting: Experimental design: no matching or pairing; Assume 
Gaussion distribution: Yes; Multi Comparison: Compare the mean of each 
column with the mean of every other column; Options: Correct for multi 
comparison, Test Tukey; Confidence interval: 0.05. The error bars are shown 
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as standard error of the mean (SEM), to show the precision of the sample 
mean. 
2.16 Prostate cancer patient samples 
83 prostate cancer patient RNA samples were kindly provided by the Welsh Cancer 
Bank (WCB). RNA was extracted from frozen tissue blocks using the QIAgen 
RNAeasy Minikit. All steps were performed according to the WCB SOP EN01. Ethics 
approval to the Welsh Cancer Bank was given by the Wales Research Ethics 
Committee (WEC) 3, as “a research tissue biobank to collect and issue biomaterials 
for cancer related research”. 
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3 ADAM15 splice profile in prostate cancer patients 
3.1 Introduction 
Biomarkers are defined as molecules found in blood or other body fluids indicating a 
change from normal to disease processes within the body. They can be further 
divided into prognostic biomarkers evaluating the disease outcome of the patient 
regardless of the treatment, or into predictive biomarkers, that evaluate the effect of 
treatment and the treatment response 283–285. Biomarkers can be proteins, epigenetic 
DNA changes, DNA or RNA, or metabolites. In the clinic, biomarkers are used to 
address seven main clinical questions such as: What is the patients risk? Does earlier 
detection decrease mortality? Who is at risk? What is the clinical outcome? Which is 
the appropriate therapy? Which therapy is effective? What is the risk of adverse 
reaction?286.  
In prostate cancer, the main diagnostic biomarker, despite its limitations, is prostate 
specific antigen (PSA). Until today, PSA is used in the clinic to diagnose prostate 
cancer, however it cannot address the clinical needs to identify patients with low PSA 
levels (<10 ng/mL), and it fails to distinguish benign from aggressive, metastatic 
disease286. 
Members of the ADAMs family have a key role in cancer formation and progression 
due to their role in regulating a number of signalling pathways79. Aberrant expression 
of especially ADAM9, ADAM10, ADAM15 and ADAM17 has been linked to cancer 
progression and it can contribute to decreased survival in breast cancer81, prostate 
cancer132 and NCSL157. Consequently, they have been considered as predictive 
markers for cancer patients.  
The predictive potential of ADAM9 and ADAM10 was assessed in a study with 259 
samples from estrogen receptor positive breast cancer patients, showing disease 
relapse upon Tamoxifen treatment. High expression levels of ADAM9, but not 
ADAM10, showed a significant higher efficacy in tamoxifen therapy. Sieuwerts et al. 
concluded that high ADAM9 expression levels predict good outcome in response to 
tamoxifen therapy287. Contrary to the beneficial effect of ADAM9 expression in breast 
cancer, Fritzsche et al. used ADAM9 expression as a PSA-independent marker in 
prostate cancer (PCa). High ADAM9 expression levels were linked to decreased 
relapse-free survival in PCa patients104. They suggested ADAM9 as a prognostic 
marker for disease aggressiveness and tumour behaviour. 
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ADAM17 is known to promote proteolytic cleavage of growth factors, including TGF-
α, amphiregulin, and TNF-α among others. It is considered to promote cancer onset 
and progression and was used by McGowan et al. as  a prognostic readout for breast 
cancer patients. The expression levels were independent from tumour size, lymph 
node stage, estrogen status or age. Patients with high ADAM17 expression levels 
showed reduced survival. Furthermore, McGowan et al. suggested ADAM17 as 
predictive for patients that are resistant to EGFR and HER-2 targeting therapies, as 
ADAM17 is known to cleave the EGFR ligand TGF-α.  
ADAM15 is associated with aggressive prostate cancer105 and breast cancer100. DNA 
levels were examined in cDNA microarrays, and ADAM15 expression was found to 
be dominant in prostate and breast carcinomas, and was linked to disease 
progression by Kuefer et al.288. Prior to this, Ortiz et al. identified the alternative exon 
use of ADAM15, which affects the intracellular domain composition, in breast cancer 
cells and they suggested an extensive investigation to characterize clinical 
tumours134. These findings and suggestions were taken further by Kleino et al.. In 
2007, Kleino et al. identified in total 13 splice variants and analysed the abundance 
of those transcripts in normal human tissues. ADAM15 splice variant A was 
predominantly expressed (up to 88%) in all analysed tissues such as, ovary, placenta, 
kidney, liver and colon. ADAM15 splice variant D was also expressed but with an 
abundance of 10 to 40%289. Zhong et al. assessed the function of the ADAM15 ICD 
splice variants, A-D, in breast cancer patients. In their study cohort, ADAM15-B and 
C were found to be significantly higher when compared to healthy tissue. ADAM15-D 
was hardly detectable and excluded from further patient analysis. In a next step, 229 
breast cancer patient samples with a follow-up period of up to 15 years were analysed 
for their ADAM15-A, B and C expression. ADAM15 expression levels were correlated 
against age, menopausal status, tumour size or grade, nodal status, Nottingham 
Prognostic Index, or steroid hormone receptor status. Relapse-free survival was 
assessed by Cox regression analysis. ADAM15-A and B were linked with poor 
prognosis in patients although they were lymph node metastasis free. Strikingly, 
patients with lymph node metastasis and high expression levels of ADAM15-C were 
found to have a better prognosis. These findings led to the conclusion that alternative  
ADAM15 splicing has functional relevance and ADAM15-A and B may drive disease 
progression. They might affect the site of the primary tumour, i.e. initiating the spread 
of cancer cells. ADAM15 splice variant C was suggested to have a positive influence 
and might have an impact on metastatic spread. However, the splice variant specific 
effect in breast cancer is complex and might affect both the tumour origin and the 
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metastatic site81. Based on Zhong et al’s. findings, Maretzky et al. found a splice 
variant specific interaction of ADAM15-B with the tyrosine kinase Src. The interaction 
led to enhanced proteolytic activity of ADAM15- B, when compared to ADAM15-A, 
and cleavage of FGFR2iiib. Src has been linked to aggressive breast cancer, 
however, FGFR2iiib is considered as tumour suppressor. The interaction of Src with 
ADAM15-B and the enhanced cleavage of the FGFR2iiib could be used to treat breast 
cancer patients, as the authors suggested that enhanced cleavage of the tumour 
suppressor FGFR2iiib by ADAM15-B leads to disease progression.156  
A recent study by Burdelski et al. (2017), analysed total ADAM15 expression in 9826 
prostate tumour tissue microarrays. High staining levels for ADAM15 were linked to 
high Gleason grade and advanced tumour stage. Additionally, PCa aggressiveness 
was linked to high ADAM15 expression levels in a small patient population132.  
Prognostic markers are important as they help to classify cancer as either benign or 
malignant. Prognostic markers are needed to prevent over or under treatment of 
patients. Herein, we want to validate and establish a qualitative qPCR method to 
analyse the splice profile of ADAM15 in PCa patients. Another prostate cancer 
marker, which is abundantly expressed, is PTK6. PTK6 relocates during prostate 
cancer progression from the nucleus to the cytoplasm leading to signalling pathway 
disruption and phenotypic changes in tumour cells273. PTK6 interacts with ADAM15 
in a splice variant specific manner and will be analysed in parallel81. 
3.1.1 Aim of the chapter 
The aim of this chapter was to develop and validate a quantitative PCR diagnostic 
method and to analyse the ADAM15 splice profile in PCa patients, in order to test 
whether the ADAM15 splice profile may predict disease outcome.  
Accordingly, a qPCR method was established and assessed for specificity, accuracy, 
sensitivity and reproducibility.  
qPCR with the ADAM15 splice variant specific primers was optimized, and validated. 
As endogenous control GAPDH was chosen. PTK6 primers were designed and 
validated accordingly. Cell lines expressing ADAM15 splice variants were initially 
used to validate the qPCR method. Subsequently, RNA samples with RIN values > 6 
of PCa patients, obtained from the Wales Cancer Bank, were analysed for their 
ADAM15 splice profile and PTK6 expression levels. The ADAM15 splice profile was 
correlated with clinical data. In addition to PCa patient tissue, RNA from 8 healthy 
77 
 
prostate tissue samples, kindly provided by Dr. Lin Ye (Cardiff University, School of 
Medicine), were analysed for ADAM15 splice variant and PTK6 expression. 
3.2 Results 
3.2.1 ADAM15 splice variant specific primers 
To analyse a quantitative ADAM15 splice profile in PCa patients, splice variant 
specific primers, designed against the ICD of ADAM15 A-E, were kindly provided by 
Dr Christian Roghi (University of East Anglia, UK) (Figure 3.1).  
 
Figure 3.1 Schematic overview of the ADAM15 ICD splice variant specific primer 
design. 
The primer design for the ADAM15 splice variants is shown, using the cDNA sequences of 
the ADAM15 ICDs for each variant. Primer pairs for each splice variant are shown in 
different colours, the calculated amplicon size is shown next to each FWD primer. Primer 
pairs were designed across exon-intron boundaries to ensure specificity. 
 
In addition, primers for the endogenous control, GAPDH, and PTK6 were designed. 
To analyse the total expression of ADAM15 in the patient samples, primers against 
the extracellular metalloproteinase domain of ADAM15 were designed and included 
in the subsequent analysis (Table 31).  
ADAM15	ICD Primer	 Amplicon
ADAM15-B     TGGACATGGGGTCTGTGACAGCAACAGGCACTGCTACTGTGAGGAGGGCTGGGCACCCCC
ADAM15-C     TGGACATGGGGTCTGTGACAGCAACAGGCACTGCTACTGTGAGGAGGGCTGGGCACCCCC
ADAM15-A     TGGACATGGGGTCTGTGACAGCAACAGGCACTGCTACTGTGAGGAGGGCTGGGCACCCCC
ADAM15-D     TGGACATGGGGTCTGTGACAGCAACAGGCACTGCTACTGTGAGGAGGGCTGGGCACCCCC
ADAM15-E     TGGACATGGGGTCTGTGACAGCAACAGGCACTGCTACTGTGAGGAGGGCTGGGCACCCCC
………
ADAM15-B     CCAGCGACTCTGCCAGCTCAAGGGACCCACCTGCCAGTACAGGGCAGCCCAATCTGGTCC
ADAM15-C     CCAGCGACTCTGCCAGCTCAAGGGACCCACCTGCCAGTACAGGGCAGCCCAATCTGGTCC
ADAM15-A     CCAGCGACTCTGCCAGCTCAAGGGACCCACCTGCCAGTACAGGGCAGCCCAATCTGGTCC
ADAM15-D     CCAGCGACTCTGCCAGCTCAAGGGACCCACCTGCCAGTACAG-----------------
ADAM15-E     CCAGCGACTCTGCCAGCTCAAGGGACCCACCTGCCAGTACAGGGCAGCCCAATCTGGTCC
ADAM15-B     CTCTGAACGGCCAGGACCTCCGCAGAGGGCCCTGCTGGCACGAGGCACTAAGCAGGCTAG
ADAM15-C     CTCTGAACGGCCAGGACCTCCGCAGAGGGCCCTGCTGGCACGAGGCACTAAGCAGGCTAG
ADAM15-A     CTCTGAACGGCCAGGACCTCCGCAGAGGGCCCTGCTGGCACGAGGCACTAAG-------
ADAM15-D     ------------------------------------------------------------
ADAM15-E     CTCTGAACGGCCAGGACCTCCGCAGAGGGCCCTGCTGGCACGAGGCACTAAG--GCTAG
ADAM15-B     TGCTCTCAGCTTCCCGGCCCCCCCTTCCAGGCCGCTGCCGCCTGACCCTGTGTCCAAGAG
ADAM15-C     TGCTCTCAGCTTCCCGGCCCCCCCTTCCAGGCCGCTGCCGCCTGACCCTGTGTCCAAGAG
ADAM15-A     ----------------------------------------------------TC------
ADAM15-D     ------------------------------------------------------------
ADAM15-E     TGCTCTCAGCTTCCCGGCCCCCCCTTCCAGGCCGCTGCCGCCTGACCCTGTGTCCAAGAG
ADAM15-B     ACTCCAG----------------------------------------------------
ADAM15-C     ACTCCAGGCTGAGCTGGCTGACCGACCCAATCCCCCTACCCGCCCTCTGCCCGCTGACCC
ADAM15-A      -----------------------------------------------------------
ADAM15-D      -----------------------------------------------------------
ADAM15-E     ACTCCAGGCTGAGCTGGCTGACCGACCCAATCCCCCTACCCGCCCTCTGCCCGCTGACCC
ADAM15-B      ------------------TCTCAGGGGCCAGCCAAGCCCCCACCCCCAAGGAAGCCACT
ADAM15-C     GGTGGTGAGAAGCCCGAAGTCTCAGGGGCCAGCCAAGCCCCCACCCCCAAGGAAGCCACT
ADAM15-A      --------------------TCAGGGGCCAGCCAAGCCCCCACCCCCAAGGAAGCCACT
ADAM15-D      ------------------TCTCAGGGGCCAGCCAAGCCCCCACCCCCAAGGAAGCCACT
ADAM15-E     GGTGGTGAGAAGCCCGAAGTCTCAGGGGCCAGCCAAGCCCCCACCCCCAAGGAAGCCACT
……
FWD-A
FWD-D
FWD-B
FWD-C
FWD-E
REV-B
REV-C
REV-A
REV-D
REV-E
288bp
218bp
95bp
154bp
92bp
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Table 31 Sequence overview for qPCR primer sets. 
 
 
3.2.2 Analysis of ADAM15 splice variants, PTK6 and GAPDH primers 
To ensure that obtained primers were optimally designed to perform high quality 
qPCR, all primer sequences were first checked using the OligoEvaluator software 
(Sigma-Aldrich) for secondary structures, self-dimers and cross-dimer formation. The 
ΔG values, Gibbs Free Energy G, to break secondary structures were required to be 
up to – 5 kcal/mol for self dimer and – 6 kcal/mol for cross-dimers for each primer 
pair, but none of the ADAM15 ICD primers showed self or cross-primer dimer 
formation (Table 32). Secondary structures were found for all ICD primers, with the 
exception of ADAM-15-E FWD. The ADAM15-C and E REV primers showed 
secondary structures, which were found to be very strong, however, they were below 
the calculated annealing temperature and therefore irrelevant.  
Primer	Sets NCBI-ID
Sequence
(5’->3’)
Start-Stop Amplicon	 size	bp
ADAM15-A NM_001261464.1
FWD GTGACAGCAACAGGCACTGCTACTG 2101-2125bp
288
REV GCCCCTGAGACTTAGTGCCTC 2388-2368bp
ADAM15-B NM_207194.2
FWD CGAGGCACTAAGCAGGCTAGTGCTC 2367-2391bp
218
REV GCCCCTGAGACTGGAGTCTC 2463-2444bp
ADAM15-C NM_207196.2
FWD CGAGGCACTAAGGCTAGTGCTCTC 2367-2390bp
95
REV GCCCCTGAGACTTCGGGCTTC 2532-2512bp
ADAM15-D NM_207191.2
FWD GTGACAGCAACAGGCACTGCTACTG 2101-2125bp
154
REV GCCCCTGAGACTGTACTGGC 2318-2299bp
ADAM15-E NM_207195.2
FWD CGAGGCACTAAGGCTGAGCTGG 2367-2388bp
92
REV GCCCCTGAGACTTCGGGCTTC 2460-2440bp
ADAM15-MP NM_00126146.1
FWD GCTGATCACTCGGAGGCCCAGAAATACCGGGACTTC 1040-1074bp
237
REV CCTGGTAGGAAGTCTGTGGAGGCCTCC 1305-1279bp
GAPDH NM_001289746.1
FWD GGCACCGTCAAGGCTGAGAACGGGAAGC 274-301bp
170
REV CCCTGCAAATGAGCCCCAGCCTTCTCC 443-417bp
PTK6 NM_005975.3
FWD GATCAGGGTCAGCGAGAAGC 365-384bp
163
REV GGCCCTGTGGTAGTTCACAA 527-508bp
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Table 32 Overview of secondary primer structures for the qPCR primer sets. 
 
 
3.2.3 Temperature and primer concentration optimization  
The melting temperature (Tm) of ADAM15 ICD specific primers, PTK6, ADAM15-MP 
and GAPDH primers was also calculated using the OligoEvaluator (Sigma-Aldrich). 
Based on this evaluation, temperature gradients for each primer sets were chosen 
and tested (Table 33). Splice variant specific expression plasmids were kindly 
provided by Dr. Z. Poghosyan. 10ng of either pcDNA4-ADAM15 A to E plasmids for 
the ADAM15 splice variant specific primers, or 100 ng of PC3 PCa cell line cDNA, for 
GAPDH, PTK6 and ADAM15-MP primers were used to run temperature gradients. All 
samples were analysed in triplicate in the iQ 96-Well real time semi skirted PCR 
plates which were sealed with an adhesive seal. Primer titrations from 100 nM-400 nM 
per reaction were used per temperature step. Annealing temperature for ADAM15-A, 
C, E and MP primers was optimized to 66 °C, whereas ADAM15-B, D and PTK6 
primers were optimized to 64 °C. The GAPDH primer set was optimized for both 
temperatures, as they were needed as endogenous controls (Table 33). Primer 
concentrations for all primer sets were optimized to 400 nM (Table 33).  
Primer Secondary	Structure
Tm of	secondary	structure	<	
annealing	 Tm
ΔG	<-5kcal/mol	 	(Self-
dimer)
ΔG	<-6kcal/mol	 					 				 				 				
(cross	dimer)
Expected	self	and	
cross	dimers
A
FWD moderate Yes Yes Yes no
REV weak Yes Yes Yes no
B
FWD strong Yes Yes Yes no
REV moderate Yes Yes Yes no
C
FWD strong Yes Yes Yes no
REV very	strong Yes Yes Yes no
D
FWD moderate Yes Yes Yes no
REV moderate Yes Yes Yes no
E
FWD none Yes Yes Yes no
REV very	strong Yes Yes Yes no
ADAM15-MP
FWD Moderate Yes Yes Yes no
REV weak Yes Yes Yes no
GAPDH
FWD Strong Yes Yes Yes no
REV moderate Yes Yes Yes no
PTK6
FWD moderate Yes Yes Yes no
REV Weak Yes Yes Yes no
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Table 33 Overview of primer concentration and Tm optimization. 
 
 
qPCR was performed using the CFX Connect Real–Time PCR Detection System 
from Bio-Rad, using the protocol shown below (Table 34). 
Table 34 qPCR cycle condition overview. 
 
 
3.2.4 Product specificity 
To ensure product specificity of the ADAM15 A-E splice variant specific primer sets, 
following annealing temperature and primer concentration optimization, the melting 
curves were analysed using ADAM15 A-E splice variant specific expression vectors 
as the template.  
ADAM15 A-E splice variant specific products showed a single melt peak with no 
shoulder, representing a single amplicon for all splice variants. As a representative 
Primer Calculated	 Tm	°C
Gradient
°C
Optimized	
Tm°C
Primer	
concentration	
gradient	nM
Optimized	 primer	
concentrations	 nM
A
FWD 66.3
59	- 71 66
100- 400 400
REV 63.7
B
FWD 67.9
59	- 72 64
REV 63.5
C
FWD 66.1
61	- 71 66
REV 65.7
D
FWD 66.3
59	- 71 64
REV 63.5
E
FWD 65.8
60	- 70 66
REV 65.7
ADAM15-MP
FWD 73 60-73
66
REV 71
GAPDH
FWD 70 60-73
64+66
REV 72
PTK6
FWD 66.4
59-69 64
REV 64.9
	 Temperature	 Duration	 Cycles	
Enzyme	activation	 95°C	 3min	 1	
Denaturation	 95°C	 10sec	
39	
Annealing/extension	 Primer	Tm	dependent	 30sec	
Dissociation/	Melt	curve	 Primer	Tm	dependent	-	95°C	
increment	0.5°C	for	
5sec	
1	
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example, ADAM15- D was chosen. The negative first derivative (- d (RFU)/dt) of the 
change in fluorescence (RFU), is plotted versus the temperature, showing a single 
peak for ADAM15- D and no detectable peak for the non-template controls (NTCs) 
(Figure 3.2 A). Agarose gel electrophoresis for PC3 cDNA samples, analysed for all 
primer sets, showed PCR amplicons of the correct size (Figure 3.2 C). However, 
ADAM15- MP domain primers showed two products on the gel, which were not 
detectable by qPCR (Figure 3.2 D). As expected from the melt curve analysis, a single 
band for all primer set amplicons, with exception of the ADAM15- MP primers, was 
detectable. No product amplification was detectable for NTCs (Figure 3.2 B).  
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Figure 3.2 qPCR method specificity verification using melt curves and agarose gel 
electrophoresis. 
(A) Melt curve analysis of generated products for all primer sets were generated. An 
example is shown for ADAM15-D. The expression plasmid, pcDNA-4-ADAM15-D, was 
used as template. The plot for the negative first derivative of the fluorescence versus 
temperature (-d(RFU)/dt vs T) shows 1 single peak for each the ADAM15-D triplicates, 
using a Tm of 64°C, and no peak for the NTC control is detectable. (B) An 1% agarose gel 
was used to analyse the qPCR products from PC3 cells isolated cDNA. All primer sets 
showed presence of amplification product of the expected calculated amplicon size, with 
exception of the MP-domain which showed a second slightly smaller amplicon(C). qPCR 
results for Melt curve and melt peak for ADAM15-MP primers, showing no second peak. 
NTC are free from amplification products (D). 
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Primer	set Amplicon
ADAM15-A 288bp
ADAM15-B 95bp
ADAM15-C 154bp
ADAM15-D 218bp
ADAM15-E 92bp
GAPDH 170bp
PTK6 163bp
ADAM15-MP 446bp
M
P
C
PC3
Ct-Values GAPDH NTC
64 18.64 18.04 17.77  N/A N/A N/A
66 17.36 17.78 18.02  N/A N/A N/A
70 17.59 17.52 17.86  N/A N/A N/A
Ct-Values MP-2 NTC
64 22.47 22.51 22.43 34.05 33.12 33.42
66 21.87 22.22 22.91 36.01 32.11 31.8
70 22.42 21.72 22.29 32.49 33.35 32.4
Ct-Values MP-3 NTC
64 33.25 33.05 32.75 38.26  N/A N/A
66 32.72 32.42 31.33 38.62  N/A N/A
70 33.35 32.36 32.58 39.22  N/A N/A
MP-2 Primer validation 
Primer set: MP-2 REV & MP-1FWD
Template: 25ng/5uL
Primer : 400nM
MP-3 Primer validation 
Primer set: MP-3 REV & MP-1FWD
Template: 25ng/5uL
Primer : 400nM
GAPDH Primer validation 
Primer set: GAPDH FWD& REV
Template: 25ng/5uL
Primer : 400nM
Aim: Validation of GAPDH and MP-2+MP3 primers for the use in qPCR
Method: To validate the mentioned primer sets, temperature gradients were performed from 64-70C with 25ng of 
template and 400nM of primer/qPCR reaction.
Result: GAPDH primer sets work at 64 and 66C and show no unspecific binding. MP-2 also works for both 
temperatures however, primers show high amount of self-priming which is why this primer set is excluded. MP-3 
primer set needs to obtain lower Ct-values (higher primer concentration i.e. 500nM).
Validation of GAPDH and A15-Metalloproteinase MP-2 & MP3 primer sets
T	[°C]
Melt	Curve
RF
U
D
Ct-Values GAPDH NTC
64 18.64 18.04 17.77  N/A N/A N/A
66 17.36 17.78 18.02  N/A N/A N/A
70 17.59 17.52 17.86  N/A N/A N/A
Ct-Values MP-2 NTC
64 22.47 22.51 22.43 34.05 33.12 33.42
66 21.87 22.22 22.91 36.01 32.11 31.8
70 22.42 21.72 22.29 32.49 33.35 32.4
Ct-Values MP-3 NTC
64 33.25 33.05 32.75 38.26  N/A N/A
66 32.72 32.42 31.33 38.62  N/A N/A
70 33.35 32.36 32.58 39.22  N/A N/A
MP-2 Primer validation 
Primer set: MP-2 REV & MP-1FWD
Template: 25ng/5uL
Primer : 400nM
MP-3 Primer validation 
Primer set: MP-3 REV & MP-1FWD
Template: 25ng/5uL
Primer : 400nM
GAPDH Primer validation 
Primer set: GAPDH FWD& REV
Template: 25ng/5uL
Primer : 400nM
Aim: Validation of GAPDH and MP-2+MP3 primers for the use in qPCR
Method: To validate the mentioned primer sets, temperature gradients were performed from 64-70C with 25ng of 
template and 400nM of primer/qPCR reaction.
Result: GAPDH primer sets work at 64 and 66C and show no unspecific binding. MP-2 also works for both 
temperatures however, primers show high amount of self-priming which is why this primer set is excluded. MP-3 
primer set needs to obtain lower Ct-values (higher primer concentration i.e. 500nM).
Validation of GAPDH and A15-Metalloproteinase MP-2 & MP3 primer sets
-d
(R
FU
)/
dt
T	[°C]
Melt	PeakADAM15-MP
NTC	ADAM15-MP
PC3	ADAM15-A
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3.2.5 Taq-Polymerase optimization for GC – rich templates 
To validate the Taq-polymerase efficiency used for the amplification of ADAM15 
splice variants, two different Taq polymerases were tested using the cDNA from the 
PC3 prostate cancer cells. The iQ SYBR Green supermix and the KAPA SYBR Fast 
were compared. GC content for all ADAM15 splice variant specific templates was 
calculated using the EndMEMO DNA GC content calculator. 
ADAM15 A-E templates are GC-rich, as their calculated GC-content is > 75 % (Figure 
3.3 A). qPCR using both SYBR green mixes, revealed equal splice variant 
amplification for splice variants A, B, D and E. In contrast, the iQ SYBR green 
supermix failed to amplify splice variant C (Figure 3.3 B). However, using the KAPA 
SYBR Fast mix for GC rich templates, amplification of splice variant C was possible 
(Figure 3.3 B). 
 
Figure 3.3 Validation of SYBR green polymerase for GC-rich templates. 
The GC-content of the ADAM15 A-E splice variant primer amplified templates was 
calculated using the EndMEMO DNA GC content calculator. The GC content is shown in 
(A), GAPDH GC content is shown as control. All ADAM15 splice variant amplified templates 
showed a GC content >75%. To validate the KAPA SYBR FAST qPCR mix for the 
amplification of GC-rich templates, the BioRad SYBR Green Master Mix was used in 
comparison. All splice variants were amplified using the KAPA SYBR green, whereas the 
BioRad SYBR green was not able to amplify the ADAM15-C splice variant (B), indicated by 
the green circle. Ct values for GAPDH were divided by each splice variant and were plotted 
as GAPDH/splice variant ratio. 
 
3.2.6 Standard curves and qPCR efficiency optimization 
To guarantee equal amplification for all ADAM15 splice variants, ADAM15-MP and 
PTK6, standard curves were used in a range of 10-1 to 10-4 ng of the splice variant 
specific expression plasmids. For PTK6, the pcMV3-PTK6 expression vector was 
used. ADAM15-MP standard curves were generated using the ADAM15-A specific 
expression vector. 
GC	content
ADAM15-A 76%
ADAM15-B 77%
ADAM15-C 78%
ADAM15-D 75%
ADAM15-E 78%
GAPDH 56%
A B
0.0
0.5
1.0
G
A
PD
H
/ s
pl
ic
e 
va
ria
nt
 ra
tio
KAPA SYBR Fast IQ SYBR green Supermix
A B C D E
ADAM15 splice variants
84 
 
qPCR efficiency (e) was calculated following annealing temperature and primer 
concentration optimization, and calculated using the following equation, ε = 100*(10-
1/slope-1) (Figure 3.4 A). The efficiency of the splice profile analysis was in the 
recommended range of 90-105%, and all splice variants, ADAM15-MP and PTK6 
showed a similar amplification efficiency of 90-94 %. R2 for all standard curves was 
calculated with > 0.98 (Figure 3.4 B). Ct values for replicates were in a similar range. 
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Figure 3.4 Determination of qPCR reaction efficiency using standard curves. 
(A) Standard curves were used to assess the qPCR amplification efficiency (90-105%) and 
the linear dynamic range (R2 >0.980). Amplification efficiency (ε) is shown for each primer 
set. Harmonized amplification efficiency was obtained for all primer sets after temperature 
and primer amount optimization. (B)Standard curves using the ADAM15 splice variant 
specific mammalian expression vectors in pcDNA4-A and the mammalian expression 
vector pcMV3-PTK6 for PTK6. Standard curves were titrated from a range of 0.1ng to 100fg.  
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3.2.7 Analysis of the ADAM15 splice profile in prostate cancer cell lines 
Initially, the splice profile of ADAM15 expression in the prostate cancer cell lines PC3 
and LNCaP was analysed. ADAM15 splice variant A, C, E, ADAM15-MP and GAPDH 
were run on one plate, as annealing temperature was optimized to 66 °C. ADAM15-
B and D, PTK6 and GAPDH were run on a separate plate, as the annealing 
temperature was optimized to 64 °C for those primer sets. Standard curves for all 
splice variants were run on the corresponding plates. The GAPDH Ct values were 
divided by Ct values for each ADAM15 splice variant and plotted as GAPDH ratio. 
qPCR analysis of the ADAM15 splice profile in PC3 and LNCaP showed differences 
in expression levels for each splice variant. PC3 cells showed presence of 
predominantly splice variant A, weak presence of splice variant B, and similar levels 
of splice variant C, D and E (Figure 3.5 A). In LNCaPs, expression of splice variant A 
and D was found predominantly (Figure 3.5 B). ADAM15-MP primers, which were 
initially designed to show the overall ADAM15 expression, as they detect total 
ADAM15, however, for both cell lines the overall amount of ADAM15 present in the 
cell lines could not be determined. This might be linked to the fact that two amplified 
bands were present on the gel (Figure 3.2 B), and thus excluded this primer set from 
further analysis. PTK6 expression levels were enhanced in PC3 cells, when 
compared to LNCaPs (Figure 3.5 C). 
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Figure 3.5 ADAM15 splice profile and PTK6 expression in prostate cancer cell lines. 
ADAM15 A-E splice variants, and PTK6 expression was analysed by qPCR in the prostate 
cancer cell lines PC3 (A) and LNCaP (B). GAPDH was used as endogenous control. 
GAPDH-Ct values were divided by Ct values for the targets and are expressed as GADPH 
ratio. PTK6 expression between the two cell lines was compared and plotted as 
GAPDH/PTK6 ratio (C).  
 
3.2.8 Validation and reproducibility of the ADAM15 splice profile in patients 
To start the analysis of the ADAM15 splice profile and PTK6 levels in PCa patient 
samples, 5 patient RNA samples were randomly chosen and analysed twice by 
qPCR. As an additionally quality control, PCa patient samples with an RNA integrity 
number of  (RIN) >6 were included in the analysis, samples with a RIN value below 6 
were excluded, due to high RNA degradation. 
An ADAM15 splice profile was obtained for all patient samples. PTK6 expression was 
also detectable for all patient samples. Splice variant specific differences for each 
patient were obtained, when the GAPDH value was divided by that of the splice 
variants and plotted as GAPDH ratio. Reproducibility of the splice profile and PTK6 
expression was achieved for all patient samples (Figure 3.6). 
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Figure 3.6 qPCR method validation using patient samples. 
Five patient samples were analysed via qPCR for the expression of the ADAM15 splice 
variants and PTK6. Samples were re-analysed blinded, shown in red. Each graph 
represents the qPCR analysis for one patient and the blinded repeat. GAPDH-Ct values 
were divided by Ct values for the ADAM15 splice variants and PTK6 and are expressed as 
GADPH ratio. 
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3.2.9 ADAM15 splice variant and PTK6 expression is significantly lower in 
healthy prostate tissue compared to PCa patient samples 
To assess differences of ADAM15 splice variant and PTK6 expression, prostate 
cancer patient samples and healthy tissue samples were analysed using qPCR. 83 
prostate cancer patient samples obtained from the Wales Cancer Bank, and 8 healthy 
prostate samples, obtained from Dr. Lin Ye (Cardiff University, School of Medicine), 
were analysed. 
Significant upregulation of all ADAM15 splice variants and PTK6 was found when 
splice profiles from patient samples and heathy tissue were compared (Figure 3.7 A). 
In healthy tissue samples, splice variant B was expressed highest, in contrast to the 
patient samples, where splice variant C was the most abundant (Figure 3.7 A). 
Assessing statistically significant changes (Figure 3.7 C) within the splice variants, 
One-way-Anova, comparing each splice variant for healthy tissue and prostate cancer 
samples, revealed, that ADAM15-C is significantly higher expressed, compared to 
splice variants B, D, E and compared to PTK6. Significant changes for splice variants 
and PTK6 are summarized in Figure 3.7 C. 
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Figure 3.7 ADAM15 and PTK6 expression profile in healthy prostate tissue and 
prostate cancer patients. 
Using qPCR with ADAM15 splice variant specific primers and primers for PTK6 and GAPDH 
as control an expression profile was generated. (A) Expression profile of mean values for 
healthy prostate tissue (n=8) and prostate cancer samples (n=83). Significant 
overexpression of ADAM15 splice variants and PTK6 was found when compared to healthy 
tissue. (B) Splice profile in prostate cancer patients, showing all analysed patients 
individually. Ct values were normalized against GAPDH. (C) Statistical analysis of the splice 
profile generated in patients. Using One-Way-Anova, ADAM15 splice variants and PTK6 
were compared with each other. Significant changes of the splice variants with each other 
and PTK6 are summarized in the table. p>0.05 *, p<0.01 **, p<0.001 ***, p<0.0001 ****. 
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3.2.10 ADAM15 splice profile in healthy tissue and PCa patients 
To assess a difference in splice variant expression between healthy tissue and PCa 
patients, a Forest plot analysis was conducted by calculating the mean difference 
between healthy and PCa patients plotted for each splice variant and PTK6. Resulting 
calculated values, represents the change in expression from healthy to cancerous 
tissue for each splice variant. 
In Figure 3.8 A, the mean difference in expression of ADAM15 splice variants and 
PTK6 revealed that ADAM15 splice variant A shows the highest change in 
expression, followed by splice variants C and E, when comparing healthy tissue and 
PCa patient samples. Splice variant B and D showed the lowest change in 
expression, even lower than the change in PTK6 expression levels.  
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Figure 3.8 Forest plot of mean difference between ADAM15 splice variants and PTK6 
in healthy tissue and PCa patients. 
A Forest plot was conducted to plot the mean difference of the GAPDH ratios for each splice 
variant and PTK6 in healthy tissue and PCa patients (A). The mean values and standard 
deviation for each splice variant and PTK6 were calculated. The mean difference was 
calculated by subtracting PCa patient means from healthy tissue means. Upper and lower 
confidence intervals (95%) were calculated for each data point, and plotted for each data 
point as error bars. The calculated means in difference between healthy tissue and PCa 
patients for each splice variant and PTK6 are shown in the Forest plot above. The Forest 
plot was generated using GraphPad Prism. (B) Summary of data and performed 
calculations, used for the Forest plot analysis. 
 
 
3.2.11 Correlation of clinical patient data with the ADAM15 splice profile 
Clinical data such as Gleason score, tumour grade, disease relapse, deceased 
patients were obtained for the patient cohort we analysed here, and were arranged 
in a table and presented as overall percentage. Since for 17 patients clinical data for 
Gleason score, and for 20 patients clinical data for tumour grade were missing, those 
patients are presented as unknown.  
Patient classification by Gleason score is shown in Table 35. 42 patients showed a 
score of 7, 23 patients a score of 6 (Table 35). Patients with a Gleason score of 8, 9 
and 10 were excluded, as for each of the scores, only one patient was available for 
analysis (Supplementary data Figure 8.3). The most abundant tumour grades was 2, 
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with 25 patients, and then tumour grade 3a, with 21 patients. Overall, 13 patients 
suffered from disease relapse, and 5 patients were eventually deceased (Table 35). 
Table 35 Overview of clinical patient data 
 
 
In order to analyse potential correlation of ADAM15 splicing with clinical parameters 
such as Gleason score, tumour grade, disease relapse or patient’s death, Forest plot 
analysis was performed after unblinding the patient samples (Figure 3.9). 
Upon calculating the mean difference between each setting with the overall patient 
splice profile and PTK6 expression, the analysis revealed that the changes in 
ADAM15 splice variant expression and PTK6 within the different patient groups were 
very low, and further showed a very high variation, which can be explained due to the 
limited amount of patient samples (Figure 3.9A-D). Correlation of patient data with a 
high Gleason score of 9 (n=1) or 10 (n=2) could not be performed as this patient 
cohort was too small. ADAM15-D showed overall the highest variability (Figure 3.9), 
which might be linked to the distribution of patient expression levels around the overall 
mean. This might suggest, that there might be two cohorts having low and high values 
(Figure 3.7 B).  
Number	of	
patients
Gleason	score
6 23
7 42
unknown 17
Tumour grade
2 25
3 6
3a 21
3b 8
unknown 20
Relapse 13
Deceased 5
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Figure 3.9 Forest plot analysis for the correlation of clinical patient data with the 
ADAM15 splice profile and PTK6. 
Forest plot were used to assess a change in expression within the clinical patient data and 
expression of ADAM15 splice variants and PTK6. The mean difference is plotted for each 
of the ADAM15 splice variants and PTK6.  
 
3.3 Discussion 
In this chapter, we analysed and validated for the first time the ADAM15 splice profile 
in prostate cancer patients, and compared this to healthy tissue and available clinical 
data.  
According to the MIQE guidelines (Minimum Information for Publication 
of Quantitative Real-Time PCR Experiments)290, we established successfully a 
method to analyse the ADAM15 splice profile in PCa patients, using splice variant 
specific primers. We were able to generate a robust method, as standard curves 
showed a qPCR efficiency between 90-94 %, data were reproducible, and all splice 
variants were amplified to a similar extent when using the KAPA SYBR fast Master 
mix. Using cell lines, we validated our method, by analysing the ADAM15 splice profile 
and PTK6 expression.  
In prostate cancer patients (n=83) we found significant overexpression of ADAM15 
splice variants and PTK6 when compared to healthy tissue (n=8). Using a Forest plot, 
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we showed that ADAM15-A shows the highest change in expression when healthy 
tissue and PCa patient samples were correlated. In a recent study 12,427 PCa patient 
samples were analysed by immunohistochemistry for total ADAM15 expression using 
tissue microarray132. ADAM15 staining was found to be present in PCa tissue from 
patients, however not in normal prostate tissue132. Burdelski et al. grouped ADAM15 
staining from these samples into negative (87.7 %), weak (3.3 %), moderate (5.6 %) 
and strong (3 %). Patients showing strong ADAM15 staining were linked to high 
Gleason score, high tumour grade, and positive nodal stage132. Our overall splice 
profile of the 83 patients revealed that the ADAM15 splice variants A and C were the 
most abundant in prostate cancer, in contrast to ADAM15-B which is high in breast 
cancer81. However, when correlating the splice variant expression and clinical data 
using Forest plots, our analysis failed to identify a change in expression for the splice 
variants, as the study cohort in our case was too small and lacked high tumour grade 
samples. In prostate cancer until today, no ADAM15 splice profile is available, as the 
study by Burdelski et al., only assessed the presence of total ADAM15 and does not 
assess splice variants individually. Zhong et al. could identify, that in breast cancer 
patients suffering from disease relapse, ADAM15-C expression is most favourable, 
although patients were lymph node positive. In our study, unblinding of samples 
revealed, either a nodal score of NX (i.e. cannot be evaluated) or of N0 (i.e. cancer 
has not spread). Similar to this, only samples with a metastatic score of 0 were 
present in our study. At this stage, no correlation of nodal score and beneficial 
ADAM15 splice variant expression can be made. 
Zhong et al. conducted Cox regression analysis, to assess the correlation between 
relapse free survival and splice variant expression. In a subpopulation, they were able 
to correlate relapse-free survival to high expression of splice variant C81. Our data 
however, lack extensive follow up of patients and also a defined time point for disease 
onset. At this point, with regard to available patient sample data, neither Cox 
regression nor Kaplan Maier analysis can be conducted. Using the Forest plot, we 
were able to identify that ADAM15-A shows the highest change in expression, 
however, additional PCa patient samples, which are categorized as benign 
hyperplasia as this would help to define a non-effect point and also those with higher 
Gleason score and tumour grades, are required to complete this study.  
Although we see a trend in our data that a high tumour grade might be linked to high 
ADAM15 expression, which was also found by Burdelski et al. using 12,427 
samples132, we cannot draw any further conclusions, as clinical data are missing and 
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the study cohort is too small. However, the data indicate that ADAM15-A may involved 
in prostate cancer progression and thus lead us to analyse this splice variant in more 
detail, using an overexpression model in the PCa cell lines LNCaP and PC3 (Chapter 
4,5 and 6). 
In summary, within this chapter we showed the establishment of a robust qPCR 
method to assess the ADAM15 splice profile in prostate cancer patients. Further, we 
showed that ADAM15 splice variants were differently expressed in the prostate 
cancer cell lines PC3 and LNCaP. We further demonstrated, that ADAM15 splice 
variants A showed the highest change in expression when compared to the healthy 
tissue. Although our data indicate differences in splice profiles of androgen dependent 
and androgen independent cell lines we would further aim to elucidate the role of 
splice variant expression differences by including more prostate cancer cell lines in 
our analysis. To enhance the statistical power of our data we would need to include 
a larger patient cohort and further we would access the samples unblinded. Unblinded 
samples would help to ensure to include enough patients for each group such as 
benign, advanced and metastatic prostate cancer. 
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4 ADAM15 splice variant specific impact on prostate 
cancer cell characteristics 
4.1 Introduction 
Expression of ADAM15 correlates with disease aggressiveness, in as much as it 
controls cell adhesion, migration, proteolysis of growth factors, growth factor 
receptors, and modulate cytokine signalling. 
ADAM15 has been suggested to enhance prostate cancer metastasis by modulating 
the tumour endothelial cell-cell interaction105. Using shRNA to downregulate ADAM15 
in PC3 cells, Najy et al. showed that migration of shADAM15 PC3 cells was 
significantly reduced in a wound closure assay, when compared to vector control 
cells. Furthermore, cellular adhesion to fibronectin, laminin and vitronectin, was 
significantly reduced. Najy et al. showed that ADAM15 was additionally involved in 
proteolysis of N-cadherin. A different study by Dong et al. in NSCLC cells, confirmed 
the ADAM15 dependent reduction of cell invasion, when MMP9 was 
downregulated157. ADAM15 expression levels were associated with decreased 
survival and ADAM15 mechanistically upregulated MMP9 expression and also 
activated pro-MMP9 promoting invasion. The findings correlate with Martin et al., 
confirming that the proteolytic activity of ADAM15 is necessary to promote migration. 
Upon metalloproteinase inhibitor treatment, migration of mesangial cells was 
significantly reduced153.  
Splice variant specific differences in cell characteristics were found upon 
overexpression of splice variant A and B in the breast cancer cell line MDA-MB435. 
ADAM15-A expressing cells showed increased adhesion and migration compared to 
vector control and ADAM15-B cells. Furthermore, the ADAM15 levels affected the 
actin cytoskeleton organisation. ADAM15-B expressing cells had shorter actin fibres 
and a strong cortical actin staining, whereas ADAM15-A expressing cells showed 
actin resembling similar to the vector control81.  
ADAM15 was shown to interact with various intracellular kinases involved in cancer 
progression, including the tyrosine kinase PTK6, which interacts with ADAM15 A and 
B but not with C81. These data indicated that ADAM15 may play a role in regulating 
PTK6 localization. Knock out of PTK6 in PC3 cells significantly reduced invasion, 
proliferation and colony formation, and increased survival and reduced metastatic 
disease spread in a mouse model263. 
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During prostate cancer progression, tumour cells gain metastatic potential and shift 
from androgen dependent to androgen independent status32. PTK6, unlike other Src-
family kinases, lacks a myristoylation sequence. Derry et al. showed, that the altered 
localization of PTK6 in PCa patient biopsies is dependent on tumour grade. In 
androgen dependent LNCaP PCa cell line, PTK6 was predominantly nuclear, 
whereas in the androgen independent PC3 PCa cell line, expression was 
cytoplasmic, which might be an indicator of prostate cancer progression273. 
4.1.1 Aims of the chapter 
In this chapter, the impact of the ADAM15 splice variant overexpression on cell 
characteristics of LNCaP and PC3 PCa cells will be investigated. Additionally, the 
impact of ADAM15 splice variants on PTK6 localization and expression in both cell 
panels, will be evaluated. 
PC3 and LNCaP were stably transfected with the ADAM15 splice variants A-E and 
analysed for changes in cell morphology, cell size, cell cycle, and actin cytoskeleton. 
The ADAM15 splice variant specific impact on cell migration and invasion was 
assessed. The ADAM15 splice variants on PTK6 localization were assessed using 
immunofluorescence staining. 
4.2 Results 
4.2.1 Overexpression of ADAM15 splice variants in PC3 and LNCaP 
As shown in Chapter 1 (Figure 3.5), PC3 and LNCaP PCa cell lines express certain 
ADAM15 splice variants. PC3 cells express predominantly ADAM15-A, whereas 
ADAM15-A and D are expressed in LNCaPs. To study the splice variant specific effect 
of ADAM15 overexpression in prostate cancer, two cell panels, stably overexpressing 
the splice variants individually, were generated in the PC3 and LNCaP cell line by 
Lentiviral transfection with plasmids containing the coding sequence of human 
ADAM15-A, B, C, D, and E, and an additional C-terminal V5-tag (Figure 4.1 A). Cell 
lines expressing the empty pcDH vector, were used as a vector transfection control 
cell line. ADAM15 splice variant expression was confirmed using western blotting by 
staining with an anti-V5 antibody, for both cell panels (Figure 4.1 B). Stable 
overexpression was confirmed in both cell panels using qPCR with the splice variant 
specific primers (Figure 4.1 C).   
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Figure 4.1 PC3 and LNCaP cell lines, stably overexpressing ADAM15 splice variants 
A-E 
(A) Lentiviral transfection was applied to generate PC3 and LNCaP stable cell lines 
expressing the ADAM15 splice variants A-E using the human expression vector pcDH or 
the empty pcDH-Vector as a transfection control. (B) Western blot analysis of the cell lysates 
from ADAM15 splice variants A-E expressing cells as indicated. (C) Quantitative 
overexpression after stable transfection was assessed using qPCR with the splice variant 
specific primers. 
 
4.2.2 Analysis of cell morphology, cell-size and cell cycle in ADAM15 A-E 
overexpressing PCa cell lines  
To evaluate whether ADAM15 A-E variants affect cell morphology, phase contrast 
images were acquired from PC3 and LNCaP stably overexpressing ADAM15 A-E at 
72h post trypsinization and cultivation in 35mm dishes. The heterogeneous 
morphology of the PC3 cell panel was maintained when compared to the vector 
control (Figure 4.2). LNCaP cell morphology also remained unaffected (Figure 4.3). 
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Figure 4.2 Analysis of cell morphology changes in PC3 cells overexpressing ADAM15 
A-E. 
Phase contrast images of the PC3 cell panel were taken randomly 72h post trypsinization.  
 
Cell-size was determined by flow cytometry, by determining the cell volume shown 
as median forward scatter, which remained identical for both cell panels (Figure 4.5 
A and B).  
PC3-Vector PC3-ADAM15-A PC3-ADAM15-B
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Figure 4.3 Analysis of cell morphology changes in LNCaP cells overexpressing 
ADAM15 A-E. 
Phase contrast images of the LNCaP cell panel were taken randomly 72h post 
trypsinization.  
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Figure 4.4 Cell size analysis for the PC3 and LNCaP cell panel 
(A-B) The cell size after stably overexpressing the ADAM15 splice variants was assessed 
using flow cytometry. The cell volume was determined using a single parameter histogram 
and the median forward scatter (FSC-A). The FSC is proportional to the cell surface area 
and is plotted as dimensionless unit, the median of FSC-A (FSC-A Median) versus the 
splice variants. 
 
Cell cycle analysis for both cell panels was performed, by analysing changes in 
G1/G0, S-phase and G2/M phase. ADAM15 splice variant expressing PC3 and 
LNCaP cells were distributed equally among the phases, when compared to vector 
control (Figure 4.5 A,B). Additionally, a calorimetric metabolic cell proliferation (MTS) 
assay was performed using the PC3 cell panel. No changes in cell proliferation within 
the cell panel were observed (Figure 4.5 C). 
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Figure 4.5 Cell cycle analysis and proliferation analysis for the overexpressing 
ADAM15 A-E cell panels 
(A,B) DAPI stained cells were analysed using the NuceloCounter®NC-3000 by quantifying 
the DNA content, results are displayed as percentile amount of cells in the different cell 
cycle stages, and shown to be identical to vector controls in both cell panels. All experiments 
were performed three times for each cell line. (C) MTS cell proliferation assay in the PC3 
cell panel. The fold change in OD (490nm) normalized against the 24h time point is shown 
for each splice variant and the vector control over a time frame of 72h. Statistical analysis 
was performed by One-Way-Anova, using Graph Pad Prism. n=3. Error bars are shown as 
Mean + SEM. 
 
4.2.3 Actin organisation in ADAM15 A-E expressing cells. 
In order to substantiate the phase contrast image analysis shown in Figure 4.2 and 
Figure 4.3., the ADAM15 expression in the cell lines was analysed using the V5-
epitope antibody. The actin cytoskeleton was visualized using phalloidin prior to 
confocal analysis. ADAM15 A-E expression in PC3 and LNCaP is shown in red in 
Figure 4.6 A and B. In LNCaP (Figure 4.6 A) and PC3 (Figure 4.6 B), ADAM15 
staining was localized around the nucleus, in vesicle like intracellular structures, and 
at the plasma membrane, suggesting the ADAM15 A-E are expressed by all cell lines 
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analysed, and they all traffic to the cell surface. In the PC3 ADAM15 A-E cell panel, 
ADAM15 was localized to membrane protrusions, as the representative example for 
ADAM15-D shows (Figure 4.6 C). An example is shown for PC3 ADAM15-B, localized 
to focal adhesion like assemblies. However, as this investigation was not pursued 
further, no conclusion about splice variant specific differences can be drawn. In the 
LNCaP ADAM15 A-E cell panel, ADAM15 was found in cell-cell junctions and vesicle 
like structures (Figure 4.6 D). The distribution of ADAM15 across the cell panels was 
identical among all splice variants. Actin cytoskeleton staining using phalloidin, shown 
in green, revealed no differences when compared to the vector control, for both cell 
panels as judged by cortical actin staining, cell appearance, and cell spreading 
(Figure 4.6 A,B). For LNCaP, cortical actin staining was hardly detectable, compared 
to cortical actin staining present in PC3 (Figure 4.6 B). Cells were equally spread and 
did not reveal any changes in cell appearance for both cell panels. The PC3 cell panel 
showed a diverse morphology of cells, however, similar for all of the splice variants 
and vector control (Figure 4.6 B).  
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Figure 4.6 ADAM15 localization and actin cytoskeleton organization in PC3 and 
LNCaP ADAM15 cell panel. 
Cells were fixed, permeabilized and stained using the primary mouse anti-V5, secondary 
mouse anti-AlexaFlour568, and phalloidin-AlexaFlour488. DAPI was used as nuclear 
counter stain. (A) in LNCaP ADAM15-V5 (red pseudo colour), was detectable in the plasma 
membrane and within cell-cell junctions. (B) In PC3, ADAM15 was detectable inside the 
cytoplasm and at the plasma membrane (C). Cytoskeleton architecture was visualized 
(green pseudo colour) in the PC3 and LNCaP cell panel. In PC3, cortical actin staining was 
predominantly detectable. ADAM15 was detectable in membrane protrusions and also 
localised with actin to focal adhesion like structures, as shown as an example for splice 
variant B in PC3. (D) In LNCaP, ADAM15 was localized to the membrane and was 
detectable in cell-cell junctions and in vesicle-like structures. 
 
4.2.4 PTK6 localisation is not altered by ADAM15 splice variants 
overexpression 
In order to test the hypothesis that PTK6 localization is altered in LNCaP and PC3, 
as stated by Derry et al., and ADAM15 might contribute to this re-localization, both 
cell panels were assessed for PTK6 localization using confocal microscopy. A stable 
PTK6 knock down cell line in PC3 cells was used as negative control. A significant 
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PTK6 knock down was confirmed by western blotting and densitometry (Figure 4.7). 
Confocal microscopy of the PC3 shPTK6 cell line showed reduced staining for PTK6 
(green) in the cytoplasm and the absence of detectable membrane staining, when 
compared to the PC3 shRNA non-target control cell line (Figure 4.7).  
 
Figure 4.7 PTK6 knockdown 
(A,B) Western blot results and densitometry, confirmed PTK6 knock-down in PC3, *p<0.05. 
The experiments were performed with n=4. (C). The PC3 non-target and shPTK6 cells were 
stained using the primary anti-PTK6-mouse, secondary anti-mouse-AlexaFlour488 (green 
pseudo colour). The mounting media contained DAPI (blue pseudo colour), which was used 
as nuclear counter stain.  
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In the PC3 cell panel, PTK6 localization was found to be cytoplasmic and at the 
plasma membrane (Figure 4.8 A). In LNCaP cells, localization of PTK6 was found 
predominantly, in the cytoplasm and within cell-cell junctions, but nuclear localization 
could not be detected (Figure 4.8 B). For both cell panels, no splice variant related 
difference in PTK6 localization was found. 
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Figure 4.8 PTK6 localization in PC3 and LNCaP cell panels. 
The PC3 and LNCaP ADAM15 cell panels were stained using the primary anti-PTK6-rabbit, 
secondary anti -AlexaFlour488-mouse (green pseudo colour). The mounting media 
contained DAPI (blue pseudo colour), which was used as nuclear counter stain. 
Representative pictures for the PC3 and LNCaP cell panel are shown. (A) In PC3-Vector 
and PC3-ADAM15-A cells, PTK6 (green) was detectable within the cytoplasm and the 
plasma membrane. (B) For LNCaP-Vector and ADAM15-A expressing cells, PTK6 (green 
pseudo colour) was detectable in the cytoplasm and in membrane junctions. LNCaP 
ADAM15-D expressing cells show a representative example for the presence of PTK6 in 
membrane junctions in the LNCaP ADAM15 cell panel.  
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4.2.5 The expression of ADAM15 does not change the rate of cell migration 
The effect of ADAM15 A-E splice variant overexpression in regulation of LNCaP or 
PC3 migration was assessed using a transwell migration assay, and 10% serum as 
chemoattractant in the bottom chamber.  
When compared to the vector control cells, both cell panels, showed identical 
numbers of migrating cells, over a timeframe of 8 and 24h (Figure 4.9 A, B). LNCaP 
cells did not show any splice variant specific differences in migrating cells, when 
compared to the vector control (Figure 4.9 A). After 48h, the LNCaP cell panel 
showed, approximately 1.5 fold reduction of migrating cells, when compared to the 
PC3 cell panel. PC3 cells overexpressing ADAM15-B migrated towards the 
chemotactic gradient more efficiently than A, C, D or E (Figure 4.9 B). To exclude that 
the enhanced migration seen for ADAM15-B is proliferation dependent, data obtained 
from the calorimetric metabolic cell proliferation (MTS) assay were checked, showing 
no enhanced proliferation of ADAM15-B in PC3 (Figure 4.5 C). Additionally, cell 
proliferation of the ADAM15 splice variant panel was identical to the proliferation rate 
seen for the vector control cell line. 
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Figure 4.9 ADAM15 splice variants do not alter PC3 or LNCaP cell migration 
(A-B) 20,000 cells were seeded in transwell inserts and incubated with FBS containing 
medium in the bottom chamber, for 8, 24 and 48h. They were fixed, stained and analysed 
using ImageJ. The number of migrating cells is plotted versus the indicated time points.  
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4.2.6 ADAM15-A expression enhances the invasion of PC3 cells via its 
proteolytic activity 
In order to determine whether ADAM15 A-E overexpression influenced the invasion 
of LNCaP and PC3 cells, matrigel invasion assays were performed and invaded cell 
numbers determined at the 24h time point using serum free conditions or in response 
to 10% serum in the bottom chamber.  
As shown in Figure 4.10 A, LNCaPs overexpressing ADAM15 A-E showed identical 
invasive behaviour compared to vector control cells, indication that ADAM15 variants 
do not affect LNCaP invasion. When overexpressing the splice variants in PC3 cells, 
ADAM15-A expression led to a 2-fold increase in the number of invading cells, when 
compared to vector control cells in either condition tested (Figure 4.10 B). In contrast, 
ADAM15 B-E cellular invasion levels were identical to vector control cells (Figure 4.10 
B). To test whether the enhanced invasion of ADAM15-A cells, is mediated by its 
proteolytic domain, a proteolytically inactive ADAM15-A mutant was generated and a 
corresponding PC3 cell line established. The ADAM15 mutant carries an amino acid 
change in the active site, from E to A at position 349 of the metalloproteinase domain. 
ADAM15-A-E349A mutant expressing cells showed similar levels of invasion, when 
compared to the vector control cells (Figure 4.10 C). 
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Figure 4.10 The enhanced invasion of ADAM15-A in PC3 is dependent on ADAM15 
proteolytic activity. 
The PC3 and LNCaP expressing ADAM15 cell panels were seeded into matrigel coated 
invasion chambers and treated for 24h with or without 10% FBS in the bottom chamber. (A) 
LNCaP invasion is independent of ADAM15 A-E expression. (B) In PC3, an increase in cell 
invasion was found in ADAM15-A overexpressing cells. (C) Upon an amino acid change 
from glutamic acid (E) to alanine (A) at position 349 in the ADAM15 proteolytic domain, the 
ADAM15-A cell invasion was reduced, below Vector invasion. The number of invaded cells 
was analysed using ImageJ, and plotted against the treatment.  Statistical analysis was 
performed by One-WAY-Anova, using Graph Pad Prism. The experiment was performed 
with n=3. Error bars are shown as Mean + SEM. 
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4.3 Discussion 
The aim of this chapter was to assess the effect of ADAM15 splice variants on PCa 
cell characteristics in response to stable overexpression. 
ADAM15 expression for the PC3 cell panel was found at the plasma membrane in 
membrane protrusions, however predominantly in the cytoplasmic region, within ER-
like structures, which suggested the trafficking of ADAM15 A-E splice variants to the 
plasma membrane. Although ADAM15 is a transmembrane protein confocal images 
show predominantly cytoplasmic localization of ADAM15, which might be caused due 
to saturation due to the overexpression or a high protein turn-over rate. For ADAM15 
detection, a V5-antibody was used, as ADAM15 contained a C-terminal V5-tag. In 
LNCaP ADAM15 A-E expressing cells, vesicle-like structures were more prominent 
compared to PC3 cells. However, ADAM15 was also localized at the plasma 
membrane and cell-cell junctions.  
The overexpression of ADAM15 A-E splice variant did not result in obvious changes 
in cell morphology, cell size or cell cycle, when compared to the vector control in 
either PCa cell panel. In PC3 and LNCaP cells,  ADAM15 A-E overexpression did not 
alter actin cytoskeleton arrangement. Cells were equally spread and showed similar 
actin staining, however weaker detectable in LNCaP. This is in contrast with the data 
in MDA-MB-435 breast cancer cells, where ADAM15-B expressing cells appeared 
smaller compared to ADAM15-A and vector expressing cells81. Changes in actin 
cytoskeleton were assessed, as in MDA-MB-435 breast cancer cells, Zhong et al. 
found differences in cytoskeleton arrangement, when overexpressing ADAM15-B. 
Vector control cells were well spread, with distinct actin stress fibers. ADAM15-B 
expressing cells were less spread, and showed shorter actin fibers. ADAM15-A 
expressing cells, however, showed similar spreading, and distinct actin stress fibers 
spreading, like the vector control81. 
PTK6 is expressed in normal prostate epithelia regulating growth and differentiation. 
In LNCaP and PC3 parental cells, differences in PTK6 expression levels were found 
(Chapter 3). PTK6 was expressed higher in PC3s when compared to LNCaPs. Upon 
analysing the ADAM15 A-E splice variant cell panel, PTK6 expression was equal 
throughout (Supplementary data Figure 8.7). Change in androgen response, as well 
as PTK6 upregulation, correlates with disease progression9,291. Zheng et al. showed 
in patient data from the NCBI human genome microarray that PTK6 mRNA 
expression levels during prostate cancer progression were significantly increased 
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compared to normal tissue292. Derry et al. reported the altered localization of PTK6 in 
the prostate cancer cell lines PC3 and LNCaP. In the androgen dependent LNCaPs, 
PTK6 was found in the nucleus, whereas in the androgen independent cell line PC3, 
PTK6 was found in the cytoplasm273. In the present study, when analysing the cell 
panels for PTK6 localisation after overexpression of the ADAM15 splice variants no 
changes were found. Further, when comparing nuclear or cytoplasmic localization of 
PTK6 in both cell panels, only cytoplasmic and membrane localization of PTK6 was 
detectable, in contrast to Derry’s findings. However, our  findings are in agreement 
with the results by Zheng et al. as they showed predominantly cytoplasmic localization 
of PTK6 in LNCaP and PC3 cells263. The generated stable PC3 shPTK6 cell panel, 
showed weak PTK6 staining within the cytoplasm. The expression of ADAM15 splice 
variants did not alter PTK6 localization in either cell panel. 
Cell migration is one essential characteristic for cancer cell tumourigenicity and was 
assessed for both PCa cell panels. Knock down of ADAM15, via lentiviral shRNA in 
PC3, showed reduced migration compared to the control, in a wound healing 
assay105. qPCR analysis of the parental PC3 and LNCaP cDNA, revealed, that 
ADAM15 splice variants are differently expressed in these two cell lines. For instance, 
PC3s show predominantly endogenous expression of ADAM15-A, whereas LNCaPs 
show, expression of splice variant D and A (Chapter 3). For LNCaPs, stably 
overexpressing the ADAM15 A-E splice variants, no splice variant specific difference 
was found in a transwell assay over 48h, with 10% serum as chemoattractant. In the 
PC3 cell panel, ADAM15-B overexpressing cells showed a higher number of 
migrating cells after 48h, however it did not reach statistical significance when 
compared to the vector. Zhong et al. showed that overexpression of ADAM15-A but 
not B in MDA-MB-435 breast cancer cells led to enhanced migration81. To exclude a 
proliferation dependent effect for the ADAM15-B enhanced migration, a proliferation 
assay was performed, showing no changes in proliferation throughout the panel. 
Additionally for PC3 ADAM15-A, B, D and vector cells, a scratch wound assay was 
performed however, cells overgrew and wound closure after 48h was only 50%, and 
therefore PC3 ADAM15 splice variant specific migration was not further assessed 
using this methodology (Supplementary Data Figure 8.4). As our data indicate that 
ADAM15-B expressing cells might show an enhanced migration trend, however not 
significant to vector control cells , a new assay set up with different pore sizes of the 
transwell inserts might be reasonable to assess migration. 
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ADAM15 has been shown to increase cell invasion of the human bladder cancer cell 
lines UM-UC-9 and UM-UC-6. Knock down of ADAM15 in those cell lines significantly 
reduced cell invasion162. In lung cancer, Dong et al., confirmed the ADAM15 
dependent invasion157. In MDA-MB-435 breast cancer cells splice variant A was found 
to significantly enhance invasion, compared to splice variant B and the vector 
control81. For LNCaP prostate cancer cell, Najy et al. found only weak invasion ability, 
when compared to PC3 cell lines105. In this study, with both PCa cell panels, Matrigel 
invasion assays were performed, and 10% serum was used as chemoattractant. The 
LNCaP ADAM15 A-E cell panel showed no change in invasion, when splice variants 
were compared, with each other or the vector controls, which confirms the findings 
by Najy et al.105. Within the PC3 ADAM15 cell panel, only the overexpression of 
ADAM15-A led to a 2-fold increase in the number of invading cells compared to vector 
control. As ADAM15s metalloproteinase domain is known to result in degradation of 
the ECM, the proteolytically inactive ADAM15EA mutant was generated, having an 
amino acid change from E to A at position 349, in the active metalloproteinase site. 
Maretzky et al. showed., that ADAM15 E to A mutants, showed a reduction in 
proteolytic activity, as shedding of the FGFR2iiib was decreased compared to 
ADAM15 wild type156. When comparing ADAM15-A wild type (WT) and E349 A (EA) 
mutant using the matrigel invasion assay, the enhanced number of invaded cells seen 
for ADAM15-A WT was reduced to vector invasion levels in the inactive ADAM15-A-
EA mutant. 
In summary, the data of this chapter showed that ADAM15 splice variant 
overexpression did not lead to a change in cell size, cell cycle, actin cytoskeleton 
rearrangement or migration in either of the two cell lines. Moreover, PTK6 expression 
in both cell panels was not altered after overexpression of the splice variants. In PC3 
cells overexpression of splice variant A lead to a trend of increased cell invasion which 
we could further link to the catalytic function of ADAM15. LNCaP cells overexpression 
the ADAM15 splice variants did not lead to enhanced invasion. As we could confirm 
ADAM15 splice variant expression in both cell lines we would further need an 
ADAM15 knock-out cell lines as additional control to the vector cells. To tackle this 
approach we would used the genome editing technology of Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISP) cas-9. We would further focus on 
splice variant specific structures for both cell panels in confocal microscopy such as 
focal adhesion assemblies when assessing changes in the actin cytoskeleton in more 
detail. With the knock-out cell line we would further assess changes in PTK6 
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localization, as the endogenous ADAM15 might have caused the cytoplasmic 
localization in both cell panels. 
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5 ADAM15 interaction with the prostate cancer 
promotor PTK6 
5.1 Introduction 
The intracellular domain of ADAM15 is subject to alternative splicing leading to 13 
splice variants, differing in the number of their proline rich regions. Proline rich regions 
enable the association with SH3-domain containing proteins inside the cytoplasm. 
ADAM15 splice variants, A to E, which the subject of this study, contain 3 to 5 proline 
rich regions. ADAM15-C contains 5 proline rich regions, whereas B and E contain 4, 
and ADAM15-A, only 3. A frame shift mutation upstream of exon 19, results in a 
premature stop codon in splice variant D, and the absence of any proline rich 
regions81. Proteins that were identified to interact via their SH3-domains with the 
proline rich ADAM15 ICD, are Src family kinases such as Lck, Abl and Src, or sorting 
nexins such as SNX9 and SNX33, adapter proteins such as Grb2 and Nck, and the 
tyrosine kinases such as Btk and PTK6144,145,150. The interaction of the ADAM15-ICD 
with these proteins suggests a potential role of ADAM15 in regulation of cell signalling 
pathways and cell function. 
Kleino et al. showed that alternative exon use influences not only the ability, but also 
the strength and specificity to associate with SH3-domain containing proteins. For 
example splice variants B, C and E show a strong association with nephrocystin, 
whereas splice variant A shows a weak association144. Prior to this, Zhong et al. 
identified the ADAM15 splice variant specific impact on patient survival in breast 
cancer81. Although ADAM15-A was identified to interact with the tyrosine kinases Src 
and the adaptor protein Nck, compared to ADAM15-B and C the interaction was much 
weaker, which was likely dependent on proline rich regions, present in ADAM15-B 
and C. Martetzky et al. linked the splice variant specific interaction with Src to 
enhanced proteolytic activity of ADAM15-B. Upon comparison of splice variants 
ADAM15-A and B, B showed enhanced proteolytic cleavage of the FGFR2iiib, which 
was linked to breast cancer progression293. Inhibition of Src via inhibitor treatment or 
via knock down, confirmed the Src dependent enhancement of ADAM15-B activity156. 
ADAM15-B was suggested as a possible target in breast cancer.  
PTK6 is related to the Src family kinases, and is linked to prostate cancer progression 
and disease aggressiveness294. PTK6 was identified to associate with ADAM15 A and 
B but not to C in breast cancer81. Breast cancer patients expressing high levels of 
ADAM15-C had enhanced relapse-free survival, compared to ADAM15-A and B 
expressing patients. PTK6 contains an N-terminal SH3 domain followed by an SH2-
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domain, the linker region and a C-terminal kinase domain. PTK6 localization is flexible 
due to a lack of a myristoylation sequence. This allows shuttling of PTK6 between cell 
compartments and the interaction with proteins in the nucleus, the cytoplasm or the 
plasma membrane. The SH2-domain of PTK6 enable the interaction with phospho-
tyrosines of other interaction partners, such as Sam68 in the nucleus, or AKT within 
the cytoplasm. In normal prostate epithelium, PTK6 is found in the nucleus, where it 
co-localizes with Sam68295. Zheng et al. showed that PTK6 directly associates with 
AKT via its SH3 domain. The interaction is enhanced upon SH2 domain interactions, 
leading to AKT tyrosine phosphorylation at position 315 and 326277. AKT can be 
phosphorylated by growth factor signalling, such as EGFR, promoting cell 
proliferation. Knock down of PTK6 in BHP-1 PCa cells showed reduced 
phosphorylation of AKT in response to EGF stimulation, suggesting a direct influence 
of PTK6 on AKT signalling and cell proliferation277. 
 
5.1.1 Aims of the chapter 
The aims of this chapter were to assess splice variant dependent interactions of 
ADAM15 and PTK6 in PCa cell lines, and to identify whether the activity of PTK6 itself 
is necessary for the interaction with ADAM15.  
Therefore, PC3 and LNCaP ADAM15 A-E cell panels were used in 
immunoprecipitation assays to determine the splice variant specific interaction with 
PTK6 in both cell panels. Immunofluorescence and confocal microscopy were used 
to determine the spatial overlap of ADAM15 and PTK6. A kinase assay was used to 
detect changes in ADAM15 phosphorylation by PTK6. To further elucidate the role of 
active or inactive PTK6 on the ADAM15 interaction, HEK293FT cells were transiently 
co-transfected using PTK6-wildtype or the inactive kinase mutant, PTK6-K219M, with 
ADAM15-A. 
5.2 Results 
5.2.1 All ADAM15 splice variants form a complex with PTK6  
In order to identify an ADAM15 splice variant specific interaction with PTK6, total cell 
lysates of PC3 ADAM15 A-E overexpressing cells were used for immunoprecipitation 
(IP) of either the endogenous PTK6 or the overexpressed ADAM15.  IPs were 
performed both ways, i.e. immunoprecipitating ADAM15 and testing for the presence 
of PTK6 by western blotting, and in the reverse order, i.e. immunoprecipitating PTK6 
and testing for the presence of ADAM15 by western blotting. 
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PC3 cells expressing ADAM15 A-E tagged with the V5 epitope, were grown and lysed 
in RIPA buffer. 350µg/200µL total lysate for the IP using rabbit-anti-PTK6 coated 
Dynabeads, and 250µg/200µL for the reverse IP using anti-V5-coated agarose resins 
were used. Eluted proteins were separated by SDS-PAGE, and western blotting was 
performed with anti-V5 and anti-PTK6 antibodies, respectively. Total lysate was 
probed additionally for actin as a loading control (Figure 5.1 A). PC3 vector cells were 
used as negative controls for V5-IPs. PTK6-IP was validated using the PC3-shPTK6 
cell panel (Supplementary data Figure 8.8).   
Western blotting for V5 in the PTK6-IPs revealed that all ADAM15 splice variants 
were found in PTK6-IPs (Figure 5.1 A), indicating that PTK6 interaction is not 
ADAM15 splice variant dependent. Due to the lack of proline rich-regions in ADAM15-
D, it was surprising to detect it in the PTK6 IPs. To exclude sample contamination, 
supernatants of washing steps after O/N incubation were run on SDS-PAGE gels and 
probed for V5 and PTK6. Supernatants were found to be negative for V5 and PTK6 
(Supplementary data Figure 8.8). The reverse IP, using anti-V5-coated agarose 
resins was performed simultaneously. PTK6 was found in all ADAM15 splice variant 
IPs, whereas no PTK6 was detectable in the vector control IP serving as negative 
control (Figure 5.1 A). To quantify potential differences in splice variant association, 
densitometry was applied for the PTK6-IPs and normalized against total lysate actin 
levels. ADAM15/PTK6 ratios are plotted for each splice variant (Figure 5.1 B). No 
significant difference for the ADAM15 splice variant specific interaction with PTK6 
was detectable. However, as shown in Chapter 3, PC3 cells endogenously express 
ADAM15, which might have an impact on the exogenous splice variant association 
with PTK6, and this will be discussed later in this chapter. 
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Figure 5.1 ADAM15 splice variant A-E and PTK6 interaction in PC3 cells. 
Total lysates of PC3 ADAM15 A-E expressing cells were used for Immunoprecipitation.(A) 
Endogenous PTK6 or overexpressed ADAM15 tagged with V5, were immunoprecipitated, 
using rabbit anti-PTK6 coated Dynabeads or mouse anti-V5 coated agarose beads, 
respectively. Western blotting was used with mouse anti-PTK6 and mouse anti-V5 
antibodies, and actin as loading control. Membranes were cut prior to probing with V5-
ADAM15 (100kDA), PTK6 (45 kDA), and actin (40kDA). (B) ADAM15 A-E and PTK6 
association was analysed using densitometry for PTK6-Ips. Each splice variant is plotted 
against the PTK6/ADAM15(V5) ratio. Statistical analysis was performed using Graph Pad 
Prism, One-Way-Anova (n=6), error bars are shown as Mean+SEM. 
 
5.2.2 The interaction is cell line independent 
To assess, whether the ADAM15/PTK6 interaction is cell line dependent, the LNCaP 
ADAM15 A-E expressing cell panel was subject to immunoprecipitation as described 
in the previously paragraph. Additionally, MDA-MB-231 ADAM15-A and vector control 
breast cancer cells, were analysed. 
The LNCaP cell panel showed that all ADAM15 splice variants in PTK6-IPs. 
Moreover, in the reverse IPs using the V5-resin, PTK6 was present for all splice 
variants but it was not detectable for the vector negative control (Figure 5.2 A). MDA-
MB-231 cells also showed the presence of ADAM15 in the PTK6-IPs, and the 
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presence of PTK6 in the V5-IPs, suggesting a cell line independent ADAM15/PTK6 
interaction (Figure 5.2 B).  
 
Figure 5.2 ADAM15 splice variant A-E and PTK6 interaction in LNCaP and MDA-MB-
231 cells. 
Total lysates of LNCaP ADAM15 A-E expressing cells were used for IP. (A) Endogenous 
PTK6 or overexpressed ADAM15 tagged with V5, were immunoprecipitated, using rabbit 
anti-PTK6 coated Dynabeads or mouse anti-V5 coated agarose beads, respectively. 
Western blotting was used with mouse anti-PTK6 and mouse anti-V5 antibodies. Actin was 
used as IP loading control. Membranes were cut prior to primary antibody probing. For 
PTK6-Ips, 350μg, and for V5-IPs 250 μg of total protein were used. n=3 (B) MDA-MB-231 
breast cancer cells expressing ADAM15-A, and vector control, were used for IP with V5 and 
PTK6, n=1.  
 
5.2.3 Endogenous ADAM15 is present in ADAM15-D-V5 IPs 
In 5.2.1 we showed that all ADAM15 splice variants form a complex with PTK6. 
However due to lack of proline-rich regions ADAM15-D was unlikely to interact with 
PTK6. To investigate the ADAM15-D/PTK6 complex formation, anti-V5-IPs were 
probed for endogenous ADAM15, with an ADAM15-ICD specific antibody. This 
approach would show whether ADAM15-D was forming complexes with the 
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endogenous ADAM15 present in PC3 cells (Chapter 3). The antibody was raised 
against the most C-terminal part of ADAM15-A, B, C and E, which is absent in 
ADAM15-D, and thus cannot detect ADAM15-D. 
Anti-V5-IPs were performed from PC3 vector and ADAM15-A cells as the controls, 
and ADAM15-D total cell lysates (Figure 5.3 A). The IPs were split and run on two 
separate gels. Western blotting was performed with antibodies to V5, ADAM15-ICD 
and PTK6. Anti-V5 immunoblotting confirmed the presence of overexpressed 
ADAM15 in total lysates and V5-IPs. PTK6 was present in the anti-V5-IPs for both 
splice variants (Figure 5.3 A). Probing for ADAM15 using the ADAM15-ICD antibody, 
showed presence of endogenous ADAM15 in the vector control, and the ADAM15-A 
and D cells in the total lysate (Figure 5.3 B). In anti-V5-IPs, exogenous ADAM15 was 
not detectable in the vector control cells. Interestingly, exogenous ADAM15-A and 
ADAM15-D-IPs showed presence of endogenous ADAM15 (Figure 5.3 B), 
suggesting an interaction between the endogenous ADAM15 present in PC3 and the 
overexpressed ADAM15-D. 
 
Figure 5.3 Endogenous ADAM15 is present in anti-V5-ADAM15-D IPs. 
PC3 ADAM15 A and D and vector cells were used for anti-V5-IPs. IPs were split in half and 
run on two gels, membranes were probed for V5 and ADAM15 using an antibody to the 
most C-terminal part of the ADAM15-ICD, which is absent in ADAM15-D. (A) V5-IPs and 
total lysate for PC3 ADAM15 A, D and Vector cells, showing V5-ADAM15 present in 
ADAM15-A and D, and PTK6. The vector control shows no detectable PTK6. (B) V5-IPs 
and total lysate for PC3 cells expressing ADAM15 A and D and vector as control. This time 
membranes were probed using the ADAM15-ICD specific antibody. Endogenous ADAM15 
was detectable in all lysates. In the IPs, endogenous ADAM15 was detectable in ADAM15 
D V5-IPs.  (n=3) 
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5.2.4 ADAM15 can dimerize, allowing ADAM15-D complex formation with 
PTK6 
To confirm if the protein-protein interaction of endogenous ADAM15 and 
overexpressed ADAM15-D is caused by the ADAM15 ability to dimerize, a stable 
chemical linkage of the transient protein-protein interaction was achieved by chemical 
crosslinking. The homobifunctional crosslinker, glutaraldehyde was used, carrying 
two reactive carbonyl groups on both ends, enabling reaction with primary amines, 
present at the N-terminus of each polypeptide and the side chain of lysines present 
in ADAM15 (Figure 5.4 A). PC3-ADAM15-A and D expressing cells, and additionally 
HEK293FT cells transiently transfected with ADAM15-A and D were used, as 
HEK293 cells express only small amounts of ADAM15. Cells were harvested in 
homogenisation buffer and sonicated. Glutaraldehyde (0.0025%v/v) was added to the 
lysate for 2, 5, 10, 15, 20, 30 and 60min. The reaction was terminated using 20% 
hydrazine. Samples were analysed by SDS-PAGE and western blotting, probing for 
V5. 
In HEK293FT and PC3 cells, the ADAM15-A and D monomer was equally detectable 
for each time-point at 80-100kDa (active ADAM15 80kDa, inactive ADAM15 100kDa) 
by V5-antibody. Importantly, ADAM15-A and D dimers running at 190-200kDa, were 
detectable after 5min and increased over time (Figure 5.4 B). A representative 
example of ADAM15-D dimerization is shown. Dimer formation in PC3 cells, stably 
overexpressing the ADAM15 splice variants A and D, was analysed, and the 
monomer to dimer ratio is plotted for each splice variant for the 0 and 60min time 
points. The dimer/monomer ratio was significantly increased after 60min for both 
splice variants (Figure 5.4 C).  
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Figure 5.4 ADAM15 dimerization using cross-linking. 
A time response for ADAM15-A and D dimerization was performed using the 
homobifunctional crosslinker glutaraldehyde. (A) Schematic overview of chemical 
crosslinking. Lysine amino acid side chains, can from a stable amino bond with the 
crosslinker’s glutharaldehyde, carbonyl reactive groups. Lysines are present in the 
ADAM15 ECD and ICD allowing the stable dimer formation after crosslinking, 
detectable using the V5-antibody. (B) Crosslinking time response of ADAM15-D in 
HEK239FT cells. Cells were homogenized and run on 6% SDS-gels after crosslinking. 
Membranes were probed using the V5-antibody. The ADAM15-D active monomer 
without the pro-domain (80kDA) and the inactive ADAM15-D monomer (95kDa) are 
present throughout. The ADAM15-D dimer (190kDa), is detectable after 5min, and 
increases over time. (C) Densitometry results of dimer to monomer ratio in PC3 
ADAM15-A and D expressing cells. A significant increase in ADAM15 dimer to 
monomer ration was detectable, when comparing the 0 and 60 min time points. 
Statistical analysis was performed using Graph Pad Prism and One-Way-Anova. n=3. 
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5.2.5 ADAM15 splice variants and PTK6 co-localize in PC3 and LNCaP cells 
In as much as it was possible to show ADAM15 splice variant A-E and PTK6 
interactions using IP, confocal microscopy was further used to visualize the complex 
formation within the PC3 and LNCaP cell panels. Cells were fixed and permeabilized, 
using 4% paraformaldehyde and 0.01% saponin, followed by co-staining with the 
primary mouse anti-V5 and rabbit anti-PTK6. Anti-mouse-AlexaFlour-568nm (red) 
and rabbit-anti-AlexaFlour-488nm (green) were used as secondary antibodies, and 
cells were mounted in DAPI containing media (blue). PC3-shPTK6 and vector cell 
lines were used as PTK6 and V5-control. 
In the PC3 cell panel, PTK6 and ADAM15 were detectable within the cytoplasm and 
at the plasma membrane (Figure 5.5 A). In ADAM15-A and ADAM15-B expressing 
PC3 cells, a co-localization for ADAM15 and PTK6 at the plasma membrane was 
detectable. For ADAM15-C, D and E co-localization was found predominantly in the 
cytoplasm (Figure 5.5 A). In LNCaP ADAM15 A-E expressing cells PTK6 and 
ADAM15 were detectable in the cytoplasm and cell-cell junctions (Figure 5.5 B), 
ADAM15 was detectable in vesicle-like structures, and the cytoplasm, however not 
as predominantly in the membrane or in cell-cell junctions as seen before for PC3 
cells. A co-localization for PTK6 and ADAM15 was found in the cytoplasm for all splice 
variants. Co-localization was also visible for all splice variants within cell-cell 
junctions, however less distinct than for PC3 cells. A difference in abundance of co-
localization within the cell panels and splice variants was not found. The co-
localization seen for PC3 ADAM15 A and B, could not be quantified due to the 
variations in ADAM15 expression for the individual cells and also due to expression 
of endogenous ADAM15 which could have influenced PTK6 localisation. Since 
ADAM15 dimerizes, a PC3 ADAM15 knock out cell line would be necessary to reduce 
background endogenous ADAM15/PTK6 association levels. Moreover, as both cell 
lines showed variation of ADAM15-V5 expression for individual cells, a clonal 
selection might be further required to reduce the experimental variation within the cell 
panels.  
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Figure 5.5 Co-localization of ADAM15 A-E splice variants and PTK6 in PC3 and 
LNCaP. 
The PC3 and LNCaP ADAM15 A-E and PC3 shPTK6 cell panels were co-stained using the 
primary rabbit anti-PTK6, labelled with the secondary anti-rabbit-AlexaFlour-488 (green), 
and the primary mouse-anti-V5, labelled with the secondary anti-mouse-AlexaFlour-568 
(red). The mounting media contained DAPI, as nuclear counter stain. Cell panels were 
analysed using confocal microscopy (A) The PC3 ADAM15 A-E panel showed a 
co-  localization of PTK6 and ADAM15 in the plasma membrane for splice variant A and B 
(white arrows). A representative picture for the co-localization of ADAM15 and PTK6 at the 
plasma membrane is shown for splice variant A. Cytoplasmic localization was detectable 
for all splice variants. (B) In LNCaP co-localization of ADAM15 and PTK6  was detectable 
in the cytoplasm for all splice variants. PTK6 and ADAM15 in LNCaP were found for all 
splice variants in the cytoplasm and in cell-cell junctions. An example for PTK6/ADAM15 
co-localization in cell-cell junction is given for splice variant A, indicated by white arrows. 
The experiment was performed for both cell panels with n=3. 
 
5.2.6 Presence of active and inactive PTK6 in anti-V5-IPs of ADAM15-A and 
D expressing PC3 cells. 
To identify whether active or the inactive kinase PTK6 was present in the anti-V5-IPs, 
membranes were probed with specific antibodies, detecting either the active kinase 
phosphorylated at tyrosine 342 (p-342), or the inactive kinase phosphorylated at 
tyrosine 442 (p-442).  
In the PC3 vector and ADAM15- A and D expressing cells, PTK6 and V5 were 
detectable in total lysate and IPs. Probing for active PTK6, using the pY342 antibody, 
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showed weak staining in the total lysate at 48kDa, as well as high background and 
unspecific staining (Figure 5.6). Probing of the IP membrane showed small amounts 
of pY342 PTK6 at 48kDa and also background staining. Using the pY442-antibody, 
background staining levels were even higher, although blocking and washing 
conditions were optimized. In total lysate, a band at 48kDa was detectable, which was 
also present in IPs using ADAM15-A and D. However, for both antibodies, high 
background staining was present, which did not allow assessment of changes in 
association between active or inactive PTK6 and ADAM15-A and D, as PTK6 bands 
were close to the detection limit (Figure 5.6). 
 
Figure 5.6 Difference in active and inactive PTK6 in anti-V5-IPs 
To assess if the ADAM15/PTK6 interaction is dependent on PTK6 activity, anti-V5-IPs with 
ADAM15-A and D expressing PC3 cells and vector control cells were performed. 
Differences in the presence of active PTK6, pPTK6 Y342, or inactive PTK6, pPTK6 Y442, 
was assessed. Phospho-PTK6 antibodies were used. 250μg of total protein was used per 
IP. Western blotting results for total lysate and anti-V5-IPs, probing for V5, PTK6, pPTK6 
(Y342) and pPTK6 (Y442). No difference was detectable, for the active and inactive form 
of PTK6 in both IPs, (n=2).  
 
5.2.7 PTK6 activity is not required for the complex formation with ADAM15 
To assess whether the interaction between ADAM15 and PTK6 is dependent on 
PTK6 kinase activity, HEK293FT cells were co-transfected with PTK6 expression 
vector for the active and inactive kinase and ADAM15-A. PTK6 inactive kinase 
expression plasmids containing an amino acid change from lysine (K) to methionine 
(M) at position 219 in the active site of the kinase, was kindly provided by Dr. Amanda 
Harvey (Brunel University, London) (Figure 5.7 A). Co-transfected cells were 
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incubated 48h post-transfection, harvested and lysed. PTK6 and anti-V5-IPs were 
performed with cell lysates to assess differences in complex formation. 
HEK293FT cells, co-transfected with PTK6-wild type (WT) or PTK6-KM and 
ADAM15-A, showed similar expression levels for both PTK6 and ADAM15-A in total 
cell lysates. IPs, using either PTK6 or V5, did not reveal a difference in association 
between ADAM15-A and active or inactive PTK6, suggesting that the interaction is 
independent of PTK6 activity (Figure 5.7 B). 
 
Figure 5.7 ADAM15/PTK6 interaction is independent of PTK6 activity. 
(A) pcMV3 expression plasmids containing human PTK6 wild type (WT) or the KM-mutant, 
FLAG-tagged. (B) HEK293FT cells were transiently co-transfected with ADAM15-A and 
PTK6-wildtype or inactive K219M mutant, in a 1:1 ratio. IPs with anti-PTK6 and anti-V5 were 
performed and analysed using western blot probing for V5 and PTK6,respectively; actin 
was used as loading control n=4. 
 
5.2.8 No changes in ADAM15/PTK6 association upon PTK6 kinase activation 
To assess whether the kinase activity of PTK6 has an impact on ADAM15 
phosphorylation, a kinase assay was performed. Endogenous PTK6 from PC3-
ADAM15-A expressing cells, serum starved for 30h and treated for 30min with HGF 
(20ng/mL) or serum free medium, was immunoprecipitated. IP samples were 
resuspended in kinase buffer, containing 20nM MgCl2 and 5µM ATP, and were 
incubated for 1h at 37°C followed by western blotting probing for phospho-tyrosines 
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using the pan-phospho-tyrosine antibody 4G10. HGF was used to enhance the 
association between ADAM15 and PTK6, as unpublished data from our lab showed 
an increase in association upon HGF treatment in MDA-MB-435 cells. 
Western blotting results for PC3-ADAM15-A total lysate, treated as indicated, did not 
show any differences in phosphorylation when membranes were probed with the 
4G10 antibody (Figure 5.8). Kinase activation of PTK6 by ATP after 
immunoprecipitation, did not show any detectable bands present at the estimated 
molecular weight of PTK6 (48kDa). Additionally, no difference in association of 
ADAM15/PTK6, upon HGF treatment, was detectable when probing for V5. 4G10 
western blotting results did not show detectable bands for the molecular weights of 
ADAM15 (100kDA) or PTK6 (48kDa) in the PTK6-IPs (Figure 5.8). 
 
Figure 5.8 No changes in ADAM15/PTK6 association upon HGF treatment. 
A kinase assay was used to identify an increase in ADAM15 or PTK6 phosphorylation upon 
PTK6-kinase activation. Cells were treated with or without HGF (20ng/mL) and incubated 
for 30min. 500μg total protein was used per anti-PTK6-IP. A pan phospho-tyrosine 
antibody, 4G10, was used to detect changes in phosphorylation of either ADAM15 (100kDa) 
or PTK6 (48kDa), (n=2). 
 
5.3 Discussion 
The aim of this chapter was to identify an ADAM15 splice variant dependent 
interaction with the prostate cancer promotor PTK6, and to identify whether the 
interaction was dependent on the kinase activity of PTK6 itself. 
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The cytoplasmic domain of ADAM15 varies in its number of proline rich binding motifs, 
allowing binding of cytoplasmic proteins containing SH3 domains. Poghosyan et al. 
showed, that the ICD of ADAM15 can interact with SH3 domains of Src family kinases 
such as Lck, Fyn, Abl and Src in a pull-down assays from Jurkat, THP-1, U937 and 
K562 haematopoieitic cell extracts145. Using GST-ADAM15-A, B and C ICD fusion 
proteins, Zhong et al. confirmed a splice variant specific interaction of PTK6 and 
ADAM15-A and B, but not C. 
Using the PC3 ADAM15 A-E expressing cell panel immunoprecipitations were 
performed using either PTK6 coated Dynabeads or anti-V5-conjugated agarose 
resins. All ADAM15 splice variants were found in the PTK6 IP samples. By performing 
the reverse IP using anti-V5, PTK6 was found in all ADAM15 splice variant IPs. IPs 
using the LNCaP ADAM15 cell panel, also showed interactions of all splice variants 
with PTK6. Compared to the prostate tissue, where PTK6 is expressed in both healthy 
and cancerous tissue, PTK6 is not detectable in healthy breast tissue, but only in 
breast cancer296. MDA-MB-231 cells are known to express high levels of endogenous 
PTK6. The ADAM15/PTK6 interaction was also shown for MDA-MB-231 ADAM15-A 
expressing breast cancer cells, suggesting a cell line and cell type independent 
interaction. ADAM15 ICD splice variants show differences in the number of their 
proline rich binding motifs, however, no difference in complex formation with PTK6 
was found in our experiments. However, Maretsky et al. showed a difference in Src 
association for ADAM15-A and ADAM15-B, due to the additional proline rich region, 
present in B 156. Confocal microscopy revealed co-localization of PTK6 and ADAM15 
A-E splice variants, in PC3 cells at the plasma membrane and in the cytoplasm. 
However, when trying to quantify the ADAM15/PTK6 membrane staining for ADAM15 
splice variants A and B in PC3s, no difference between the splice variants was 
detectable, as individual cells showed high variation in ADAM15 expression. As no 
clonal selection was used after Lentiviral infection with the ADAM15 viral particles, 
the cell panel appeared diverse in ADAM15 expression, which influences the confocal 
microscopy results. To quantify the ADAM15/PTK6 membrane staining seen in PC3, 
equal expression of ADAM15 among cells would be necessary. For LNCaP, spatial 
overlap of ADAM15 and PTK6 was detectable in the cytoplasm. Although PTK6 cell-
cell junction staining was very prominent for the LNCaP panel, ADAM15 staining was 
detectable in cell-cell junctions, however not as distinct as PTK6. A difference 
between cytoplasmic and nuclear localization, as found by Derry et al.273, for the PC3 
and LNCaP panel could not be detected. ADAM15 A-E splice variant overexpression 
did not result in detectable differences in PTK6/ADAM15 spatial overlap. For confocal 
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microscopy, PC3 and LNCaP cells with knock down of ADAM15 would be necessary, 
as endogenous ADAM15 present in both cell panels, might contribute to background 
spatial overlap. 
Due to the lack of proline-rich interaction motifs, ADAM15-D was not expected to form 
a complex with PTK6. As PC3 cells express endogenous ADAM15 (Chapter 3), dimer 
formation between endogenous ADAM15 and overexpressed ADAM15-D was 
assessed. In PC3 ADAM15-D V5-IPs, endogenous ADAM15 was detectable using 
an ADAM15-ICD antibody, indicating dimer formation between ADAM15-D and the 
endogenous ADAM15. This suggested that the PTK6 interaction observed for 
ADAM15-D could be indirect, mediated via the endogenous ADAM15 ICD, i.e the 
ADAM15-D dimerization partner. Crosslinking experiments between ADAM15-A or D 
using transiently transfected HEK293FT cells, chosen due to their low expression 
level of endogenous ADAM15, showed a significant ADAM15 dimer formation as 
assessed by crosslinking. ADAM dimerization has been reported previously, although 
not for ADAM15 specifically. Xu et al. identified that ADAM17 is found in an inactive 
state, as a homodimer at the plasma membrane during basal conditions. Upon 
activation of the p38 MAPK pathway, ADAM17 monomer to dimer ratio changed, 
which resulted in an increase in ADAM17 monomer and enhanced proteolytic activity 
of ADAM17, such as shedding of TGF-a297. They further identified the homo 
dimerization of ADAM10, and suggested that dimer formation might be an inherent 
characteristic of ADAMs, regulating their functions as proteases or cytoplasmic signal 
transductors297,298. 
In an in-vitro kinase assay using 32P-labeled phosphoproteins, Derry et al. showed 
higher activity of PTK6 in LNCaPs compared to PC3s273. This led to the conclusion 
that PTK6 localizing to the nucleus shows higher activity compared to PTK6 localized 
to the cytoplasm. Here, we used the PC3 ADAM15-A, D and vector cells in anti-V5-
IPs to identify, whether active or inactive PTK6 is present in the ADAM15/PTK6 
complex. SDS-PAGE and western blotting followed by probing with phospho-
antibodies able to detect active or inactive PTK6, showed no difference in the PTK6 
association pattern, as both antibodies showed high background levels. Furthermore, 
we identified that PTK6 activity is not necessary for the complex formation with 
ADAM15, as both WT-PTK6 as well as mutant, catalytically inactive KM-PTK6 
immunoprecipitate equally with ADAM15.   
Association of Src with the ADAM15-A and B ICD led to differences in ADAM15 
proteolytic activity, i.e. shedding of the FGFR2iib, shown by Maretzky et al.. They 
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identified that the third tyrosine (Y), Y735, of the ADAM15-A-ICD is important for Src 
activation of ADAM15-B. Additionally for PTK6, Castro et al. showed, that the 
motogenic factor HGF, can increase PTK6 phosphorylation and activity in MDA-MB-
231 breast cancer cells. Using a kinase assay, we assessed changes in ADAM15 
phosphorylation upon PTK6 association after HGF stimulation using the PC3-
ADAM15-A expressing cells. No changes in phosphorylation of ADAM15 and PTK6 
were detectable using the pan-phospho-tyrosine 4G10 antibody in total lysate. 
Moreover, performing the kinase assay after immunoprecipitation of PTK6 in treated 
or untreated cells, western blotting did not reveal any phospho-tyrosine bands for the 
corresponding molecular weights of ADAM15 (100kDa) or PTK6 (48kDa), suggesting 
that PTK6 might not influence ADAM15 phosphorylation or activity, as shown for Src.  
Using a different approach, with radioactive labelled 32P-ATP the assay sensitivity 
might increase and changes in phosphorylation might be detectable299. As PC3 cells 
express high levels of the HGF receptor cMET, self activation due to endogenous 
presence of HGF or spontaneous dimerization of cMET without HGF activation 
cannot be excluded. PC3 cells with HGF or cMET knock down would be required to 
exclude background HGF stimulation. The HGF treatment to activate the cMET/HGF 
axis in PC3 cells is questionable according to kinase assay data, since no difference 
in phosphoprotein content could be detected with or without HGF treatments, 
suggesting that the cMET pathway may be constitutively active. In this case, cMET 
inhibition using  cMET kinase inhibitors might be required to assess differences in 
ADAM15/PTK6 complex formation. 
In summary, our data showed that all ADAM15 splice variants interact with PTK6 in 
a cell line independent manner. We could further confirm that PTK6 activity itself is 
not needed for this interaction. Surprisingly we found that ADAM15 splice variant D 
was found in a complex with PTK6. Consequently, this lead to the observation that 
ADAM15 dimerizes, leading to a dimer formation between the endogenous and the 
overexpressed ADAM15. To further elucidate the role of ADAM15 dimerization we 
aim to identify the ADAM15 splice variant leading to the dimer formation. For this we 
would overexpress different combination of the ADAM15 splice variants in a PC3 
ADAM15 knock-out cell line. Using total cell lysates, we would assess differences in 
ADAM15 monomer to dimer ratio. Using confocal microscopy we would further aim 
to quantify the co-localization of ADAM15 and PTK6. For this we would choose cells 
with equal ADAM15 overexpression. Using the Pearson’s correlation coefficient we 
would assess the amount of co-localization for each splice variant. 
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6 ADAM15/PTK6/cMET complex formation 
 
6.1 Introduction 
Some aspects of tumourgenicity of cells is regulated by transmembrane tyrosine kinase 
receptors, such as the HGF receptor cMET. Dysfunction in the cMET/HGF axis is linked 
to initiation of cancer and correlates with disease progression, as cMET is a key driver 
of cell invasion, migration and proliferation, and EMT247,300,301. 
Han et al. used the androgen dependent, cMET negative, LNCaP PCa cell line, to 
assess the HGF/cMET dependent changes in EMT upon cMET overexpression. They 
showed that cMET overexpression caused EMT, indicated by loss of E-cadherin and 
gain of the mesenchymal marker vimentin. The cMET dependent increase in invasion 
and migration was also confirmed using LNCaP cMET overexpressing cells300. In the 
pancreatic cell lines MIA-Paca2 and PK-45H, inhibition of cMET upon treatment with 
the cMET inhibitor SU11274, showed reduction of invasion and proliferation302. 
Prostate cancer progression, due to the loss of androgen dependence after androgen 
ablation therapy, often correlated with cMET upregulation. Tu et al. showed that colony 
formation and proliferation was reduced in PC3 and DU-145 PCa cell lines, upon cMET 
kinase inhibitor PHA-665762 and PF-2311066 treatment251. Dai et al. showed in PC3 
cells that cMET is constitutively active. While treatment using anti-HGF-neutralizing 
antibodies did not reduce invasion or proliferation, cMET tyrosine kinase inhibition 
reduced proliferation and invasion in PC3s231. In ovarian cancer, cMET/HGF signalling 
is associated with poor overall survival and the cMET inhibitor capmatinib (INC280) 
reduced proliferation, migration, invasion and reduced cMET phosphorylation in 
SKOV3, CaOV3 and OVCAR3 ovarian cancer cells. Further, capmatinib reduced 
adhesion of SKOV3 and OVCAR3 cells to the peritoneum303. 
cMET signalling can be targeted either via HGF-antagonists, cMET tyrosine kinase 
inhibitors, such as capmatinib or SU11274, or anti-cMET antibodies. Additionally, 
soluble cMET can disrupt the HGF/cMET signalling axis. Coxon et al. showed that a 
soluble cMET fragment, consisting of the cMET-ECD fused to Fc blocks HGF-
dependent cMET signalling, and inhibits tumour growth in-vivo304. Targeting the cMET 
receptor with the anti-cMET antibody DN30, which binds to the ECD of cMET, led to 
enhanced proteolytic cleavage of cMET-ECD, generating a soluble cMET (s-cMET) 
decoy fragment, which in turn inhibits HGF binding. Schelter et al. revealed that 
ADAM10 was involved in cMET cleavage, and the generation of s-cMET305. Prior to this 
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finding, they suggested that ADAM10 was a cMET sheddase, as knock down of 
ADAM10 in NIH3T3 mouse embryonic fibroblast cells increased cMET surface levels, 
and reduced soluble cMET in the cell supernatant 121. ADAM10 itself can be also 
proteolytically processed. Tousseyn et al. identified ADAM15 as an ADAM10 sheddase, 
cleaving the ECD of ADAM10 from the cell membrane. The metalloproteinase fragment 
of ADAM10 is subject to g-secretase cleavage, the resulting ADAM10 ICD translocates 
to the nucleus, where it is thought to be involved in gene regulation161. 
As cMET is a key player in cell migration and invasion, Castro et al. found, that PTK6, 
downstream of cMET, mediates enhanced migration of MDA-MB-231 breast cancer 
cells upon HGF stimulation. Subsequently, ADAM15 was identified by Poghosyan et al. 
to associate with the cMET adaptor protein Grb2. The association was mediated by 
proline-rich binding motifs, present in the ADAM15-ICD, and the SH3-domain of 
Grb2145. Grb2, when bound to cMET, activates the Erk/MAPK pathway, which can 
upregulate MMP levels, such as MMP9, known to be upregulated by ADAM15 via 
Erk/MEK, leading to enhanced invasion in NCSCL157. cMET dependent interaction of 
Grb2, induces cell proliferation, cell-cycle progression and migration199. Grb2 can either 
bind directly to cMET or associates with the cMET adaptor protein Gab1306. HGF 
binding to cMET mediates receptor dimerization and transphosphorylation of the C-
terminal multi docking site, enabling the association and phosphorylation of Gab1, 
which is important for cMET signal transduction. Upon overnight SU11274 treatment 
followed by 10min of HGF treatment of A549 cells, Gab1 phosphorylation was 
significantly reduced when compared to control307. 
6.2 Aims of the chapter 
The aim of this chapter was to evaluate whether ADAM15 overexpression affects 
invasion in response to HGF and if this invasion can be decreased upon cMET 
signalling inhibition. Furhter we aim to assess if the ADAM15 catalytic function is 
involved in HGF dependent invasion of PC3 cells. Using zymography we aim to assess 
the cell supernatant of PC3 expressing ADAM15-WT and catalytically inactive cells with 
regard to differences in presence of MMPs. Lastly we aim to elucidate the role of how 
HGF/cMET signalling regulates the ADAM15/PTK6 complex formation in PC3s and 
MDA-MB-231 breast cancer cells.  
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6.3 Results 
6.3.1 LNCaP invasion independent of cMET signalling 
To assess the effect of HGF induced cell invasion in the LNCaP ADAM15 A-E splice 
variant expressing cells, a matrigel invasion assay was performed, where 20,000 cells 
were seeded in the top chamber, containing serum free RPMI culture medium. Cells 
were incubated for 24h following HGF addition to the bottom chamber, fixed and 
stained, and the number of invading cells were counted and plotted as number of 
invaded cells for each splice variant. For each splice variant, an untreated control, was 
used and compared to the vector cell line.  
As shown in Figure 6.1 A, cellular invasion was independent of HGF treatment or 
ADAM15 splice variant expressed, when compared to vector control cells. When 
LNCaP parental cells were treated with HGF in a time dependent manner, cMET was 
detectable, using western blotting however, cMET dependent phosphorylation was not 
detectable (Figure 6.1 B).  
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Figure 6.1 HGF treatment does not increase LNCaP ADAM15 A-E cell invasion.  
(A)20,000 cells were seeded in invasion chambers, with serum free medium in the top and 
20ng/mL HGF (added after O/N incubation) in the bottom chamber as chemoattractant. As 
invasion control, for each splice variant cells were seeded in an invasion chamber without 
HGF in the bottom chamber (serum starvation). Cell were incubated for 24h, fixed, stained 
and analyzed. No difference in cell invasion was found. Statistical analysis was performed by 
One-WAY-Anova, using Graph Pad Prism. The experiment was performed with n=3. Error 
bars are shown as Mean + SEM, * p<0.05; **p<0.01; ***p<0.001, ****p<0.0005. (B) Western 
blotting results for HGF time course in LNCaP, using pMET and cMET specific antibodies. 
Actin was used as loading control. cMET time dependent phosphorylation was not detectable 
in LNCaP.  
 
 
6.3.2 ADAM15-A overexpression promotes HGF dependent invasion in PC3  
Previously we showed, that ADAM15-A overexpression led to a 2-fold increase in PC3 
cell invasion in a proteolytically dependent manner (Chapter 3 Figure 4.10). In order to 
test, whether ADAM15 invasion may be regulated by cMET signalling, invasion assays 
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were performed in the presence and absence of HGF using the PC3 cell panel 
expressing ADAM15 A-E and compared to vector control cells. 
PC3 vector cells showed a significant increase in invasion in response to HGF 
treatment. ADAM15-B to D expressing cells showed an increase in number of invading 
cells, however when compared to the control treatment this was not significant. 
ADAM15-A expressing cells showed significant increase in cell invasion in non-
stimulated and HGF stimulated conditions, when compared to vector HGF control 
treated cells (Figure 6.2 A). Western blotting results for HGF time response using the 
PC3 vector expressing cells, revealed increased cMET phosphorylation over time 
(Figure 6.2 B). 
145 
 
 
Figure 6.2 ADAM15-A cell invasion is significantly enhanced by HGF  
(A) Invasion assays with PC3 ADAM15-A to E were performed as described before. ADAM15-
A overexpressing PC3 cells showed a significant increase in cell invasion, in response to HGF 
treatment, when compared to vector control cells. Statistical analysis was performed by One-
WAY-Anova, using Graph Pad Prism. The experiment was performed with n=3. Error bars 
are shown as Mean + SEM, * p<0.05; **p<0.01; ***p<0.001, ****p<0.0005. (B) Western 
blotting results for the treatment HGF treatment time course in PC3, using pMET (black arrow) 
and cMET specific antibodies (black arrow). Actin was used as loading control. cMET time 
dependent phosphorylation increased after 30min of HGF treatment.  
 
 
6.3.3 ADAM15-A HGF dependent invasion is dependent on ADAM15 
proteolytic activity 
To clarify the HGF dependent increased invasion seen for ADAM15-A overexpressing 
PC3 cells, we used the ADAM15-A-EA proteolyically inactive mutant overexpressing 
cells and subsequently analysed their invasion capability with the matrigel invasion 
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assay. To exclude a splice variant specific HGF dependent effect, EA-mutants were 
generated for all ADAM15 splice variants, as the HGF dependent invasion results 
showed trends of increased invasion for all splice variants, however these were only 
statistically significant for ADAM15-A, when compared to vector control cells.  
Figure 6.3. shows that the ADAM15-A-EA mutant cells were significantly less invasive 
and importantly, HGF treatment failed to induce invasion (Figure 6.3). For ADAM15-
B/C/D/E-EA or ADAM15-B/C/D/E-WT no significant results were obtained (Figure 6.3).  
The data therefore show that the proteolytic activity of ADAM15A is required to promote 
PC3 cell invasion under basal and HGF stimulated conditions.  
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Figure 6.3 Comparison of invasion between active and inactive ADAM15 splice 
variant expressing PC3 cells. 
The PC3 ADAM15 A-E WT and EA mutant panel were used for an invasion assay and 
incubated with 20ng/mL HGF for 24h in the bottom of the invasion chamber. ADAM15 splice 
variant A showed a significant enhanced invasion when compared to the vector control 
cells. Invasion was reduced to vector levels for the EA-mutant, when treated with HGF. All 
other splice variants, did not show a significant increase in invasion when compared to 
vector control cells. Statistical analysis was performed by One-WAY-Anova, using Graph 
Pad Prism. The experiment was performed with n=3. Error bars are shown as Mean + SEM, 
* p<0.05; **p<0.01; ***p<0.001, ****p<0.0005. 
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6.3.4 Differences in the presence of MMPs in the supernatant of ADAM15-WT 
versus EA-mutant  
To assess the differences in invasion seen for the proteolytically active ADAM15 
expressing cells when compared to the inactive mutant, gelatinase levels of MMP2 and 
MMP9 in the supernatant were analysed using zymography.  
Medium from the proteolytically active ADAM15-A-WT expressing cells showed 
increased presence of pro-MMP2 and MMP2 (Figure 6.4 A) at approximately 65kDA, 
when compared to vector and the EA-mutant, for all three repeats. A corresponding 
band for MMP9 activity at 100kDa could not be detected, however a band at 150kDa 
(1, shown with the arrow) was detectable, possibly showing an MMP9 complex or/and 
ADAM15.  Enhanced gelatin degradation in ADAM15-A-WT compared to medium from 
vector and ADAM15-A-EA expressing cells was detectable also for those bands. 
ADAM15 is known as gelatinase, as Martin et al. described153, however, as vector 
control and EA-mutant also showed gelatinase activity (Figure 6.4 A), which could be 
due to the endogenous ADAM15.  ADAM15 knock down PC3 cells would be required 
to confirm our hypothesis, and moreover a control for MMP2 and also MMP9 would be 
required to confirm their identity. To accurately quantify the differences seen in the 
zymogram, the total protein amount per lysed dish cell lysates, were used for 
normalization against the zymogram bands (Figure 6.4 B). Total protein amount ratios 
were plotted for each cell line, confirming the increase in gelatinase activity of the 
ADAM15-A-WT cells compared to the vector control and inactive ADAM15-A-EA 
cells(Figure 6.4 B,C).  For the pro-MMP2 band a significant increase for ADAM15-A-
WT cells was determined, when compared to vector control and proteolytic inactive 
ADAM15-A-EA mutant cells (Figure 6.4 C). 
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Figure 6.4 MMP levels in supernatants of proteolytically active and inactive ADAM15. 
A zymogram was used to assess differences of MMP levels in conditioned medium. 
Supernatants of ADAM15-A-WT, inactive ADAM15-A-EA mutant and vector control PC3 cells 
were run on a 6% SDS-PAGE gel containing 100μg/mL gelatin. The gel was incubated in 
0.05M Tris-HCl supplemented with 5mM CaCl2 O/N at 4ºC, followed by 2h staining in 
Coomassie brilliant blue. (A) Enhanced gelatin degradation (white bands) was seen for 
ADAM15A-WT when compared to vector control and ADAM15A-EA, for the corresponding 
MW of pro-MMP2 and MMP2 at approximately 68kDa. Bands 1 at (150kDa), might correspond 
to a complex of ADAM15 and MMP9. (B,C) Quantification of zymogram bands was performed 
using the inverted image and Image J. Bands were normalized against the total protein 
amount per lysed dish. The ratios are plotted for each cell line for band 1(B) and the pro-
MMP2 band (C). Error bars show Mean +SEM, * p<0.05; **p<0.01; ***p<0.001, ****p<0.0005. 
 
6.3.5 cMET inhibition reverses ADAM15-A dependent increase in invasion  
In order to address the question whether the increase in cell invasion seen in PC3 
ADAM15-A overexpressing cells requires functional cMET signalling, invasion assays 
were performed in the presence of the selective cMET tyrosine kinase inhibitor 
SU11274. Cells were seeded in the inserts on top of martigel, following over night 
incubation, the cMET inhibitor SU11274 was added for 1h, followed by the addition of 
HGF in the bottom chamber. The level of invasion was analysed 24h after addition of 
HGF. 
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cMET inhibition led to a significant reduction in PC3 ADAM15-A invasion, when 
compared to HGF alone (Figure 6.5). Further, upon comparison with the vector control, 
PC3-ADAM15-A dependent invasion was significantly increased for untreated control 
and HGF treated cells. The cMET inhibition showed similar levels of invading cells in 
vector control cells, and ADAM15-A cells. 
 
Figure 6.5 PC3 ADAM15-A invasion depends on HGF/cMET signalling. 
PC3 ADAM15-A expressing cells and vector control cells were compared in an invasion 
assay for their HGF/cMET-dependent invasion. HGF was added as chemoattractant to the 
bottom chamber. 1h before HGF treatment, the selective cMET inhibitor SU11274 was 
added to the top chamber. Serum starved cells, containing the solvent control, HGF and 
SU11274 alone were used as control. The ADAM15-A HGF dependent invasion was 
reduced to background invasion levels with cMET inhibition by SU11274. Statistical 
analysis was performed by One-WAY-Anova, using Graph Pad Prism. The experiment was 
performed with n=3. Error bars are shown as Mean + SEM, * p<0.05; **p<0.01; ***p<0.001, 
****p<0.0005. 
 
6.3.6 Complex formation of ADAM15 and PTK6 is HGF dependent  
Unpublished data from our lab suggested that the complex formation between ADAM15 
and PTK6 in MDA-MB-231 breast cancer cells was enhanced upon HGF treatment. 
However, Kinase-assay data showed a high background phosphorylation present in 
PC3 and no detectable difference with or without HGF treatment (Figure 5.8). Using 
MDA-MB-231 ADAM15-A and PC3 ADAM15-A expressing cells we tested the 
hypothesis if the complex formation of ADAM15 and PTK6 can be enhanced using 
HGF. 
In PC3 ADAM15-A expressing cells changes in phosphorylation after HGF treatment 
were not detectable, when probing total lysate with a 4G10 antibody (pan-phospho 
tyrosine antibody). Moreover, ADAM15/PTK6 complex formation remained unaffected 
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after IP with anti-PTK6 (Figure 6.6). However, in MDA-MB-231 ADAM15-A expressing 
cells, the complex formation between ADAM15 and PTK6 was affected by HGF 
treatment, as less complex was present in untreated cells, when compared to HGF 
treated cells, after anti-PTK6 IPs (Figure 6.6).  
 
Figure 6.6 ADAM15/PTK6 complex formation in PC3 and MDA-MB-231 cells 
PC3 ADAM15-A and MDA-MB-231 ADAM15-A expressing cells were serum starved for 
30h followed by treatment with 20ng/mL HGF for 30min. Total cell lysates were used for 
IPs with anti-PTK6 followed by western blotting. MDA-MB-231 ADAM15-A expressing cells 
showed more complex formation of ADAM15 and PTK6 upon HGF addition. PC3 
ADAM15- A expressing cells showed no enhanced complex formation in presence of HGF. 
 
 
6.3.7 The interaction of ADAM15 and PTK6 is lost upon cMET inhibition 
Although our data showed that HGF did not alter the ADAM15/PTK6 complex formation 
in PC3 cells, we assessed the hypothesis, whether the complex formation can be 
decreased when using specific cMET or PTK6 inhibitor. IP experiments were performed 
using cell lysates from cells treated either with SU11274 or a second selective cMET 
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inhibitor Capmatinib, which both target the cMET kinase domain. Additionally, the PTK6 
inhibitor Tilfrinib was used to confirm that PTK6 activity is not required for the 
PTK6/ADAM15A complex formation. 
Western blotting analysis of total cell lysates using a p-cMET specific antibody raised 
against the phosphorylated tyrosines at position 1234 and 1235 of the cMET kinase 
domain, showed that both cMET inhibitors reduced cMET phosphorylation levels 
compared to the control or the PTK6 inhibitor treatment (Figure 6.7). ADAM15-A, PTK6 
and actin levels were consistent and independent of inhibitor treatment (Figure 6.7). 
Analysis of PTK6-IPs revealed that cMET inhibition resulted in loss of ADAM15A/PTK6 
association (Figure 6.7). The reverse IP performed with anti-V5 confirmed these 
findings, as ADAM15/PTK6 complexes dissociated when cMET signalling was 
interrupted due to cMET inhibition. 
PTK6 inhibition did not alter ADAM15/PTK6 complex formation as evidenced by both 
PTK6-IP and V5-IP, confirming that PTK6 activity is not needed for ADAM15/PTK6 
complex formation, which we also described previously in Chapter 5. 
cMET activity was necessary for the complex formation between PTK6 and ADAM15 
splice variants in PC3 cells. cMET inhibition with the selective cMET inhibitor SU11274 
(n=2) led to ADAM15/PTK6 complex disruption for all ADAM15 splice variants 
(Supplementary data Figure 8.13).  
To assess, whether the complex disruption of ADAM15 and PTK6 is cell line dependent, 
the LNCaP ADAM15-A and vector control cells were used, and IP experiments were 
performed as described before. Upon cMET inhibitor treatments, complex disruption of 
ADAM15/PTK6 was not seen in LNCaPs (Supplementary data Figure 8.10). Western 
blotting results which indicated low cMET levels in LNCaPs, and no detectable HGF 
dependent activation of cMET when probing with p-cMET (Figure 6.1 B), suggesting 
that the HGF/cMET pathway is not prominent in LNCaP cells. 
153 
 
 
Figure 6.7 Loss of ADAM15/PTK6 interaction upon cMET inhibition. 
PC3 ADAM15-A expressing cells were treated with the selective cMET inhibitor SU11274 
or Capmatinib, additionally the PTK6 inhibitor Tilfrinib was used. As vehicle control, serum 
starved PC3 vector and PC3 ADAM15-A cells were used. Lysates were split in two and IPs 
were performed with either anti-PTK6-rabbit coated Dynabeads or anti-V5-mouse coated 
agarose resins. IPs and total lysate were analyzed by western blotting and probed for 
V5(ADAM15), PTK6, p-cMET and actin. Upon cMET treatment with both inhibitors, 
ADAM15/PTK6 complex formation was lost in PTK6 and V5-IPs when cMET inhibition 
treatment was applied. Treatment with the PTK6 inhibitor did not change the association 
between ADAM15 and PTK6. p-cMET detection revealed less phosphorylation present in 
cMET inhibitor treatments. 
 
6.3.8 Loss of ADAM15/PTK6 complex upon cMET inhibition is dose dependent  
To assess whether the loss of the ADAM15/PTK6 complex upon cMET inhibition is 
dose dependent a dose response with both inhibitors was performed. For this, cells 
were treated with decreasing doses of SU11274 inhibitor starting from 20nM to 1.25nM 
and for Capmatinib from 400µM to 25µM. Lysates were processed by performing IPs 
using anti-PTK6 and analysed by western blotting for ADAM15-A. 
IP-α-PTK6
IP-α-V5
50kDa
37kDa
100kDa
150kDa
50kDa
37kDa
50kDa
37kDa
50kDa
37kDa
100kDa
150kDa
100kDa
75kDa
100kDa
75kDa
SU11274	10nM
Capmatinib 200µM
HGF	20ng/mL
- - - - - + +
+ +
Tilfrinib 1μM + +
- -
- -- -- --
- - - - - - -
+ + + +-----
PC3	ADAM15-A
Ve
ct
or
Total	lysate
PTK6
PTK6
PTK6
Actin
p-cMET
V5	(ADAM15)
V5	(ADAM15)
V5	(ADAM15)
154 
 
IP results revealed decreasing level of complex formation between PTK6 and ADAM15-
A as the concentration of the inhibitors increased. The analysis of corresponding total 
cell lysates confirmed equal levels of ADAM15 and PTK6 throughout the experimental 
conditions (Figure 6.8 A and B).  
 
Figure 6.8 cMET inhibitor dose dependent ADAM15/PTK6 complex disruption in PC3 
ADAM15-A expressing cells. 
PC3 ADAM15-A expressing cells were treated with decreasing doses of SU11274 (A) or 
Capmatinib (B). Cell lysates were subjected to IP using anti-PTK6, and analysed by western 
blotting and probing for ADAM15 (V5) and PTK6.  
 
6.3.9 Co-localization of ADAM15 and PTK6 in response to cMET inhibition 
As IP analysis revealed loss of the ADAM15/PTK6 complex formation upon cMET 
inhibition, the co-localization of ADAM15/PTK6 interaction was assessed using 
confocal microscopy. PC3 ADAM15-A and vector cells, and additionally PC3 shPTK6, 
as a PTK6 negative control cell line, were seeded on coverslips, and grown for 3 days, 
prior to immune-histochemical analysis using permeabilizing conditions.  
In Chapter 5, we demonstrated that PC3 ADAM15A-E expressing cells showed some 
co-localization with PTK6. Untreated PC3 ADAM15A cells, did not show a difference in 
co-localization of PTK6 and ADAM15, when compared to cells treated with HGF. 
However, cells treated with HGF showed more ADAM15 present at the plasma 
membrane compared to untreated cells. Upon treatment with the cMET inhibitors 
SU11274 and Capmatinib, ADAM15 staining was seen predominantly inside the 
cytoplasm and around the nucleus. For Capmatinib treatment, ADAM15 membrane 
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staining was detectable. PTK6 staining appeared distinctly weaker when compared to 
the untreated control. PTK6 staining was present in the plasma membrane and the 
cytoplasm, while cMET inhibitor treated PC3 cells showed PTK6 staining only in the 
cytoplasm. A clear co-localization as seen before for untreated and HGF treated PC3 
cells was not detectable, which might be also because of the weak PTK6 staining. PTK6 
inhibition by Tilfrinib on the other hand, showed a similar staining for the inhibitor alone 
or the combination with HGF, as seen for the untreated ADAM15-A and HGF treated 
cells. (Figure 6.9). Areas of co-localization for ADAM15A and PTK6 are indicated with 
white arrows.  
PTK6 was localized within the cytoplasm and the plasma membrane in vector control 
and ADAM15A expressing cells. PC3 shPTK6 cells showed weak staining for PTK6 
inside the cytoplasm but not at the plasma membrane. Overall, shPTK6 cells showed a 
much weaker staining, confirming antibody specificity. ADAM15, detected via V5, was 
seen for all cells with exception of the vector control and PC3 shPTK6, around the 
nucleus and at the plasma membrane (Figure 6.9). 
To exclude that the weaker staining, seen for PC3 ADADM15A expressing cells, related 
to the cMET inhibitor treatment was due to degradation of PTK6 or cMET, protein and 
cDNA levels were assessed, without any detectable changes in either cDNA or protein 
expression level (Supplementary data Figure 8.11 Figure 8.12).  
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Figure 6.9 Co-localization of ADAM15/PTK6 after cMET inhibitor treatments in PC3. 
PC3 ADAM15-A, vector control cells and shPTK6 antibody control cells were grown for 3 
days on coverslips. Permeabilizing conditions were applied, and anti-PTK6 conjugated to 
AlexFlour-488nm and anti-V5 conjugated to AlexaFlour-568nm were used to analyze cells 
after treatment with cMET or PTK6 inhibitors using confocal microscopy. Co-localization for 
ADAM15 and PTK6 was detectable in serum starved control and HGF treated PC3 
ADAM15A cells (white arrows). Tilfrinib treatment in presence or absence of HGF showed 
co-localization for ADMA15 and PTK6 (white arrows). In cMET inhibitor treatments, in 
presence or absence of HGF, PTK6 staining was indistinct and co-localization for ADAM15 
and PTK6 could not be detected. Vector control cells were clear for ADAM15-V5 staining. 
shPTK6 cells showed reduced PTK6 staining suggesting antibody specificity. 
 
 
6.3.10 Complex formation of ADAM15, and PTK6 and the adaptor protein Grb2 
In order to determine whether the cMET signalling dependent interaction of ADAM15 
and PTK6 required the ADAM15 and cMET adaptor protein Grb2, additional IP 
experiments were performed using a Grb2 antibody. This multi-protein complex 
formation would be possible via Grb2, which directly associates with ADAM15 via its 
SH3 domains, and via its SH2 domains either directly to p-cMET or to Gab1, which is 
bound to cMET. 
In the first instance, IP analysis was performed with anti-Grb2 antibodies from PC3 
ADAM15-A total cell lysates treated with HGF in the presence or absence of cMET 
inhibitors (Figure 6.10). As expected, ADAM15 was present in Grb2-IPs in all 
conditions, confirming its constitutive association with Grb2 (Figure 6.10). However, 
cMET and PTK6 were only present in Grb2 IPs in non-treated or HGF alone treated 
conditions. cMET inhibition resulted in a complete loss of cMET and PTK6 from Grb2 
IPs. Treatment with the PTK6 inhibitor Tilfrinib showed presence of PTK6, ADAM15, 
and interestingly also cMET in the Grb2 IPs (Figure 6.10).  
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Figure 6.10 cMET activity is necessary for a multi-protein complex assembly 
containing ADAM15 and PTK6. 
PC3 ADAM15A and vector control expressing cells were treated with cMET inhibitors 
SU11274 and Capmatinib, and the PTK6 inhibitor Tilfrinib. Grb2 was immunoprecipitated 
from PC3 cell lysates, followed by probing for ADAM15, Grb2, cMET and PTK6. Grb2-IPs 
showed the presence of ADAM15 regardless of any treatment, however cMET and PTK6 
complexes were lost when cells were treated with both cMET inhibitors. 
 
 
6.3.11 ADAM15 is in a complex with cMET 
Additionally, to confirm the cMET-dependent complex formation, IP experiments were 
performed using a cMET antibody. Precipitates were then analysed for ADAM15, PTK6, 
Grb2 and the cMET adaptor protein Gab1. 
Western blotting analysis of total lysates confirmed the presence of all proteins in the 
starting lysates (Figure 6.11). The cMET-IP contained Gab1 in untreated vector control 
cells. In ADAM15A expressing cells independent of HGF treatment, ADAM15, Gab1, 
Grb2, PTK6 and cMET were present. cMET inhibition led to the loss of Gab1, Grb2, 
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PTK6 and ADAM15 in the cMet-IP, suggesting that complex formation might require 
functional cMET signalling (Figure 6.11). Tilfrinib treatment did not influence the 
composition of the ADAM15-A multiprotein complex that we have shown here (Figure 
6.11).  
Probing cMET IPs with a p-cMET antibody specific for the phospho-tyrosine’s 1234 and 
1235 of the cMET kinase domain, did not give conclusive results (Supplementary data 
Figure 8.14). 
 
Figure 6.11 Loss of cMET interaction with ADAM15-A upon cMET inhibitor treatment. 
Lysates of PC3 ADAM15A expressing cells and vector control cells were treated with the 
cMET kinase inhibitors SU11274 and Capmatinib and the PTK6 inhibitor Tilfrinib, and 
analysed by IP with a cMET specific antibody. cMET inhibitor treatment revealed the loss 
of interaction of ADAM15, PTK6, Grb2 and Gab1. Treatment with the PTK6 inhibitor did not 
influence the complex formation.  
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6.3.12 ADAM15/PTK6 complex disruption in MDA-MB-231 breast cancer cells 
To assess whether the complex disruption of ADAM15/PTK6 is cell line and cell type 
independent, we evaluated the ADAM15/PTK6 complex formation and disruption via 
cMET inhibition in MDA-MB-231 breast cancer cells, stably overexpressing ADAM15-
A. 
In Chapter 5 we showed that ADAM15-A was found in a complex with PTK6 in MDA-
MB-231 breast cancer cells, in 6.3.6 we showed that the complex formation in MDA-
MB-231 cells is affected in the presence of HGF. Now, when applying the cMET 
inhibitors the complex formation between ADAM15 and PTK6 was lost in IPs with 
cMET, Grb2 and PTK6 (Figure 6.12).  PTK6 inhibition did not lead to complex disruption 
in those performed IPs. As seen before in PC3 ADAM15-A cells, Grb2 remained in a 
complex with ADAM15. Increased complex formation of ADAM15 and PTK6 was 
observed for anti-PTK6-IPs in presence of HGF. 
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Figure 6.12 cMET/ADAM15 signal complex disruption in MDA-MB-231 ADAM15-A 
breast cancer cell line. 
MDA-MB-231 ADAM15-A expressing cells were treated with the selective cMET inhibitor 
SU11274 or Capmatinib, additionally the PTK6 inhibitor Tilfrinib was used. As vehicle 
control, serum starved MDA-MB-231 vector and MDA-MB-231 ADAM15-A cells were used. 
Lysates were split in three and IPs were performed with either PTK6-rabbit, or cMET-
mouse, or Grb2-goat coated Dynabeads. IPs and total lysate were analysed by western 
blotting and probed for V5(ADAM15), PTK6, cMET, Grb2 and actin. Upon cMET treatment 
with both inhibitors, a loss of cMET/ADAM15/Grb2/PTK6 interaction was found for 
performed IPs, as found in PC3s. Treatment with the PTK6 inhibitor did not change the 
association between ADAM15 and PTK6. 
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6.4 Discussion  
In this chapter we describe for the first time, that ADAM15-A is found in a complex with 
cMET and the adaptor protein Grb2. We showed, that ADAM15-A invasion is 
significantly enhanced upon HGF treatment, and invasion can be set back to 
background levels when using the cMET inhibitor SU11274. Moreover, we identified 
that the proteolytic activity of ADAM15 led to enhanced presence of MMP2 in cell 
supernatants. 
Upon HGF binding to cMET, dimerization and autotransphosphorylation of cMET is 
induced, leading to recruitment of proteins such as Grb2, Gab1, STAT3 or PI3K, 
initiating downstream signalling promoting invasion, migration, cell cycle progression, 
and upregulation of MMPs199,202.  
In the previous Chapter 4, we showed that PC3 ADAM15-A overexpressing cells 
displayed a 2-fold increase in number of invading cells, compared to the vector control 
cells, when incubated in 10% serum. Herein we show that PC3 ADAM15-A invasion 
was significantly induced by the cMET ligand HGF. Further HGF also induced invasion 
of vector control cells significantly, which might be due to the endogenous ADAM15 
present in those cells. However, the PC3 ADAM15-A overexpressing cells still show 
significantly enhanced invasion in response to HGF treatment when compared to the 
vector control cells.  In addition, all splice variants were tested, however invasion was 
not significantly different when compared to vector control. Han et al. identified a time 
and dose dependent reversal of EMT upon knock down of cMET by siRNA in PC3 cells. 
In a separate experiment, they showed, that reduction of E-cadherin, and increase of 
vimentin, decreased invasion of PC3 siRNA cells, compared to vector control308. 
Further, in those cells, phosphorylation of Erk was enhanced upon HGF stimulation 
when compared to cMET knock down PC3s, suggesting an important role in Erk 
signalling in PC3 EMT and invasion308. ADAM15 is endogenously expressed in PC3 
cells and knock down of ADAM15 in those cells significantly reduced cell invasion105 
suggesting an ADAM15-A dependent effect on HGF induced invasion via Erk signalling.  
Using inactive ADAM15-A-EA mutants in an invasion assay, using 10% serum as 
chemoattractant, in Chapter 4, we showed, that ADAM15 invasion was reset to serum 
starved invasion levels of PC3 cells. The proteolytically inactive EA-mutants showed 
reduced invasion for all splice variants upon HGF stimulation, and also compared to 
vector control. As Dong et al. identified an ADAM15 dependent effect on MMP9 activity, 
leading to enhanced invasion in A549 lung cancer cells157, differences in MMP2 or 
MMP9 levels between ADAM15A-WT or ADAM15A-EA expressing cells were assessed 
by zymography. This revealed increased MMP2 levels in the WT compared to EA and 
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vector control PC3 cell medium. MMP2 is overexpressed in aggressive prostate cancer 
and was linked to disease relapse and Gleason score309. MMP levels may drive 
ADAM15-A invasion, however we need to include valid controls for MMP2 and MMP9 
to confirm their identity. The LNCaP cell panel, lacked HGF induced invasion, which 
corresponds with literature findings by Han et al., showing that overexpression of cMET 
in LNCaPs was required for HGF induced invasion300.  
In ovarian carcinoma cell lines, Koon et al. showed that upon treatment with the cMET 
inhibitor SU11274, cMET activation was abolished, indicating phosphorylation-
dependent inhibition of cMET. Further, they showed that HGF dependent cell motility 
and invasion was significantly reduced upon SU11274 treatment after 24h310.  Our 
results are consistent with the findings of Koon et al.. When treating the PC3 ADAM15-
A expressing cells in an invasion assay with a combination of HGF and the selective 
cMET inhibitor SU11274, invasion was kept at untreated invasion levels, which shows 
that we block the cMET dependent invasion by using a specific cMET inhibitor. As future 
experiment, we could test the hypothesis that changes in the presence of cMET itself 
might influence the invasion in PC3 expressing ADAM15. For this, changes in total 
cMET and ADAM10 lysate levels between ADAM15-A-WT and inactive ADAM15-A-EA 
mutants could be assessed. ADAM10 was identified as a cMET sheddase by Schelter 
et al.305, as knock down or ADAM10 inhibition led to enhanced presence of cMET at the 
plasma membrane. PC3 cells express endogenous ADAM10311,312 and ADAM15, and 
since ADAM15 sheds ADAM10 ECD161 and ADAM10 can cleave cMET, overexpression 
of ADAM15 might induce enhanced ADAM10 cleavage resulting in higher cMET levels 
thereby allowing enhanced signalling via the cMET/HGF axis. To test this hypothesis, 
we would assess soluble cMET decoy levels could be assessed in supernatants of 
ADAM15-A-WT or EA, which might provide evidence for a role of ADAM10 in PC3 
ADAM15-A-EA reduced invasion.  
The functional consequence of HGF stimulation and cMET inhibition was enhanced and  
decreased invasion, respectively, for the PC3 ADAM15-A overexpressing cells. To 
elucidate the mechanistic pathway, IPs were performed initially using anti-PTK6 and 
anti-V5 to assess the ADAM15/PTK6 association. In IPs, with PTK6 or V5 (ADAM15), 
of PC3-ADAM15-A cells treated with the cMET inhibitors SU11274 and Capmatinib. 
ADAM15/PTK6 interaction was lost upon cMET inhibitor treatments, but not upon PTK6 
inhibition with Tilfrinib. Koon et al.310, showed inhibition of cMET activity upon SU11274 
treatment, which was confirmed in our study. Probing total lysate of treated cells with 
phospho cMET specific antibody, showed reduced phosphorylation when treated with 
cMET inhibitor, but not when treated with Tilfrinib as expected. Assessing the co-
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localization of ADAM15/PTK6 interaction upon cMET inhibitor treatment by confocal 
microscopy gave unclear results, as PTK6 staining remained indistinct and weaker 
upon inhibitor treatment. As we showed in Chapter 5 that ADAM15 dimerizes, 
endogenous ADAM15 knock down PC3 cells are required, to get clearer results. This 
will reduce background association levels between endogenous ADAM15 and the 
exogenous ADAM15-V5. Endogenous ADAM15 may also lead to PTK6 membrane 
association, thus making it difficult to assess any changes due to ADAM15-V5 
overexpression. Importantly though, we found no changes in PTK6 and cMET protein 
expression, irrespectively of PTK6 or cMET inhibitor treatment.  
In Chapter 5, we showed the complex formation between ADAM15 splice variants and 
PTK6 in the prostate cancer cell lines PC3 and LNCaP, and additionally in the MDA-
MB-231 breast cancer cells expressing ADAM15-A. We could further show in this 
chapter that HGF treatment did not enhance ADAM15/PTK6 complex formation, as high 
background phosphorylation levels are present in those cells (Figure 5.8), suggesting 
that cMET is already active as also reported by Dai et al.231. Here we uncovered, that 
cMET activity is necessary for complex formation between ADAM15 and PTK6 in 
aggressive PC3 cells, but not in hormone-dependent LNCaP cells. Additionally, we 
revealed the formation of a multiprotein complex containing cMET, ADAM15, PTK6 and 
the adaptor protein Grb2. We showed that in PC3 cells the complex between ADAM15, 
PTK6 and cMET exists without further cMET activation by HGF, which might be 
explained by high expression levels of cMET in PC3231. However, upon cMET inhibition, 
the complex dissociates. We were able to demonstrate that upon cMET inhibition, only 
the interaction between ADAM15 and Grb2 remained, while the remaining complex 
dissociated. To further elucidate whether cMET activation is needed for this complex 
formation, we repeated the analysis in MDA-MB-231 breast cancer cells 
overexpressing ADAM15- A. As seen before for PC3 cells, ADAM15/PTK6/cMET 
complex formation could be disrupted upon cMET inhibition, and Grb2 remained 
attached to ADAM15 independent of any treatment. More importantly, in these cells 
HGF mediated activation of cMET and enhanced complex formation of ADAM15 and 
PTK6. 
Although we showed that Grb2 was also found in the ADAM15/PTK6 complex, the loss 
of the ADAM15/PTK6 complex required further elucidation, as we could show the loss 
of Gab1 in PC3-ADAM15-A cMET-IPs. Grb2 can bind to cMET either directly via the C-
terminal docking site or indirectly via interaction with Gab1199. Gab1 associates with 
cMET via its multi protein binding site (MBS) identified by Weidner et al.313, and once 
associated with cMET, offers binding sites for proteins such as Grb2, Shp, Src or PI3K, 
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some of which also interact with ADAM15145,202. Performing cMET IPs following cMET 
and PTK6 inhibitor treatment, revealed the loss of the interaction with Grb2 and the 
adaptor protein Gab1. In contrast, complexes remained intact in the presence of the 
PTK6 inhibitor. Loss of Gab1 might explain the decreased invasion seen for ADAM15-
A expressing PC3 cells upon inhibitor treatment, as Seiden-Long et al. found that loss 
of Gab1/cMET in DLD-1 human colorectal cancer cell lines, reduced invasion, however, 
loss of Grb2 did not lead to reduced invasion314. Gab1-/- mice showed a delayed 
invasion and migration of myogenic precursor cells into the limbs207. In addition to that, 
Wang et al. showed that treatment of A549 cells with SU11274 leads to decrease in 
Gab1 phosphorylation, which not only affects Gab1 binding to cMET but further inhibits 
the signal transduction of cMET via Gab1307. As our findings suggest that 
ADAM15/PTK6/Grb2 complex formation with cMET might be also inhibited by reduced 
association of Gab1, and Gab1 is also lost upon cMET inhibitor treatment, anti-Gab1 
IPs and Gab1 phosphorylation assessments are necessary, to further characterise the 
ADAM15/PTK6/cMET complex. 
In summary, we could confirm that ADAM15-A is found in a complex with cMET and 
that this complex formation is dependent on cMET kinase activity. The cMET adaptor 
protein Gbr2 was constitutively bound to ADAM15, independent of cMET kinase 
activity. However, PTK6 and Gab1 were lost upon cMET kinase inhibition. Using 
invasion assays we could confirm that the cMET ligand HGF could induce a significant 
enhancement of cell invasion in PC3 ADAM15-A expressing cells which was dependent 
of ADAM15s catalytic function. Further this invasion was set to control levels using a 
specific cMET inhibitor.  Assessment of cell supernatants showed presence of different 
MMP levels in ADAM15-WT or catalytic inactive mutant. With this results we would now 
aim to elucidate the complex formation of ADAM15 and cMET. For this we would 
generate Grb2 knock-out PC3 cells to identify the role of Grb2 in this complex. Further 
we would also assess the role of Gab1, in a first step we would perform IPs with Gab1 
to identify a complex formation loss upon inhibitor treatment. In a second step we would 
generate a PC3 Gab1 knock-out cell line and assess the complex formation. As results 
for LNCaP cells showed that the complex formation was not disrupted, we would aim 
to overexpress cMET in those cells to identify if overexpression of cMET might lead to 
loss of complex formation upon inhibition of cMET. To elucidate the differences in MMP 
levels, we would include controls for MMP9 and MMP2. This would enable us to assess 
the differences seen for ADAM15-WT and the catalytic inactive ADAM15-EA mutant.   
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7 Discussion and Conclusions 
7.1 Discussion, future perspectives 
ADAM15 is reported to contribute to cancer progression and disease aggressiveness. 
Via its metalloproteinase function, ADAM15 is involved in disruption of cell-cell 
attachment105, shedding of membrane-attached growth factors158,159 or disruption of 
cell-ECM interactions105 in various cancer types, such as breast81, lung157 or prostate 
cancer105. Functional consequences that could be related to a specific ADAM15 splice 
variant, A or B, were identified as enhanced invasion, migration, cell adhesion and 
attachment 81,100,105,157.  
In this work, we established and validated a qPCR method to analyse the ADAM15 
splice profile in PCa patients. With 83 patient samples (n=83), the analysis of the 
ADAM15 splice profile was successful, and when correlating it to healthy tissue (n=8) 
we found significantly enhanced ADAM15 expression. Overall, ADAM15-A and C 
variants were the most abundant and ADAM15-A showed the highest increase in 
expression. Burdelski et al. showed that a small subpopulation with aggressive prostate 
cancer, 3% of 9826 PCa samples, had high ADAM15 expression, and this was linked 
to high Gleason score and tumour grade132. We confirmed findings of Burdelski et al. 
that ADAM15 expression in healthy tissue is negative132.  
To validate the impact of ADAM15 splice variant expression in PCa, a larger sample 
cohort with defined clinical characteristics is required. To assess whether ADAM15-A 
expression correlates with high Gleason score and tumour grade, a large number of 
patients – not available for this study - with high Gleason score and tumour grade, and 
with a metastatic score of 1 and a nodal score of 1, as well as benign hyperplasia 
samples, should be investigated. By including patients who show metastasis and those 
with lymph node metastasis, we would be able to correlate patient data with disease 
outcome and relapse-free survival. To improve statistical power, we would need to 
include at least 1000 patients in this follow up study, and include clinical data, such as 
disease onset, relapse, and survival analysis. With this data, we could conduct Kaplan 
Maier plots and correlate the patient course of disease with ADAM15 splice variant 
expression. Currently our study focused on RNA samples isolated from PCa tumour 
samples, however as next step, we could also aim to include serum or plasma samples 
for those patients, to assess vesicle-ADAM15 levels in PCa patient serum and plasma, 
as ADAM15 is released into exosomes by macrophages315. Lee et al. showed that the 
presence of ADAM15-exosomes reduced tumour invasion and migration. We would aim 
to analyse the ADAM15 splice profile of those exosomes present in patient serum or 
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plasma, and correlate this to disease outcome and relapse-free survival. However, 
appropriate splice variant specific antibodies are currently lacking for this analysis. 
As the in-vitro data show that disease aggressiveness is linked to the cMET pathway in 
prostate cancer300, we could also assess cMET in our patient cohort by qPCR analysis. 
We could then correlate cMET and ADAM15 expression with the clinical data, and 
potentially establish a link between ADAM15-A/cMET expression, high Gleason score, 
tumour grade, disease relapse and metastasis score. For our analysis, we would further 
need an intense follow up of patients, as disease relapse might also correlate with cMET 
and ADAM15 expression. It would be desirable to further include samples of patients 
that were treated with cMET inhibitors, where we could assess ADAM15 expression 
and also downstream targets such as MMP2. 
 
Zhong et al. as well as Poghosyan et al. showed that the ADAM15 A-C ICD splice 
variants can interact differently with a variety of SH3-domain containing proteins, due 
to differences in number of proline-rich motifs in the ADAM15 tail81,145. However, a 
functional consequence of these interactions was not identified. ADAM15 splice variant 
A was identified to associate with the cMET adaptor protein Grb2 and the prostate 
cancer promotor PTK6. Herein, we confirm these protein interactions in the cellular 
context of prostate (PC, LNCaP) and breast (MDA-MB-231) cancer cell lines. In 
addition, we describe for the first time, that ADAM15-A is in a complex with cMET. 
Treatment with selective cMET kinase inhibitors SU11274 and Capmatinib, which block 
cMET dimerization and downstream phosphorylation of the multiprotein docking site, 
resulted in dissociation of the cMET/Gab1/Grb2/ADAM15/PTK6 complex. Wang et al. 
showed that SU11274 treatment, reduced Gab1 phosphorylation307 and Gab1 binding 
to cMET is an essential requirement for HGF/cMET signalling in cancer cells. We 
demonstrated that cMET inhibitor treatment led to Gab1 dissociation, and resulted in 
complex loss of Grb2/ADAM15/PTK6, which was not due to altered cellular protein 
levels of any of the complex’s components.  
Interestingly we found that while Grb2 remained in a complex with ADAM15, the PTK6 
interaction was lost upon cMET inhibition. This suggests that although PTK6 can 
associate directly with ADAM15, as Poghosyan et al. showed when using purified 
recombinant ADAM15-ICD-GST constructs145, in PC3 cells the ADAM15/PTK6 
interaction is regulated by the cMET pathway and could involve Gab1. The loss of the 
ADAM15/PTK6 interaction was cMET treatment dependent for all splice variants. 
Considering our finding that ADAM15 dimerizes, a mixed ADAM15 splice variant dimer 
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formation, i.e. ADAM15-A+D, might enable different signalling partners to associate to 
the dimerized ICDs, which would usually not associate to a single ICD. As PC3 cells 
express ADAM15 endogenously, PC3 ADAM15 knock out cells are required to validate 
a splice variant dependent treatment effect. 
Our data suggest that the interaction between ADAM15 and cMET could be mediated 
by Gab1 and/or Grb2 (Figure 7.1). Grb2 is able to bind to ADAM15 via its SH3 
domain145, and via its SH2 domain directly to cMET, or to Gab1 via its SH3-
domain198,207. As cMET needs to be phosphorylated for Grb2 and Gab1 to attach198, an 
interpretation of our data is that, upon cMET inhibitor treatment, Gab1 cannot bind to 
cMET, which further impairs the association of Grb2, leading to the loss of the 
Gab1/Grb2/cMET complex. As Grb2 binds to ADAM15 via its SH3 domain, the 
Grb2/ADAM15 complex stays intact. Although we showed loss of Gab1 in cMET-IP, we 
would further need to confirm the loss of Gab1 in the IPs of the other complex 
components, i.e. ADAM15, PTK6 and Grb2.  
In an attempt to confirm the loss of the co-localization of the novel 
ADAM15/cMET/Gab1/Grb2/PTK6 complex upon cMET inhibitor treatment, confocal 
microscopy was used. Although a co-localization of the ADAM15/PTK6 was seen for 
untreated and HGF treated PC3 cells at the plasma membrane and within the 
cytoplasm, cMET inhibitor treated cells showed a weak and distinct staining for PTK6, 
which made assessment of co-localization difficult. In vector control PC3 cells, PTK6 
staining was also detectable at the plasma membrane, which might be due to the 
endogenous ADAM15. To exclude this, PC3 ADAM15 knock out cells are required, 
which could be used to assess whether the membrane localization of PTK6 requires 
ADAM15 expression. Another approach to test the composition of the novel complex in 
the cellular environment is a proximity ligation assay. With this, we would use a pair of 
appropriate fluorescent probes for the V5-tag present on overexpressed ADAM15 and 
for detecting specifically PTK6, cMET, Grb2 or Gab1. Using this approach, we expect 
to obtain a specific fluorescence resonance energy transfer signal for the formed 
complexes. As the V5-tag is not present in vector control cells, a negative signal would 
be expected in control cells.  
A functional consequence of ADAM15 overexpression was found using an invasion 
assay. We demonstrated that, among the five splice variants, only ADAM15-A showed 
significantly enhanced invasion in response to HGF stimulation. Further, we showed 
that this observation was cell type specific, as invasion assays performed in the LNCaP 
ADAM15-A-E panel did not lead to enhanced invasion upon HGF treatment, most likely 
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due to the very low levels of cMET expressed in these cells. When we took this 
observation further and used a combined treatment with HGF and the SU11274 cMET 
inhibitor, or the inhibitor alone, the invasion of ADAM15-A overexpressing PC3 cells 
was reduced significantly and was at control levels. Najy et al. showed that ADAM15 
knock down in PC3 led to reduced invasion105. They further confirmed that ADAM15 
knock down in MCF-7 cells led to reduced migration100. Our experiments using the PC3 
and LNCaP ADAM15 A-E cell panels failed to show differences in migration, but we did 
see ADAM15 dependent invasion in PC3 cells linked to the cMET/HGF axis. As the 
cMET axis is a major target for cancer therapy316–318, in-vivo models are now necessary 
to evaluate the role of ADAM15 overexpression on metastatic spread when cMET 
treatments are applied. 
 
Moreover, we demonstrated that the proteolytic activity of ADAM15 is required for cell 
invasion, since proteolytically inactive ADAM15 mutants were less invasive, for splice 
variant A in PC3 cells. One possible mechanism for the enhanced invasion upon HGF 
treatment of ADAM15-A PC3 cells could involve the cMET sheddase ADAM10. 
ADAM10, which is a substrate for ADAM15-A, as shown by Tousseyn et.al using 
expression constructs for ADAM15-A161, is also expressed in PC3 cells. ADAM10 is 
cleaved from the cell surface due to ADAM15 overexpression, resulting in higher cMET 
membrane levels. To address this question, expression differences of cMET surface 
levels in vector control or ADAM15-A overexpressing PC3 cells using confocal 
microscopy were assessed. For this cMET antibodies detecting either the cMET ECD 
or ICD were used, however, our data remain preliminary as they lack a valid cMET 
negative control (Supplementary data Figure 8.15). 
The role of ADAM10 in the cMET/ADAM15 interaction needs to be clarified. ADAM10 
is a cMET sheddase, it cleaves the cMET ECD, generating a N-terminal soluble cMET 
fragment (s-cMET)198,214. Assessing changes in cMET expression levels and proteolytic 
processing in ADAM15-A-WT or EA-mutant via western blotting, might be a possible 
approach. Another approach could make use of cMET ELISAs detecting the s-cMET 
that are commercially available. As a future experiment to monitor changes in cMET 
surface expression, we could generate a cMET knock down PC3 cell line, which we 
could use in confocal microscopy or FACS analysis. Using cMET ICD and ECD 
antibodies, to detect changes in membrane bound cMET, as well as ADAM10 
antibodies to detect ADAM10 surface expression, our hypothesis could be further 
evaluated. 
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Our findings could also implicate the MMP2 as having a role in enhanced invasion 
observed for ADAM15-A expressing PC3 cells. Assessing supernatants, we found 
higher levels of pro-MMP2 and MMP2 in ADAM15-A-WT cells compared to ADAM15-
A-EA and vector control cell medium. In a patient study, Xie et al. showed, that MMP2 
expression levels in prostate cancer patients were linked to disease agressiveness319. 
In order to eliminate endogenous ADAM15 and ADAM10 activity in our experiments, 
when using PC3 cells, we could generate an ADAM15/ADAM10 double knock down 
cell line in PC3. Najy et al. showed that upon sh ADAM15 knock down, PC3 cell invasion 
was reduced100. Using the double knock down, we would therefore expect, significantly 
reduced cell invasion compared to the parental cell line, although HGF dependent 
invasion would not be inhibited, since in the absence of ADAM10 and ADAM15, cMET 
levels would be increased due to reduced shedding. ADAM15 and ADAM10 knock 
downs would help to elucidate the role of cMET and MMP2 in enhanced invasion of 
prostate cancer cells. 
172 
 
 
Figure 7.1 ADAM15/cMET complex formation 
In in PC3, the hepatocyte growth factor receptor cMET can form a complex with 
ADAM15/Gbr2/Gab1/PTK6. Two possible ways of how this interaction is formed and further 
disrupted are shown in 1. and 2. (A) cMET dimerizes either upon HGF treatment (as 
indicated) or via overexpression and spontaneous dimerization (not shown, but more likely 
in PC3 cells), leading to downstream transphosphorylation, and allowing Gab1 to associate 
to the C-terminal multi protein docking site. Association of Gab1 to cMET allows binding of 
Grb2 and other adaptor proteins to one of its docking site. Grb2 contains one SH2 domain 
which is flanked on both sites by SH3 domains. Via one of its SH3 domain, Grb2 binds to the 
proline rich regions present in the ADAM15 intracellular domain. (B) Inhibiting cMET via 
selective kinase inhibitors, such as SU11274 and Capmatinib, results in inhibition of cMET 
phosphorylation. Adaptor proteins of cMET cannot bind to its C-terminal multi protein binding 
site leading to the complex loss of PTK6/Grb2/ADAM15 (B 1.) or to loss of 
PTK6/ADAM15/Grb2/Gab1 (B 2.). More factors might be involved in this multi protein 
complex, needing further elucidation. 
An interesting observation was that MDA-MB-231 breast cancer cells, overexpressing 
ADAM15-A also required functional cMET signalling, for the 
cMET/ADAM15/Grb2/PTK6 interaction, since the complex was disrupted by the cMET 
inhibitor treatments, as seen for PC3 cells. However, unlike PC3 cells, in MDA-MB-231 
cells the complex formation between ADAM15 and PTK6 was enhanced. MDA-MB-231 
cells have high cMET levels317, enabling to target this pathway via inhibitor treatment. 
Further, they are aggressive and hormone-independent, such as PC3 cells. This 
suggests, that cMET/ADAM15 complex formation might be an important target in 
aggressive cancer, however further in-vitro and in-vivo experiments are necessary to 
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elucidate its importance. Our preliminary data with the androgen dependent LNCaP 
PCa cell line expressing ADAM15-A, which are known to be cMET negative300, showed 
that the ADAM15/PTK6 complex formation was not disrupted upon cMET inhibitor 
treatments (Supplementary data Figure 8.10).This suggests that the ADAM15/PTK6 
interaction might be independent of cMET complex formation in LNCaP, unlike the 
aggressive PC3 and MDA-MB-231 cells. However, we cannot draw any firm 
conclusions before the finding in the LNCaP cells are repeated and quantified.  
Future experiments in LNCaPs could elucidate the role of Gab1 in the PTK6/ADAM15 
interaction. As Gab1 can be phosphorylated not only via cMET but also via VEGF320 
and other growth factor signalling pathways, we could determine the mechanism of 
Gab1 phosphorylation in LNCaP. Moreover, we could generate a LNCaP cell line co-
expressing cMET and ADAM15 for the use with the cMET inhibitors, Capmatinib and 
SU11274, to test if we could recreate the cMET dependent complex seen in PC3 and 
MDA-MB-231 cells.  
An important finding of this work is that PTK6 kinase activity is not required for the 
ADAM15 interaction. This is based on two lines of evidence. First, ADAM15-A was 
found to interact with both PTK6-WT and the catalytically inactive PTK6-KM mutant in 
HEK293FT cells. Second, although low levels of active PTK6 are present in PC3 
cells295, and using a kinase assay, to facilitate PTK6 activity, we could not detect 
ADAM15 phosphorylation. When we assessed differences in PTK6 expression in our 
PCa cell panel, no change in mRNA or in PTK6 localization upon ADAM15 
overexpression were found. However, as discussed previously, endogenous ADAM15 
is present in PC3 cells, which might influence PTK6 localization. Using PC3 ADAM15 
knock out cells, it might be possible to identify a splice variant specific difference in 
PTK6 localization. 
 
According to Zhong et al. the interaction between ADAM15 and PTK6 is formed via the 
proline rich regions of the ADAM15 ICD, and only ADAM15 splice variant A and B are 
able to associate with PTK681. Strikingly, we found that all splice variants and moreover, 
the D-splice variant, lacking the proline rich binding motifs, is in a complex with PTK6 
in both PC3 and LNCaP cell panels. When using confocal microscopy, co-localization 
of ADAM15 and PTK6 in PC3 and LNCaP cell panels for all splice variants was found. 
Although these results are suggestive of PTK6 interaction in a splice variant 
independent manner, there is an alternative explanation that involves ADAM15 
dimerization with the endogenous protein. Indeed, qPCR data revealed that all 
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ADAM15 splice variants are endogenously expressed in PC3 and LNCaP cells, and 
western blotting confirmed the presence of endogenous ADAM15 in PC3 cells. 
Importantly,  crosslinking experiments revealed dimer formation of ADAM15-A and D in 
a time dependent manner. Dimer formation is published for ADAMs, such as ADAM17 
and ADAM10, and thought to regulate their protease function321. It is therefore possible 
that hetero dimerization of exogenous ADAM15 splice variants with the endogenous 
ADAM15-A takes place in cells, and exogenous ADAM15 is indirectly associated with 
PTK6 via the endogenous ADAM15-A. As Zhong et al. used isolated ADAM15-ICDs, 
tagged with GST they found specific binding of PTK6 to splice variants A and B 
individually, however, this approach did not take hetero dimerization of ADAM15 splice 
variants in cellular settings into account. 
ADAM15 dimer formation could play a physiological role and it could be worth 
investigating further. ADAM17 dimer disruption was previously linked to the MAPK and 
Erk-pathway, with pathway activation leading to a shift from ADAM17 dimer to monomer 
and enhanced activity of ADAM17297. Xu et al. found, that the ADAM17 cytoplasmic tail 
is required for its dimerization. In this inactive-dimer state, ADAM17 associates with 
TIMP3 at the plasma membrane, leading to ADAM17 inactivation. Activation of MAPK 
or ERK pathway led to dissociation of TMP3 and the activation of ADAM17297. Using 
the PCs ADAM15 knock down cell line we could further investigate the dimer formation 
of ADAM15. Further, we could investigate, whether the ADAM15 dimer can be disrupted 
upon cMET pathway activation or upon inhibitor treatment, as well as whether dimer 
formation is necessary for ADAM15 to interact with its protein partners and enhance 
PCa cell invasion. 
  
Assessing cell characteristic of our cell panels such as cell size, morphology, actin 
cytoskeleton, or cell cycle, no changes were found for LNCaP or PC3 stable expressing 
the ADAM15 splice variants, which was surprising, as Zhong et al. could show splice 
variant specific differences in cell characteristics upon overexpression in breast cancer 
cells81. 
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7.2 Conclusions 
In the present study, we showed that enhanced invasion of PC3 ADAM15 
overexpressing cells is dependent on the HGF/cMET signalling axis and on the 
proteolytic activity of ADAM15. 
Further, we demonstrated that ADAM15 is found in a complex with cMET/PTK6/Grb2, 
which could be disrupted in the aggressive cancer cell lines, PC3 and MDA-MB-231, 
by cMET inhibition. 
In prostate cancer patients, expression of all ADAM15 splice variants was significantly 
higher than in healthy tissue. 
In conclusion, our data suggest that ADAM15 overexpression might represent a 
promising clinical target for the prognosis of prostate cancer disease aggressiveness. 
 
 
 
 
 
. 
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8 Supplementary Data 
8.1 Chapter 2 
 
Figure 8.1 ADAM15 Vector Map 
pcDNA5/V5-His –A was used to generate the ADAM15 A-E splice variant specific 
primer. The restriction sites of HindIII and XhoI were used to clone the ADAM15 DNA 
inside. Both enzymes were chosen as they were not present within the ADAM15 
sequence itself, it is important to note that ADAM15 contains an endogenous EcoRI 
site which was remove out of the multiple cloning site using the sites for HindIII and 
XhoI. Adapted from Thermo Fisher (https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/pcdna4v5his_man.pdf) 
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Figure 8.2 Schematic overview of the Lentiviral packaging system 
Overview of the Lentiviral components. The Transferplasmid containing the gene of 
interest and the LTR to integrate into the host genome, the Packaging plasmid 
containing the Reverse Transcriptase (Pol) and the Nucleocapsid. The Envelope 
plasmid contains the VSV-G envelope protein, allowing a broad tropism. Adapted 
from Addgene (https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/). 
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8.2 Chapter 3 
 
Figure 8.3 ADAM15 splice profile and PTK6 expression in PCa patients with Gleason 
score 8,9 and 10. 
After unblinding of clinical data from the analyzed PCa patients, the number of patients with 
a Gleason scores of 8 and 9 was 1 and for a Gleason score of 10, two patients were included. 
The ADAM15 splice profile and PTK6 expression levels are  shown for the patients with a 
Gleason score of 8, 9 and 10.  
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8.3 Chapter 4 
 
Figure 8.4 Scratch wound assay using PC3 ADAM15 expressing cells. 
PC3 ADAM15-A, B and D expressing cells were seeded in 60mm dishes with 1x106 cells/ 
dish. After 24h incubation in serum free media, 7 scratches were introduced to the monolayer 
using a white tip (0.5-1µm). Floating cells were removed by 2 consecutive media washes. 
Pictures were taken using 100x magnification. Cells were fed and pictures were taken after 0, 
24 and 48h. (A) Wound closure in % over a time period of 48h. No significant difference 
between ADAM15-A, B and splice variant D were determined. Wound closure after 48h was 
almost 50%. However, cells were overgrowing (B). The experiment was repeated twice, as a 
100% wound closure could no achieved after 72h, the experiment was terminated. Wound 
closure in % was analyzed using the ImageJ wound closure tool. 
 
 
Figure 8.5 qPCR validation of PTK6 knock-down in the PC3 cell line. 
From PC3 sh non-target and PC3 shPTK6, RNA was isolated and cDNA was generated by 
RT-PCR. Using PTK6 specific primer, qPCR was performed. GAPDH was used as 
endogenous control. Using qPCR, a 20% knockdown of PTK6 was determined, when 
GAPDH Ct values were divided by PTK6 Ct values. 
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Figure 8.6 Antibody validation. 
Prior to the immunohistochemistry experiments, non immune anti-mouse and rabbit 
antibodies were incubated with PC3 Vector control cells on coverslips O/N at 4°C. Cells were 
stained using either the secondary Alexa-Fluor-a-mouse-568nm or the Alexa-Flour-a-rabbit. 
Cells were analyzed using confocal microscopy. 
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Figure 8.7 PTK6 expression levels in PC3 and LNCaP ADAM15 A-E panels. 
qPCR was performed with cDNA generated from extracted RNA from each cell line. GAPDH 
was used as endogenous control. Using qPCR, PC3 and LNCaP cell panel did not reveal a 
splice variant specific change in PTK6 expression levels. The PC3 cell panel shows over all 
a higher PTK6 expression compared to the LNCaP cell panel. GAPDH Ct values were divided 
by PTK6 Ct values, and plotted for each splice variant. 
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Figure 8.8 PTK6 and V5 antibody validation. 
(A) PTK6 antibodies for IP and western blotting were validated using the PC3 shPTK6 cell 
panel. PTK6-rabbit antibody was used to for IPs with PTK6, western blotting was performed 
using the PTK6-mouse antibody. (B) Unspecific antibody binding was assessed in IP-
supernatants after O/N incubation. ADAM15-A and D PC3 cells were chosen, and as PTK6 
positive control, the T47D cell line. Neither PTK6 nor V5 (ADAM15) could be detected in 
wash-supernatants after the IP. (C) Unspecific binding of antibodies and beads was further 
assessed by western blotting. Samples were; total lysate, IP-PTK6 and IP-V5, as positive 
control, Dynabeads, IgG-rabbit antibody, V5-beads and IgG-mouse without cell lysate as 
negative control. Dynabeads, IgG-mouse and rabbit remained free of unspecific binding. In 
the V5-bead sample, IgG heavy chains we detectable, but we detected above the 48kDa 
band for PTK6.  
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8.5 Chapter 6 
 
Figure 8.9 cMET and Grb2 antibody validation 
PC-3 ADAM15-A expressing cells were used for the cMET and Grb2 IP antibody validation. 
The positive control was the total lysate and the IP itself. Negative control per IP was chosen 
as, IgG-rabbit for cMET and IgG-goat for Grb2. Non-immune IgG controls for both IPs were 
found negative for unspecific binding. Both IPs were found positive for either cMET or Grb2, 
when probing membranes after western blotting. Grb2 IPs showed unspecific binding below 
75kDa and above 25kDa, which did not interfere with any of detected proteins. 
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Figure 8.10 No cMET dependent complex interruption of ADAM15 and PTK6 in LNCaP. 
LNCaP ADAM15A and vector control cells were treated with the cMET inhibitor SU11274 
and Capmatinib and additionally with the PTK6 inhibitor Tilfrinib, to assess a cell line and 
cMET dependent interaction. 
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Figure 8.11 cMET or PTK6 protein levels are not affected upon cMET inhibitor 
treatments. 
PC3 ADAM15-A expressing cells were analyzed following cMET inhibitor treatments for 
changes in expression levels. (A) RNA levels of PC3 ADAM15-A expressing cells were 
assessed for PTK6 or cMET expression, untreated cells were used as control. GAPDH was 
used as endogenous control. Cells were treated with either HGF, SU11274 or Capmatinib. 
PTK6 and cMET expression levels remained unaffected upon treatments. (B) PC3 ADAM15-
A expressing cells were treated with SU11274, the proteosomal inhibitor MG132 or a 
combined treatment. Protein expression levels for ADAM15, PTK6 and cMET remained 
unaffected by the treatments. 
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Figure 8.12 Proteosomal inhibitor treatment with PC3 ADAM15-A 
PC3 ADAM15-A expressing cells were analyzed following cMET inhibitor treatments for 
changes in expression levels using confocal microscopy. Cells were treated with either HGF, 
SU11274, the proteosomal inhibitor MG132 or a combination of both. PTK6 (green) and 
ADAM15 (red) were detected using the corresponding validated antibodies. No difference in 
presence of ADAM15 or PTK6 with or without proteosomal inhibitor treatment. The SU11274 
treated cells showed a similar weaker staining for PTK6 even in presence of the proteosomal 
inhibitor, which confirms the western blot and PCR results, however leaves open questions 
as why cells appear weaker in PTK6 staining upon SU11274 treatment. 
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Figure 8.13 cMET dependent ADAM15/PTK6 complex interruption is splice variant 
independent. 
Additionally to PC3 ADAM15A expressing cells, the whole PC3 cell panel was treated with 
the cMET inhibitor SU11274 in presence or absence of HGF. HGF alone and serum starved 
cells were used as control. For all ADAM15 splice variants the interruption of the 
ADAM15/PTK6 complex could be confirmed. The asterisk in ADAM15B expressing cells 
shows the HGF 20ng/mL treated cells, SU11274+HGF is shown in the right lane next to the 
asterisk. 
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Figure 8.14 PC3 cMET IPs probed for p-cMET 
Additionally to cMET, PTK6 and ADAM15, cMET IPs were probed using a p-cMET 
antibody, raised against the kinase domain of cMET, detecting p-tyrosines 1234 and 
1235. The three membranes presented show the three independent repeats of the 
cMET IP and the corresponding probing for p-cMET. 
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Figure 8.15 cMET ECD and ICD antibody validation 
PC3 ADAM15-A expressing cells were used to analysed differences in cMET 
presence using cMET antibodies detecting either the cMET ECD or ICD.  
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